

PRODUCTION OF ISOPRENE, ISOPRENOID PRECURSORS, AND ISOPRENOIDS
USING ACETOACETYL-COA SYNTHASE

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of US Provisional Application No. 61/515,300 filed August 4, 2011, the disclosures of which are incorporated herein by reference in their entirety.

FIELD OF THE INVENTION

[0002] The present invention relates generally to methods for producing isoprene, isoprenoid precursors, and/or isoprenoids from cultured cells and compositions that include these cultured cells.

BACKGROUND OF THE INVENTION

[0003] The products of the mevalonate-dependent pathway are isopentenyl pyrophosphate (IPP) and dimethylallyl diphosphate (DMAPP). IPP and DMAPP are precursors to isoprene as well as to isoprenoids.

[0004] Isoprene (2-methyl-1,3-butadiene) is the critical starting material for a variety of synthetic polymers, most notably synthetic rubbers. Isoprene is naturally produced by a variety of microbial, plant, and animal species. In particular, two pathways have been identified for the biosynthesis of isoprene: the mevalonate (MVA) pathway and the non-mevalonate (DXP) pathway. However, the yield of isoprene from naturally-occurring organisms is commercially unattractive. Isoprene can also be obtained by fractionating petroleum, the purification of this material is expensive and time-consuming. Petroleum cracking of the C5 stream of hydrocarbons produces only about 15% isoprene. About 800,000 tons per year of cis-polyisoprene are produced from the polymerization of isoprene; most of this polyisoprene is used in the tire and rubber industry. Isoprene is also copolymerized for use as a synthetic elastomer in other products such as footwear, mechanical products, medical products, sporting goods, and latex.

[0005] Isoprenoids are compounds derived from the isoprenoid precursor molecules IPP and DMAPP. Over 29,000 isoprenoid compounds have been identified and new isoprenoids are being discovered each year. Isoprenoids can be isolated from natural products, such as microorganisms and species of plants that use isoprenoid precursor molecules as a basic building block to form the relatively complex structures of isoprenoids. Isoprenoids are vital to most living organisms and cells, providing a means to maintain cellular membrane fluidity and electron transport. In nature, isoprenoids function in roles as diverse as natural pesticides in plants to contributing to the scents associated with cinnamon, cloves, and ginger. Moreover, the pharmaceutical and chemical communities use isoprenoids as pharmaceuticals, nutraceuticals, flavoring agents, and agricultural pest control agents. Given their importance in biological systems and usefulness in a broad range of applications, isoprenoids have been the focus of much attention by scientists.

[0006] Thus, more economical methods for producing isoprene and/or isoprenoids are needed. In particular, methods that produce isoprene and/or isoprenoids from inexpensive, renewable starting materials at rates, titers, and purity that are sufficient to meet the demands of a robust commercial process are desirable.

[0007] Such improvements are provided herein by the disclosure of recombinant microorganisms and their use in methods to produce isoprene, isoprenoid precursors, and/or isoprenoids.

[0008] Throughout this specification, various patents, patent applications and other types of publications (e.g., journal articles) are referenced. The disclosure of all patents, patent applications, and publications cited herein are hereby incorporated by reference in their entirety for all purposes.

BRIEF SUMMARY OF THE INVENTION

[0009] The invention provides, *inter alia*, compositions of recombinant microorganisms and methods of making and using these recombinant microorganisms for producing isoprene, isoprenoid precursors and/or isoprenoids. The recombinant microorganisms comprise an enzyme capable of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA which then can be used to make isoprene, isoprenoid precursors and/or isoprenoids. These

recombinant microorganisms comprise an enzyme capable of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA to produce acetoacetyl-CoA instead of an acetoacetyl-CoA thiolase enzyme capable of synthesizing acetoacetyl-CoA from two acetyl-CoA molecules.

[0010] Accordingly, in one aspect, the invention provides for a recombinant microorganism capable of producing isoprene comprising one or more nucleic acids encoding a polypeptide capable of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA and one or more nucleic acids encoding: (a) an isoprene synthase polypeptide, wherein the isoprene synthase polypeptide is encoded by a heterologous nucleic acid; and (b) one or more mevalonate (MVA) pathway polypeptides, wherein culturing of said recombinant microorganism in a suitable media provides for the production of said polypeptides and synthesis of isoprene. In one aspect, the one or more nucleic acids encoding a polypeptide capable of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA is an acetoacetyl-CoA synthase gene. In another aspect, the acetoacetyl-CoA synthase gene is a gene from an actinomycete. In another aspect, the acetoacetyl-CoA synthase gene is from the genus *Streptomyces*. In another aspect, the acetoacetyl-CoA synthase gene encodes a protein having the amino acid sequence of: MTDVRFRIIGTGAYVPERIVSNDEVGAPAGVDDDWITRKTGIRQ RRWAADDQATSDLATAAGRAALKAAGITPEQLTVIAVATSTPDRPQPPTAAYVQHHLG ATGTAAFDVNAVCSGTVFALSSVAGTLVYRGGYALVIGADLYSRILNPADRKTVVLFG DGAGAMVLGPTSTGTGPIVRRVALHTFGGLTDLIRVPAGGSRQPLDGLDAGLQYFA MDGREVRRFVTEHLPQLIKGFLHEAGVDAADISHFVPHQANGVMLDEVFGELHLPRAT MHRTVETYGNTGAASIPITMDAAVRAGSFRPGELVLLAGFGGGMAASFALIEW (SEQ ID NO: 1).

[0011] In another aspect, the acetoacetyl-CoA synthase gene encodes a protein having an amino acid sequence with an 80% or more identity to the amino acid sequence of SEQ ID NO: 1 and having a function of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA.

[0012] In any of the aspects herein, the isoprene synthase polypeptide is a plant isoprene synthase polypeptide. In any of the aspects herein, the isoprene synthase polypeptide is a polypeptide from *Pueraria* or *Populus* or a hybrid, *Populus alba* x *Populus tremula*. In any of the aspects herein, the isoprene synthase polypeptide is selected from the group consisting of *Pueraria montana* or *Pueraria lobata*, *Populus tremuloides*, *Populus alba*,

Populus nigra, and *Populus trichocarpa*. In another aspect, the plant isoprene synthase polypeptide is a kudzu isoprene synthase polypeptide.

[0013] In any of the aspects herein, the one or more nucleic acids encoding one or more MVA pathway polypeptides is a heterologous nucleic acid. In any of the aspects herein, the one or more nucleic acids encoding more MVA pathway polypeptides is a copy of an endogenous nucleic acid. In any of the aspects herein, one or more MVA pathway polypeptides is selected from (a) an enzyme that condenses acetoacetyl-CoA with acetyl-CoA to form HMG-CoA (e.g., HMG synthase); (b) an enzyme that converts HMG-CoA to mevalonate; (c) an enzyme that phosphorylates mevalonate to mevalonate 5-phosphate; (d) an enzyme that converts mevalonate 5-phosphate to mevalonate 5-pyrophosphate; and (e) an enzyme that converts mevalonate 5-pyrophosphate to isopentenyl pyrophosphate.

[0014] In any of the aspects herein, the enzyme that phosphorylates mevalonate to mevalonate 5-phosphate can be selected from the group consisting of *M. mazei* mevalonate kinase, *Lactobacillus* mevalonate kinase polypeptide, *Lactobacillus sakei* mevalonate kinase polypeptide, yeast mevalonate kinase polypeptide, *Saccharomyces cerevisiae* mevalonate kinase polypeptide, *Streptococcus* mevalonate kinase polypeptide, *Streptococcus pneumoniae* mevalonate kinase polypeptide, and *Streptomyces* mevalonate kinase polypeptide, or *Streptomyces CL190* mevalonate kinase polypeptide. In any of the aspects herein, the enzyme that phosphorylates mevalonate to mevalonate 5-phosphate is *M. mazei* mevalonate kinase.

[0015] In any of the aspects herein, the recombinant microorganism can further comprise one or more nucleic acids encoding one or more 1-deoxy-D-xylulose-5-phosphate (DXP) pathway polypeptides. In one aspect, one or more nucleic acids that encode for one or more DXP pathway polypeptides is a heterologous nucleic acid. In another aspect, one or more nucleic acids encoding one or more DXP pathway polypeptides is a copy of an endogenous nucleic acid. In another aspect, the one or more DXP pathway polypeptides is selected from (a) 1-deoxy-D-xylulose-5-phosphate synthase (DXS), (b) 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR), (c) 4-diphosphocytidyl-2C-methyl-D-erythritol synthase (MCT), (d) 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (CMK), (e) 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase (MCS), (f) 1-hydroxy-2-methyl-2-(E)-butenyl 4-

diphosphate synthase (HDS), and (g) 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate reductase (HDR). In another aspect, the DXP pathway polypeptide is DXS.

[0016] In any of the aspects herein, the one or more heterologous nucleic acids is placed under an inducible promoter or a constitutive promoter. In any of the aspects herein, the one or more heterologous nucleic acids is cloned into one or more multicopy plasmids. In any of the aspects herein, the one or more heterologous nucleic acids is integrated into a chromosome of the cells.

[0017] In any of the aspects herein, the microorganism is a bacterial, algal, fungal, yeast, or cyanobacterial cell. In one aspect, the microorganism is a bacterial cell. In another aspect, the bacterial cell is a gram-positive bacterial cell or gram-negative bacterial cell. In another aspect, the bacterial cell is selected from the group consisting of *Escherichia sp.* (e.g., *E. coli*), *L. acidophilus*, *P. citrea*, *B. subtilis*, *B. licheniformis*, *B. lentus*, *B. brevis*, *B. stearothermophilus*, *B. alkalophilus*, *B. amyloliquefaciens*, *B. clausii*, *B. halodurans*, *B. megaterium*, *B. coagulans*, *B. circulans*, *B. lautus*, *B. thuringiensis*, *Corynebacterium spp.* (e.g., *C. glutamicum*), *S. degradans 2-40*, *Alginovibrio aqualiticus*, *Alteromonas sr. strain KLIA*, *Asteromyces cruciatus*, *Beneckea pelagia*, *Corynebacterium spp.*, *Enterobacter cloacae*, *Halmonas marina*, *Klebsiella pneumonia*, *Photobacterium spp.* (ATCC 433367), *Pseudoalteromonas elyakovii*, *Pseudomonas sp.* (e.g., *Pseudomonas alginovora*, *Pseudomonas aeruginosa*, *Pseudomonas maltophilia*, *Pseudomonas putida*), *Vibrio alginolyticus*, *Vibrio haliotocol*, and *Vibrio harveyi*, *S. albus*, *S. lividans*, *S. coelicolor*, *S. griseus*, and *P. alcaligenes* cells. In another aspect, the bacterial cell is an *E. coli* cell. In another aspect, the bacterial cell is an *L. acidophilus* cell. In another aspect, the microorganism is an algal cell. In another aspect, the algal cell is selected from the group consisting of green algae, red algae, glaucophytes, chlorarachniophytes, euglenids, chromista, or dinoflagellates. In another aspect, the microorganism is a fungal cell. In another aspect, the fungal cell is a filamentous fungi. In another aspect, the microorganism is a yeast cell. In another aspect, the yeast cell is selected from the group consisting of *Saccharomyces sp.*, *Schizosaccharomyces sp.*, *Pichia sp.*, or *Candida sp.* In another aspect, the yeast cell is a *Saccharomyces cerevisiae* cell.

[0018] In another aspect, the invention provides for a recombinant microorganism capable of producing an isoprenoid comprising one or more nucleic acids encoding a polypeptide capable of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-

CoA and one or more nucleic acids encoding: (a) one or more nucleic acids encoding a polyprenyl pyrophosphate synthase; and (b) one or more nucleic acids encoding one or more mevalonate (MVA) pathway polypeptides, wherein culturing of said recombinant microorganism in a suitable media provides for production of said polypeptides and synthesis of one or more isoprenoid(s). In one aspect, the one or more nucleic acids encoding one or more MVA pathway polypeptides of (b) is a heterologous nucleic acid. In any of the aspects herein, the one or more MVA pathway polypeptides is selected from the group consisting of (a) an enzyme that condenses acetoacetyl-CoA-CoA with acetyl-CoA to form HMG-Co-A; (b) an enzyme that converts HMG-CoA to mevalonate; (c) an enzyme that phosphorylates mevalonate to mevalonate 5-phosphate; (d) an enzyme that converts mevalonate 5-phosphate to mevalonate 5-pyrophosphate; and (e) an enzyme that converts mevalonate 5-pyrophosphate to isopentenyl pyrophosphate.

[0019] In any of the aspects herein, the enzyme that phosphorylates mevalonate to mevalonate 5-phosphate is selected from the group consisting of *M. mazei* mevalonate kinase, *Lactobacillus* mevalonate kinase polypeptide, *Lactobacillus sakei* mevalonate kinase polypeptide, yeast mevalonate kinase polypeptide, *Saccharomyces cerevisiae* mevalonate kinase polypeptide, *Streptococcus* mevalonate kinase polypeptide, *Streptococcus pneumoniae* mevalonate kinase polypeptide, and *Streptomyces* mevalonate kinase polypeptide, *Streptomyces CL190* mevalonate kinase polypeptide. In one aspect, the enzyme that phosphorylates mevalonate to mevalonate 5-phosphate is *M. mazei* mevalonate kinase.

[0020] In any of the aspects herein, the one or more heterologous nucleic acids is placed under an inducible promoter or a constitutive promoter. In any of aspects herein, the one or more heterologous nucleic acids is cloned into one or more multicopy plasmids. In any of aspects herein, the one or more heterologous nucleic acids is integrated into a chromosome of the cells.

[0021] In one aspect, the microorganism is a bacterial, algal, fungal, yeast, or cyanobacterial cell. In one aspect, the microorganism is a bacterial cell. In another aspect, the bacterial cell is a gram-positive bacterial cell or gram-negative bacterial cell. In another aspect, the bacterial cell is selected from the group consisting of *Escherichia* sp. (e.g., *E. coli*), *L. acidophilus*, *P. citrea*, *B. subtilis*, *B. licheniformis*, *B. lentus*, *B. brevis*, *B. stearothermophilus*, *B. alkalophilus*, *B. amyloliquefaciens*, *B. clausii*, *B. halodurans*, *B. megaterium*, *B. coagulans*,

B. circulans, *B. lautus*, *B. thuringiensis*, *Corynebacterium* spp. (e.g., *C. glutamicum*), *S. degradans* 2-40, *Alginovibrio aqualiticus*, *Alteromonas* sr. strain KLIA, *Asteromyces cruciatus*, *Beneckea pelagia*, *Corynebacterium* spp., *Enterobacter cloacae*, *Halmonas marina*, *Klebsiella pneumonia*, *Photobacterium* spp. (ATCC 433367), *Pseudoalteromonas elyakovii*, *Pseudomonas* sp. (e.g., *Pseudomonas alginovora*, *Pseudomonas aeruginosa*, *Pseudomonas maltophilia*, *Pseudomonas putida*), *Vibrio alginolyticus*, *Vibrio halioticol*, and *Vibrio harveyi*, *S. albus*, *S. lividans*, *S. coelicolor*, *S. griseus*, and *P. alcaligenes* cells. In another aspect, the bacterial cell is an *E. coli* cell. In another aspect, the bacterial cell is an *L. acidophilus* cell. In another aspect, the microorganism is an algal cell. In another aspect, the algal cell is selected from the group consisting of green algae, red algae, glaucophytes, chlorarachniophytes, euglenids, chromista, or dinoflagellates. In another aspect, the microorganism is a fungal cell. In another aspect, the fungal cell is a filamentous fungi. In another aspect, the microorganism is a yeast cell. In another aspect, the yeast cell is selected from the group consisting of *Saccharomyces* sp., *Schizosaccharomyces* sp., *Pichia* sp., or *Candida* sp. In another aspect, the yeast cell is a *Saccharomyces cerevisiae* cell.

[0022] In any of the aspects herein, the isoprenoid is selected from group consisting of monoterpenes, diterpenes, triterpenes, tetraterpenes, sesquiterpene, and polyterpene. In one aspect, the isoprenoid is a sesquiterpene. In another aspect, the isoprenoid is selected from the group consisting of abietadiene, amorphadiene, carene, farnesene, α -farnesene, β -farnesene, farnesol, geraniol, geranylgeraniol, linalool, limonene, myrcene, nerolidol, ocimene, patchoulol, β -pinene, sabinene, γ -terpinene, terpineol and valencene.

[0023] In another aspect, the invention provides for methods of producing isoprene, the method comprising: (a) culturing a recombinant microorganism comprising one or more nucleic acids encoding (i) a polypeptide capable of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA and one or more nucleic acids encoding: (ii) an isoprene synthase polypeptide, wherein the isoprene synthase polypeptide is encoded by a heterologous nucleic acid; and (iii) one or more mevalonate (MVA) pathway polypeptides, and (b) producing isoprene. In one aspect, the method further comprises recovering the isoprene produced by the recombinant microorganism.

[0024] In another aspect, the one or more nucleic acids encoding a polypeptide capable of synthesizing acetoacetyl Co-A from malonyl Co-A and acetyl-CoA is an

acetoacetyl-CoA synthase gene. In another aspect, the isoprene synthase polypeptide is a plant isoprene synthase polypeptide. In another aspect, the one or more MVA pathway polypeptides is selected from the group consisting of (a) an enzyme that condenses acetoacetyl-CoA with acetyl-CoA to form HMG-Co-A; (b) an enzyme that converts HMG-CoA to mevalonate; (c) an enzyme that phosphorylates mevalonate to mevalonate 5-phosphate; (d) an enzyme that converts mevalonate 5-phosphate to mevalonate 5-pyrophosphate; and (e) an enzyme that converts mevalonate 5-pyrophosphate to isopentenyl pyrophosphate. In another aspect, the recombinant microorganism further comprises one or more nucleic acids encoding one or more 1-deoxy-D-xylulose-5-phosphate (DXP) pathway polypeptides.

[0025] In another aspect, the microorganism is a bacterial, algal, fungal or yeast cell. In another aspect, the microorganism is a bacterial cell. In another aspect, the bacterial cell is a gram-positive bacterial cell or gram-negative bacterial cell. In another aspect, the bacterial cell is an *E. coli* cell. In another aspect, the bacterial cell is an *L. acidophilus* cell. In another aspect, the microorganism is a yeast cell. In another aspect, the yeast cell is a *Saccharomyces cerevisiae* cell.

[0026] In another aspect, provided herein is a method of producing an isoprenoid, the method comprising: culturing a recombinant microorganism comprising one or more nucleic acids encoding (i) a polypeptide capable of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA and one or more nucleic acids encoding: (ii) a polyprenyl pyrophosphate synthase polypeptide, wherein the polyprenyl pyrophosphate synthase polypeptide is encoded by a heterologous nucleic acid; and (iii) one or more mevalonate (MVA) pathway polypeptides, and producing said isoprenoid.

BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 is a plasmid map of Strep CL190 Upper.

[0028] Figure 2 is a plasmid map of pMCM1187.

[0029] Figure 3 is a plasmid map of pCL-Ptrc-mvaR-mvaS-nphT7 isolated from strains MCM1320 and MCM1321.

[0030] Figure 4 is a graph showing the levels of isoprene produced by strains engineered to encode Acetoacetyl-CoA (NphT7). Isoprene levels were detected using a Gas Chromatography-Flame Ionization Detector. Strains MCM1684 and MCM1685, which produce MVA via Acetoacetyl-CoA, generated significantly higher levels of isoprene as compared to the MCM1686 strain that produces isoprene via the DXP pathway.

[0031] Figure 5 is a vector map of construct pMCM1221.

[0032] Figure 6 is a vector map of construct nphT7 with *S. suis* HMGRS/pCL. The genes encoding the upper MVA pathway enzymes are highlighted in the figure, as well as the IPTG-inducible Trc promoter governing expression of the 3 gene operon. The HMG-CoA Reductase (HMGR) and the HMG-CoA Synthase (HMGS) enzymes are encoded by genes derived from *Streptococcus suis* and the NphT7 Acetoacetyl-CoA Synthase is encoded by the *nphT7* gene derived from *Streptomyces* sp. strain CL190. The spectinomycin resistance gene (*aadA1*) and the gene encoding the RepA protein required for plasmid replication (*repA*) common to the pCL1920 vector backbone are included in the construct, but are not shown in the figure.

[0033] Figure 7 is a graph depicting the specific productivity of isoprene (ug/L OD hr. units), represented by the black and gray bars, and the optical density (OD 600nm), represented as a black diamond, for each of the cultures tested. Isoprene data for the strains harboring the upper MVA pathway enzymes consisting of the *S. suis* HMGR and HMGS together with NphT7 Acetoacetyl-CoA Synthase are depicted by the black bars (labeled NphT7 a-c in the graph representing REM C8_25, REM C9_25, and REM D1_25 respectively); isoprene data for the strains harboring the upper MVA pathway enzymes encoded by *nphT5*, *nphT6*, and *nphT7* genes derived from *Streptomyces* sp. strain CL190 are depicted by gray bars (labeled MCM1684 and MCM1685); isoprene data for the control strain which lacks an exogenous upper MVA pathway system is also shown in gray (labeled IspS alone). Isoprene specific productivity is represented on the left y-axis. The OD measurements were taken 3.5 hours post IPTG-induction of relevant gene expression and are represented on the right y-axis.

[0034] Figure 8 is a graph showing NADP+/time/OD from a catalytic activity assay of coupled NphT7, HMG-CoA synthase, and HMG-CoA Reductase. The strains *nphT7* test-strain 1-3 correspond to REM C8_25, REM C9_25, and REM D1_25 respectively.

The Control-Parental-IspS alone strain is REM F3_25. These results are consistent with NphT7 activity dependence on the presence of both acetyl-CoA and malonyl-CoA.

[0035] Figure 9 is a graph showing Isoprene/time/OD from catalytic assays using strains nphT7 test-strain 1-3, which correspond to REM C8_25, REM C9_25, and REM D1_25 respectively. The Control-Parental-IspS alone strain is REM F3_25.

DETAILED DESCRIPTION

[0036] The invention provides, *inter alia*, compositions and methods for the increased production of isoprene, isoprenoid precursor molecules, and/or isoprenoids in recombinant microorganisms that have been engineered to express an enzyme capable of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA as the first step in directing carbon flux towards the production of isoprene, isoprenoid precursor and /or isoprenoids.

General Techniques

[0037] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature, “*Molecular Cloning: A Laboratory Manual*”, third edition (Sambrook et al., 2001); “*Oligonucleotide Synthesis*” (M. J. Gait, ed., 1984); “*Animal Cell Culture: A practical approach*”, third edition (J. R. Masters, ed., 2000); “*Methods in Enzymology*” (Academic Press, Inc.); “*Current Protocols in Molecular Biology*” (F. M. Ausubel et al., eds., 1987, and periodic updates); “*PCR: The Polymerase Chain Reaction*”, (Mullis et al., eds., 1994). Singleton et al., *Dictionary of Microbiology and Molecular Biology* 3rd revised ed., J. Wiley & Sons (New York, N.Y. 2006), and *March’s Advanced Organic Chemistry Reactions, Mechanisms and Structure* 6th ed., John Wiley & Sons (New York, N.Y. 2007), provide one skilled in the art with a general guide to many of the terms used in the present application.

Definitions

[0038] The term “isoprene” refers to 2-methyl-1,3-butadiene (CAS# 78-79-5). It can be the direct and final volatile C5 hydrocarbon product from the elimination of pyrophosphate from 3,3-dimethylallyl diphosphate (DMAPP). It may not involve the linking or

polymerization of IPP molecules to DMAPP molecules. The term “isoprene” is not generally intended to be limited to its method of production unless indicated otherwise herein.

[0039] As used herein, the term “polypeptides” includes polypeptides, proteins, peptides, fragments of polypeptides, and fusion polypeptides.

[0040] As used herein, an “isolated polypeptide” is not part of a library of polypeptides, such as a library of 2, 5, 10, 20, 50 or more different polypeptides and is separated from at least one component with which it occurs in nature. An isolated polypeptide can be obtained, for example, by expression of a recombinant nucleic acid encoding the polypeptide.

[0041] By “heterologous polypeptide” is meant a polypeptide encoded by a nucleic acid sequence derived from a different organism, species, or strain than the host cell. In some embodiments, a heterologous polypeptide is not identical to a wild-type polypeptide that is found in the same host cell in nature.

[0042] As used herein, a “nucleic acid” refers to two or more deoxyribonucleotides and/or ribonucleotides covalently joined together in either single or double-stranded form.

[0043] By “recombinant nucleic acid” is meant a nucleic acid of interest that is free of one or more nucleic acids (*e.g.*, genes) which, in the genome occurring in nature of the organism from which the nucleic acid of interest is derived, flank the nucleic acid of interest. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (*e.g.*, a cDNA, a genomic DNA fragment, or a cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences.

[0044] By “heterologous nucleic acid” is meant a nucleic acid sequence derived from a different organism, species or strain than the host cell. In some embodiments, the heterologous nucleic acid is not identical to a wild-type nucleic acid that is found in the same host cell in nature.

[0045] As used herein, an “expression control sequence” means a nucleic acid sequence that directs transcription of a nucleic acid of interest. An expression control sequence can be a promoter, such as a constitutive or an inducible promoter, or an enhancer. An expression control sequence can be “native” or heterologous. A native expression control sequence is derived from the same organism, species, or strain as the gene being expressed. A heterologous expression control sequence is derived from a different organism, species, or strain as the gene being expressed. An “inducible promoter” is a promoter that is active under environmental or developmental regulation.

[0046] By “operably linked” is meant a functional linkage between a nucleic acid expression control sequence (such as a promoter) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.

[0047] As used herein, the terms “minimal medium” or “minimal media” refer to growth medium containing the minimum nutrients possible for cell growth, generally without the presence of amino acids. Minimal medium typically contains: (1) a carbon source for cell growth; (2) various salts, which can vary among host cell species and growing conditions; and (3) water. The carbon source can vary significantly, from simple sugars like glucose to more complex hydrolysates of other biomass, such as yeast extract, as discussed in more detail below. The salts generally provide essential elements such as magnesium, nitrogen, phosphorus, and sulfur to allow the cells to synthesize proteins and nucleic acids. Minimal medium can also be supplemented with selective agents, such as antibiotics, to select for the maintenance of certain plasmids and the like. For example, if a microorganism is resistant to a certain antibiotic, such as ampicillin or tetracycline, then that antibiotic can be added to the medium in order to prevent cells lacking the resistance from growing. Medium can be supplemented with other compounds as necessary to select for desired physiological or biochemical characteristics, such as particular amino acids and the like.

[0048] As used herein, the term “isoprenoid” refers to a large and diverse class of naturally-occurring class of organic compounds composed of two or more units of hydrocarbons, with each unit consisting of five carbon atoms arranged in a specific pattern. As used herein, “isoprene” is expressly excluded from the definition of “isoprenoid.”

[0049] As used herein, the term “terpenoid” refers to a large and diverse class of organic molecules derived from five-carbon isoprenoid units assembled and modified in a variety of ways and classified in groups based on the number of isoprenoid units used in group members. Hemiterpenoids have one isoprenoid unit. Monoterpenoids have two isoprenoid units. Sesquiterpenoids have three isoprenoid units. Diterpenoids have four isoprene units. Sesterterpenoids have five isoprenoid units. Triterpenoids have six isoprenoid units. Tetraterpenoids have eight isoprenoid units. Polyterpenoids have more than eight isoprenoid units.

[0050] As used herein, “isoprenoid precursor” refers to any molecule that is used by organisms in the biosynthesis of terpenoids or isoprenoids. Non-limiting examples of isoprenoid precursor molecules include, e.g., isopentenyl pyrophosphate (IPP) and dimethylallyl diphosphate (DMAPP).

[0051] As used herein, the term “mass yield” refers to the mass of the product produced by the host cells divided by the mass of the glucose consumed by the host cells multiplied by 100.

[0052] By “specific productivity,” it is meant the mass of the product produced by the host cell divided by the product of the time for production, the host cell density, and the volume of the culture.

[0053] By “titer,” it is meant the mass of the product produced by the host cells divided by the volume of the culture.

[0054] As used herein, the term “cell productivity index (CPI)” refers to the mass of the product produced by the host cells divided by the mass of the host cells produced in the culture.

[0055] Unless defined otherwise herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.

[0056] As used herein, the singular terms “a,” “an,” and “the” include the plural reference unless the context clearly indicates otherwise.

[0057] It is intended that every maximum numerical limitation given throughout this specification includes every lower numerical limitation, as if such lower numerical limitations were expressly written herein. Every minimum numerical limitation given throughout this specification will include every higher numerical limitation, as if such higher numerical limitations were expressly written herein. Every numerical range given throughout this specification will include every narrower numerical range that falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein.

Recombinant Microorganisms capable of production of Isoprene, Isoprenoid precursors or Isoprenoids

[0058] The mevalonate-dependent biosynthetic pathway (MVA pathway) is a key metabolic pathway present in all higher eukaryotes and certain bacteria. In addition to being important for the production of molecules used in processes as diverse as protein prenylation, cell membrane maintenance, protein anchoring, and N-glycosylation, the mevalonate pathway provides a major source of the isoprenoid precursor molecules DMAPP and IPP, which serve as the basis for the biosynthesis of terpenes, terpenoids, isoprenoids, and isoprene.

[0059] As described herein, the upper portion of the MVA pathway utilizes acetyl Co-A and malonyl Co-A produced during cellular metabolism as the initial substrates for the production of mevalonate via the actions of polypeptides having acetoacetyl-CoA synthase, HMG-CoA reductase, and HMG-CoA synthase enzymatic activity. First, acetyl Co-A and malonyl Co-A are converted to acetoacetyl CoA via the action of an acetoacetyl-CoA synthase. Next, acetoacetyl CoA is converted to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) by the enzymatic action of HMG-CoA synthase. This Co-A derivative is reduced to mevalonate by HMG-CoA reductase, which is the rate-limiting step of the mevalonate pathway of isoprenoid production. Mevalonate is then converted into mevalonate-5-phosphate via the action of mevalonate kinase which is subsequently transformed into mevalonate-5-pyrophosphate by the enzymatic activity of phosphomevalonate kinase. Finally, IPP is formed from mevalonate-5-pyrophosphate by the activity of the enzyme mevalonate-5-pyrophosphate decarboxylase.

[0060] Thus, the recombinant microorganisms of the present invention are recombinant microorganisms having the ability to produce isoprene, isoprenoid precursors or isoprenoids wherein the recombinant microorganisms comprise by a gene encoding an enzyme

capable of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA (e.g., acetoacetyl-CoA synthase gene or *nphT7*) and a one or more of a group of genes involved in isoprene biosynthesis or isoprenoid biosynthesis that enables the synthesis of isoprene or isoprenoids from acetoacetyl-CoA in the host microorganism.

Acetoacetyl-CoA Synthase Gene

[0061] The acetoacetyl-CoA synthase gene (aka *nphT7*) is a gene encoding an enzyme having the activity of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA and having minimal activity (e.g., no activity) of synthesizing acetoacetyl-CoA from two acetyl-CoA molecules. *See, e.g.*, Okamura et al., *PNAS* Vol 107, No. 25, pp. 11265-11270 (2010), the contents of which are expressly incorporated herein for teaching about *nphT7*. An acetoacetyl-CoA synthase gene from an actinomycete of the genus *Streptomyces* CL190 strain was described in JP Patent Publication (Kokai) No. 2008-61506 A and US2010/0285549. Acetoacetyl-CoA synthase can also be referred to as acetyl CoA:malonyl CoA acyltransferase. A representative acetoacetyl-CoA synthase (or acetyl CoA:malonyl CoA acyltransferase) that can be used is Genbank AB540131.1.

[0062] In one embodiment, acetoacetyl-CoA synthase of the present invention synthesizes acetoacetyl-CoA from malonyl-CoA and acetyl-CoA via an irreversible reaction. The use of acetoacetyl-CoA synthase to generate acetyl-CoA provides an additional advantage in that this reaction is irreversible while acetoacetyl-CoA thiolase enzyme's action of synthesizing acetoacetyl-CoA from two acetyl-CoA molecules is reversible. Consequently, the use of acetoacetyl-CoA synthase to synthesize acetoacetyl-CoA from malonyl-CoA and acetyl-CoA can result in significant improvement in productivity for isoprene, isoprenoid precursors and/or isoprenoids, compared with using thiolase to generate the end same products.

[0063] Furthermore, the use of acetoacetyl-CoA synthase to produce isoprene, isoprenoid precursors and/or isoprenoids provides another advantage in that acetoacetyl-CoA synthase can convert malonyl CoA to acetyl CoA via decarboxylation of the malonyl CoA. Thus, the stores of starting substrate is not limited by the starting amounts of acetyl CoA. The synthesis of acetoacetyl-CoA by acetoacetyl-CoA synthase can still occur when the starting substrate is only malonyl-CoA. In one embodiment, the pool of starting malonyl-CoA is increased by using host strains that have more malonyl-CoA. Such increased

pools can be naturally occurring or be engineered by molecular manipulation. See, for example Fowler, et. al, *Applied and Environmental Microbiology*, Vol. 75, No. 18, pp. 5831-5839 (2009), Zha et al., *Metabolic Engineering*, 11: 192-198 (2009), Xu et al., *Metabolic Engineering*, (2011)doi:10.1016/j.ymben.2011.06.008, Okamura et al., *PNAS* 107: 11265-11270 (2010), and US 2010/0285549, the contents of which are expressly incorporated herein by reference in their entirety.

[0064] In any of the aspects or embodiments described herein, an enzyme that has the ability to synthesize acetoacetyl-CoA from malonyl-CoA and acetyl-CoA can be used. Non-limiting examples of such an enzyme are described herein. In certain embodiments described herein, an acetoacetyl-CoA synthase gene derived from an actinomycete of the genus *Streptomyces* having the activity of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA can be used.

[0065] An example of such an acetoacetyl-CoA synthase gene is the gene encoding a protein having the amino acid sequence of SEQ ID NO: 1. Such a protein having the amino acid sequence of SEQ ID NO: 1 corresponds to an acetoacetyl-CoA synthase having activity of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA and having no activity of synthesizing acetoacetyl-CoA from two acetyl-CoA molecules.

[0066] In one embodiment, the gene encoding a protein having the amino acid sequence of SEQ ID NO: 1 can be obtained by a nucleic acid amplification method (e.g., PCR) with the use of genomic DNA obtained from an actinomycete of the *Streptomyces* sp. CL190 strain as a template and a pair of primers that can be designed with reference to JP Patent Publication (Kokai) No. 2008-61506 A.

[0067] As described herein, an acetoacetyl-CoA synthase gene for use in the present invention is not limited to a gene encoding a protein having the amino acid sequence of SEQ ID NO: 1 from an actinomycete of the *Streptomyces* sp. CL190 strain. Any gene encoding a protein having the ability to synthesize acetoacetyl-CoA from malonyl-CoA and acetyl-CoA and which does not synthesize acetoacetyl-CoA from two acetyl-CoA molecules can be used in the presently described methods. In certain embodiments, the acetoacetyl-CoA synthase gene can be a gene encoding a protein having an amino acid sequence with high similarity or substantially identical to the amino acid sequence of SEQ ID NO: 1 and having the

function of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA. The expression “highly similar” or “substantially identical” refers to, for example, at least about 80% identity, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, and at least about 99% identity. As used above, the identity value corresponds to the percentage of identity between amino acid residues in a different amino acid sequence and the amino acid sequence of SEQ ID NO: 1, which is calculated by performing alignment of the amino acid sequence of SEQ ID NO: 1 and the different amino acid sequence with the use of a program for searching for a sequence similarity.

[0068] In other embodiments, the acetoacetyl-CoA synthase gene may be a gene encoding a protein having an amino acid sequence derived from the amino acid sequence of SEQ ID NO: 1 by substitution, deletion, addition, or insertion of 1 or more amino acid(s) and having the function of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA. Herein, the expression “more amino acids” refers to, for example, 2 to 30 amino acids, preferably 2 to 20 amino acids, more preferably 2 to 10 amino acids, and most preferably 2 to 5 amino acids.

[0069] In still other embodiments, the acetoacetyl-CoA synthase gene may consist of a polynucleotide capable of hybridizing to a portion or the entirety of a polynucleotide having a nucleotide sequence complementary to the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 1 under stringent conditions and capable of encoding a protein having the function of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA. Herein, hybridization under stringent conditions corresponds to maintenance of binding under conditions of washing at 60.degree. C. 2.times.SSC. Hybridization can be carried out by conventionally known methods such as the method described in J. Sambrook et al. Molecular Cloning, A Laboratory Manual, 3rd Ed., Cold Spring Harbor Laboratory (2001).

[0070] As described herein, a gene encoding an acetoacetyl-CoA synthase having an amino acid sequence that differs from the amino acid sequence of SEQ ID NO: 1 can be isolated from potentially any organism, for example, an actinomycete that is not obtained from the Streptomyces sp. CL190 strain. In addition, acetoacetyl-CoA synthase genes for use herein can be obtained by modifying a polynucleotide encoding the amino acid sequence of SEQ ID NO: 1 by a method known in the art. Mutagenesis of a nucleotide sequence can be carried out

by a known method such as the Kunkel method or the gapped duplex method or by a method similar to either thereof. For instance, mutagenesis may be carried out with the use of a mutagenesis kit (e.g., product names; Mutant-K and Mutant-G (TAKARA Bio)) for site-specific mutagenesis, product name; an LA PCR in vitro Mutagenesis series kit (TAKARA Bio), and the like.

[0071] The activity of an acetoacetyl-CoA synthase having an amino acid sequence that differs from the amino acid sequence of SEQ ID NO: 1 can be evaluated as described below. Specifically, a gene encoding a protein to be evaluated is first introduced into a host cell such that the gene can be expressed therein, followed by purification of the protein by a technique such as chromatography. Malonyl-CoA and acetyl-CoA are added as substrates to a buffer containing the obtained protein to be evaluated, followed by, for example, incubation at a desired temperature (e.g., 10°C to 60°C). After the completion of reaction, the amount of substrate lost and/or the amount of product (acetoacetyl-CoA) produced are determined. Thus, it is possible to evaluate whether or not the protein being tested has the function of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA and to evaluate the degree of synthesis. In such case, it is possible to examine whether or not the protein has the activity of synthesizing acetoacetyl-CoA from two acetyl-CoA molecules by adding acetyl-CoA alone as a substrate to a buffer containing the obtained protein to be evaluated and determining the amount of substrate lost and/or the amount of product produced in a similar manner.

MVA Pathway Nucleic Acids and Polypeptides

[0072] Exemplary MVA pathway polypeptides that can be used in conjunction with acetoacetyl-CoA synthase include, but are not limited to: 3-hydroxy-3-methylglutaryl-CoA synthase (HMG-CoA synthase) polypeptides (e.g., an enzyme encoded by *mvaS*), 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase) polypeptides (e.g., enzyme encoded by *mvaR* or enzyme encoded by *mvaE* that has been modified to be thiolase-deficient but still retains its reductase activity), mevalonate kinase (MVK) polypeptides, phosphomevalonate kinase (PMK) polypeptides, diphosphomevalonate decarboxylase (MVD) polypeptides, phosphomevalonate decarboxylase (PMDC) polypeptides, isopentenyl phosphate kinase (IPK) polypeptides, IPP isomerase polypeptides, IDI polypeptides, and polypeptides (e.g., fusion polypeptides) having an activity of two or more MVA pathway polypeptides. In particular, MVA pathway polypeptides include polypeptides, fragments of polypeptides,

peptides, and fusions polypeptides that have at least one activity of an MVA pathway polypeptide. Exemplary MVA pathway nucleic acids include nucleic acids that encode a polypeptide, fragment of a polypeptide, peptide, or fusion polypeptide that has at least one activity of an MVA pathway polypeptide. Exemplary MVA pathway polypeptides and nucleic acids include naturally-occurring polypeptides and nucleic acids from any of the source organisms described herein. In addition, variants of MVA pathway polypeptide that confer the result of better isoprene production can also be used as well.

[0073] Non-limiting examples of MVA pathway polypeptides which can be used are described in International Patent Application Publication No. WO2009/076676; WO2010/003007 and WO2010/148150, the contents of which are expressing incorporated by reference herein.

Exemplary 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase) polypeptides and nucleic acids

[0074] Enzymes that catalyze the reaction that convert HMG-CoA to mevalonate polypeptides can be used, for example, 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase). Another example is an enzyme that is coded by *mvaE* that has been modified to be thiolase-deficient but still retains its reductase activity. It has been reported that *mvaE* gene encodes a polypeptide that possesses both thiolase and HMG-CoA reductase activities. The thiolase activity of the polypeptide encoded by the *mvaE* gene converts acetyl Co-A to acetoacetyl CoA whereas the HMG-CoA reductase enzymatic activity of the polypeptide converts 3-hydroxy-3-methylglutaryl-CoA to mevalonate. Exemplary *mvaE* polypeptides and nucleic acids that can be used for this invention include naturally-occurring or modified polypeptides and nucleic acids from any of the source organisms described herein that do not have thiolase activity but have HMG-CoA reductase activity.

[0075] Modified *mvaE* polypeptides include those in which one or more amino acid residues have undergone an amino acid substitution while retaining HMG-CoA reductase activity while having minimal or no thiolase activity. The amino acid substitutions can be conservative or non-conservative and such substituted amino acid residues can or can not be one encoded by the genetic code. The standard twenty amino acid “alphabet” has been divided into chemical families based on similarity of their side chains. Those families include

amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a chemically similar side chain (*i.e.*, replacing an amino acid having a basic side chain with another amino acid having a basic side chain). A “non-conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a chemically different side chain (*i.e.*, replacing an amino acid having a basic side chain with another amino acid having an aromatic side chain).

[0076] Amino acid substitutions in the *mvaE* polypeptide can be introduced to improve the functionality of the molecule. For example, amino acid substitutions improve its ability to convert 3-hydroxy-3-methylglutaryl-CoA to mevalonate can be introduced into the thiolase-deficient *mvaE* polypeptide. In some aspects, the thiolase-deficient *mvaE* polypeptides contain one or more conservative amino acid substitutions.

[0077] In one aspect, thiolase-deficient *mvaE* proteins that are not degraded or less prone to degradation can be used for the production of mevalonate, isoprene, isoprenoid precursors, and/or isoprenoids. Examples of gene products of *mvaEs* that are not degraded or less prone to degradation which can be used include, but are not limited to, those from the organisms *E. faecium*, *E. gallinarum*, *E. casseliflavus*, *E. faecalis*, and *L. grayi*. One of skill in the art can express *mvaE* protein in *E. coli* BL21 (DE3) and look for absence of fragments by any standard molecular biology techniques. For example, absence of fragments can be identified on Safestain stained SDS-PAGE gels following His-tag mediated purification or when expressed in mevalonate, isoprene or isoprenoid producing *E. coli* BL21 using the methods of detection described herein.

[0078] Standard methods, such as those described in Hedl et al., (*J Bacteriol.* 2002, April; 184(8): 2116–2122) can be used to determine whether a polypeptide has thiolase-deficient, HMG CoA reductase-proficient *mvaE* activity, by measuring the absence of acetoacetyl-CoA thiolase and/or the presence of HMG-CoA reductase activity. In an exemplary assay, acetoacetyl-CoA thiolase activity is measured by spectrophotometer to monitor the

change in absorbance at 302 nm that accompanies the formation or thiolysis of acetoacetyl-CoA. Standard assay conditions for each reaction to determine synthesis of acetoacetyl-CoA, are 1 mM acetyl-CoA, 10 mM MgCl₂, 50 mM Tris, pH 10.5 and the reaction is initiated by addition of enzyme. Assays can employ a final volume of 200 µl. For the assay, 1 enzyme unit (eu) represents the synthesis or thiolysis in 1 min of 1 µmol of acetoacetyl-CoA. In another exemplary assay, of HMG-CoA reductase activity can be monitored by spectrophotometer by the appearance or disappearance of NADP(H) at 340 nm. Standard assay conditions for each reaction measured to show reductive deacylation of HMG-CoA to mevalonate are 0.4 mM NADPH, 1.0 mM (*R,S*)-HMG-CoA, 100 mM KCl, and 100 mM K_xPO₄, pH 6.5. Assays employ a final volume of 200 µl. Reactions are initiated by adding the enzyme. For the assay, 1 eu represents the turnover, in 1 min, of 1 µmol of NADP(H). This corresponds to the turnover of 0.5 µmol of HMG-CoA or mevalonate.

[0079] Alternatively, production of mevalonate in host cells can be measured by, without limitation, gas chromatography (see U.S. Patent Application Publication No.: US 2005/0287655 A1) or HPLC (See U.S. Patent Application No.: 12/978,324). As an exemplary assay, cultures can be inoculated in shake tubes containing LB broth supplemented with one or more antibiotics and incubated for 14h at 34°C at 250 rpm. Next, cultures can be diluted into well plates containing TM3 media supplemented with 1% Glucose, 0.1% yeast extract, and 200 µM IPTG to final OD of 0.2. The plate are then sealed with a Breath Easier membrane (Diversified Biotech) and incubated at 34°C in a shaker/incubator at 600 rpm for 24 hours. 1 mL of each culture is then centrifuged at 3,000 x g for 5 min. Supernatant is then added to 20% sulfuric acid and incubated on ice for 5 min. The mixture is then centrifuged for 5 min at 3000 x g and the supernatant was collected for HPLC analysis. The concentration of mevalonate in samples is determined by comparison to a standard curve of mevalonate (Sigma). The glucose concentration can additionally be measured by performing a glucose oxidase assay according to any method known in the art. Using HPLC, levels of mevalonate can be quantified by comparing the refractive index response of each sample versus a calibration curve generated by running various mevalonate containing solutions of known concentration.

[0080] HMG-CoA reductase can be expressed in a host cell on a multicopy plasmid. The plasmid can be a high copy plasmid, a low copy plasmid, or a medium copy plasmid. Alternatively, HMG-CoA reductase can be integrated into the host cell's chromosome.

For both heterologous expression of HMG-CoA reductase on a plasmid or as an integrated part of the host cell's chromosome, expression of the nucleic acid can be driven by either an inducible promoter or a constitutively expressing promoter. The promoter can be a strong driver of expression, it can be a weak driver of expression, or it can be a medium driver of expression of the HMG-CoA reductase.

Exemplary HMG-CoA Synthase polypeptides and nucleic acids

[0081] Enzymes that catalyze the conversion of acetoacetyl-CoA to HMG-CoA (e.g., HMG-CoA synthase or HMGS) can be used. In one embodiment, the polypeptide encoded by *mvaS* gene can be used. The *mvaS* gene encodes a polypeptide that possesses HMG-CoA synthase activity. This polypeptide can convert acetoacetyl CoA to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). Exemplary *mvaS* polypeptides and nucleic acids include naturally-occurring polypeptides and nucleic acids from any of the source organisms described herein as well as mutant polypeptides and nucleic acids derived from any of the source organisms described herein that have at least one activity of a *mvaS* polypeptide.

[0082] Mutant *mvaS* polypeptides include those in which one or more amino acid residues have undergone an amino acid substitution while retaining *mvaS* polypeptide activity (*i.e.*, the ability to convert acetoacetyl CoA to 3-hydroxy-3-methylglutaryl-CoA). Amino acid substitutions in the *mvaS* polypeptide can be introduced to improve the functionality of the molecule. For example, amino acid substitutions that increase the binding affinity of the *mvaS* polypeptide for its substrate, or that improve its ability to convert acetoacetyl CoA to 3-hydroxy-3-methylglutaryl-CoA can be introduced into the *mvaS* polypeptide. In some aspects, the mutant *mvaS* polypeptides contain one or more conservative amino acid substitutions.

[0083] Standard methods, such as those described in Quant et al. (*Biochem J.*, 1989, 262:159-164), can be used to determine whether a polypeptide has *mvaS* activity, by measuring HMG-CoA synthase activity. In an exemplary assay, HMG-CoA synthase activity can be assayed by spectrophotometrically measuring the disappearance of the enol form of acetoacetyl-CoA by monitoring the change of absorbance at 303 nm. A standard 1 ml assay system containing 50 mM-Tris/HCl, pH 8.0, 10 mM-MgCl₂ and 0.2 mM-dithiothreitol at 30 °C; 5 mM-acetyl phosphate, 10, M-acetoacetyl- CoA and 5 u1 samples of extracts can be added,

followed by simultaneous addition of acetyl-CoA (100 μ M) and 10 units of PTA. HMG-CoA synthase activity is then measured as the difference in the rate before and after acetyl-CoA addition. The absorption coefficient of acetoacetyl-CoA under the conditions used (pH 8.0, 10 mM-MgCl₂), is $12.2 \times 10^3 \text{ M}^{-1} \text{ cm}^{-1}$. By definition, 1 unit of enzyme activity causes 1 μ mol of acetoacetyl-CoA to be transformed per minute.

[0084] Alternatively, production of mevalonate in host cells can be measured by, without limitation, gas chromatography (see U.S. Patent Application Publication No.: US 2005/0287655 A1) or HPLC (See U.S. Patent Application No.: 12/978,324). As an exemplary assay, cultures can be inoculated in shake tubes containing LB broth supplemented with one or more antibiotics and incubated for 14h at 34°C at 250 rpm. Next, cultures can be diluted into well plates containing TM3 media supplemented with 1% Glucose, 0.1% yeast extract, and 200 μ M IPTG to final OD of 0.2. The plate are then sealed with a Breath Easier membrane (Diversified Biotech) and incubated at 34°C in a shaker/incubator at 600 rpm for 24 hours. 1 mL of each culture is then centrifuged at 3,000 x g for 5 min. Supernatant is then added to 20% sulfuric acid and incubated on ice for 5 min. The mixture is then centrifuged for 5 min at 3000 x g and the supernatant was collected for HPLC analysis. The concentration of mevalonate in samples is determined by comparison to a standard curve of mevalonate (Sigma). The glucose concentration can additionally be measured by performing a glucose oxidase assay according to any method known in the art. Using HPLC, levels of mevalonate can be quantified by comparing the refractive index response of each sample versus a calibration curve generated by running various mevalonate containing solutions of known concentration.

[0085] The mvaS nucleic acid can be expressed in a host cell on a multicopy plasmid. The plasmid can be a high copy plasmid, a low copy plasmid, or a medium copy plasmid. Alternatively, the mvaS nucleic acid can be integrated into the host cell's chromosome. For both heterologous expression of an mvaS nucleic acid on a plasmid or as an integrated part of the host cell's chromosome, expression of the nucleic acid can be driven by either an inducible promoter or a constitutively expressing promoter. The promoter can be a strong driver of expression, it can be a weak driver of expression, or it can be a medium driver of expression of the mvaS nucleic acid.

Nucleic acids encoding polypeptides of the lower MVA pathway

[0086] In some aspects of the invention, the cells described in any of the compositions or methods described herein further comprise one or more nucleic acids encoding a lower mevalonate (MVA) pathway polypeptide(s). In some aspects, the lower MVA pathway polypeptide is an endogenous polypeptide. In some aspects, the endogenous nucleic acid encoding a lower MVA pathway polypeptide is operably linked to a constitutive promoter. In some aspects, the endogenous nucleic acid encoding a lower MVA pathway polypeptide is operably linked to an inducible promoter. In some aspects, the endogenous nucleic acid encoding a lower MVA pathway polypeptide is operably linked to a strong promoter. In a particular aspect, the cells are engineered to over-express the endogenous lower MVA pathway polypeptide relative to wild-type cells. In some aspects, the endogenous nucleic acid encoding a lower MVA pathway polypeptide is operably linked to a weak promoter.

[0087] The lower mevalonate biosynthetic pathway comprises mevalonate kinase (MVK), phosphomevalonate kinase (PMK), and diphosphomevalonate decarboxylase (MVD). In some aspects, the lower MVA pathway can further comprise isopentenyl diphosphate isomerase (IDI). Cells provided herein can comprise at least one nucleic acid encoding isoprene synthase, one or more upper MVA pathway polypeptides, and/or one or more lower MVA pathway polypeptides. Polypeptides of the lower MVA pathway can be any enzyme (a) that phosphorylates mevalonate to mevalonate 5-phosphate; (b) that converts mevalonate 5-phosphate to mevalonate 5-pyrophosphate; and (c) that converts mevalonate 5-pyrophosphate to isopentenyl pyrophosphate. More particularly, the enzyme that phosphorylates mevalonate to mevalonate 5-phosphate can be from the group consisting of *M. mazei* mevalonate kinase, *Lactobacillus* mevalonate kinase polypeptide, *Lactobacillus sakei* mevalonate kinase polypeptide, yeast mevalonate kinase polypeptide, *Saccharomyces cerevisiae* mevalonate kinase polypeptide, *Streptococcus* mevalonate kinase polypeptide, *Streptococcus pneumoniae* mevalonate kinase polypeptide, *Streptomyces* mevalonate kinase polypeptide, *Streptomyces CL190* mevalonate kinase polypeptide, and *M. Burtonii* mevalonate kinase polypeptide. In another aspect, the enzyme that phosphorylates mevalonate to mevalonate 5-phosphate is *M. mazei* mevalonate kinase.

[0088] In some aspects, the lower MVA pathway polypeptide is a heterologous polypeptide. In some aspects, the cells comprise more than one copy of a

heterologous nucleic acid encoding a lower MVA pathway polypeptide. In some aspects, the heterologous nucleic acid encoding a lower MVA pathway polypeptide is operably linked to a constitutive promoter. In some aspects, the heterologous nucleic acid encoding a lower MVA pathway polypeptide is operably linked to an inducible promoter. In some aspects, the heterologous nucleic acid encoding a lower MVA pathway polypeptide is operably linked to a strong promoter. In some aspects, the heterologous nucleic acid encoding a lower MVA pathway polypeptide is operably linked to a weak promoter. In some aspects, the heterologous lower MVA pathway polypeptide is a polypeptide from *Saccharomyces cerevisiae*, *Enterococcus faecalis*, or *Methanosarcina mazei*.

[0089] The nucleic acids encoding a lower MVA pathway polypeptide(s) can be integrated into a genome of the cells or can be stably expressed in the cells. The nucleic acids encoding a lower MVA pathway polypeptide(s) can additionally be on a vector.

[0090] Exemplary lower MVA pathway polypeptides are also provided below: (i) mevalonate kinase (MVK); (ii) phosphomevalonate kinase (PMK); (iii) diphosphomevalonate decarboxylase (MVD); and (iv) isopentenyl diphosphate isomerase (IDI). In particular, the lower MVK polypeptide can be from the genus *Methanosarcina* and, more specifically, the lower MVK polypeptide can be from *Methanosarcina mazei*. Additional examples of lower MVA pathway polypeptides can be found in U.S. Patent Application Publication 2010/0086978 the contents of which are expressly incorporated herein by reference in their entirety with respect to lower MVK pathway polypeptides and lower MVK pathway polypeptide variants.

[0091] Any one of the cells described herein can comprise IDI nucleic acid(s) (*e.g.*, endogenous or heterologous nucleic acid(s) encoding IDI). Isopentenyl diphosphate isomerase polypeptides (isopentenyl-diphosphate delta-isomerase or IDI) catalyzes the interconversion of isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP) (*e.g.*, converting IPP into DMAPP and/or converting DMAPP into IPP). Exemplary IDI polypeptides include polypeptides, fragments of polypeptides, peptides, and fusions polypeptides that have at least one activity of an IDI polypeptide. Standard methods (such as those described herein) can be used to determine whether a polypeptide has IDI polypeptide activity by measuring the ability of the polypeptide to interconvert IPP and DMAPP *in vitro*, in a cell extract, or *in vivo*. Exemplary IDI nucleic acids include nucleic acids that encode a polypeptide, fragment of a

polypeptide, peptide, or fusion polypeptide that has at least one activity of an IDI polypeptide. Exemplary IDI polypeptides and nucleic acids include naturally-occurring polypeptides and nucleic acids from any of the source organisms described herein as well as mutant polypeptides and nucleic acids derived from any of the source organisms described herein.

[0092] Lower MVA pathway polypeptides include polypeptides, fragments of polypeptides, peptides, and fusions polypeptides that have at least one activity of a lower MVA pathway polypeptide. Exemplary lower MVA pathway nucleic acids include nucleic acids that encode a polypeptide, fragment of a polypeptide, peptide, or fusion polypeptide that has at least one activity of a lower MVA pathway polypeptide. Exemplary lower MVA pathway polypeptides and nucleic acids include naturally-occurring polypeptides and nucleic acids from any of the source organisms described herein. In addition, variants of lower MVA pathway polypeptides that confer the result of better isoprene production can also be used as well.

[0093] In some aspects, the lower MVA pathway polypeptide is a polypeptide from *Saccharomyces cerevisiae*, *Enterococcus faecalis*, or *Methanosarcina mazei*. In some aspects, the MVK polypeptide is selected from the group consisting of *Lactobacillus* mevalonate kinase polypeptide, *Lactobacillus sakei* mevalonate kinase polypeptide, yeast mevalonate kinase polypeptide, *Saccharomyces cerevisiae* mevalonate kinase polypeptide, *Streptococcus* mevalonate kinase polypeptide, *Streptococcus pneumoniae* mevalonate kinase polypeptide, *Streptomyces* mevalonate kinase polypeptide, *Streptomyces* CL190 mevalonate kinase polypeptide, and *Methanosarcina mazei* mevalonate kinase polypeptide. Any one of the promoters described herein (e.g., promoters described herein and identified in the Examples of the present disclosure including inducible promoters and constitutive promoters) can be used to drive expression of any of the MVA polypeptides described herein.

Isoprene synthase – nucleic acids and polypeptides

[0094] In some aspects of the invention, the recombinant cells described in any of the compositions or methods described herein further comprise one or more nucleic acids encoding an isoprene synthase polypeptide or a polypeptide having isoprene synthase activity. In some aspects, the isoprene synthase polypeptide is an endogenous polypeptide. In some aspects, the endogenous nucleic acid encoding an isoprene synthase polypeptide is operably linked to a constitutive promoter. In some aspects, the endogenous nucleic acid encoding an

isoprene synthase polypeptide is operably linked to an inducible promoter. In some aspects, the endogenous nucleic acid encoding an isoprene synthase polypeptide is operably linked to a strong promoter. In some aspects, more than one endogenous nucleic acid encoding an isoprene synthase polypeptide is used (e.g, 2, 3, 4, or more copies of an endogenous nucleic acid encoding an isoprene synthase polypeptide). In a particular aspect, the cells are engineered to overexpress the endogenous isoprene synthase pathway polypeptide relative to wild-type cells. In some aspects, the endogenous nucleic acid encoding an isoprene synthase polypeptide is operably linked to a weak promoter. In some aspects, the isoprene synthase polypeptide is a polypeptide from *Pueraria* or *Populus* or a hybrid such as *Populus alba* x *Populus tremula*.

[0095] In some aspects, the isoprene synthase polypeptide is a heterologous polypeptide. In some aspects, the cells comprise more than one copy of a heterologous nucleic acid encoding an isoprene synthase polypeptide. In some aspects, the heterologous nucleic acid encoding an isoprene synthase polypeptide is operably linked to a constitutive promoter. In some aspects, the heterologous nucleic acid encoding an isoprene synthase polypeptide is operably linked to an inducible promoter. In some aspects, the heterologous nucleic acid encoding an isoprene synthase polypeptide is operably linked to a strong promoter. In some aspects, the heterologous nucleic acid encoding an isoprene synthase polypeptide is operably linked to a weak promoter.

[0096] The nucleic acids encoding an isoprene synthase polypeptide(s) can be integrated into a genome of the host cells or can be stably expressed in the cells. The nucleic acids encoding an isoprene synthase polypeptide(s) can additionally be on a vector.

[0097] Exemplary isoprene synthase nucleic acids include nucleic acids that encode a polypeptide, fragment of a polypeptide, peptide, or fusion polypeptide that has at least one activity of an isoprene synthase polypeptide. Isoprene synthase polypeptides convert dimethylallyl diphosphate (DMAPP) into isoprene. Exemplary isoprene synthase polypeptides include polypeptides, fragments of polypeptides, peptides, and fusions polypeptides that have at least one activity of an isoprene synthase polypeptide. Exemplary isoprene synthase polypeptides and nucleic acids include naturally-occurring polypeptides and nucleic acids from any of the source organisms described herein. In addition, variants of isoprene synthase can possess improved activity such as improved enzymatic activity. In some aspects, an isoprene

synthase variant has other improved properties, such as improved stability (*e.g.*, thermo-stability), and/or improved solubility.

[0098] Standard methods can be used to determine whether a polypeptide has isoprene synthase polypeptide activity by measuring the ability of the polypeptide to convert DMAPP into isoprene *in vitro*, in a cell extract, or *in vivo*. Isoprene synthase polypeptide activity in the cell extract can be measured, for example, as described in Silver *et al.*, *J. Biol. Chem.* 270:13010-13016, 1995. In one exemplary assay, DMAPP (Sigma) can be evaporated to dryness under a stream of nitrogen and rehydrated to a concentration of 100 mM in 100 mM potassium phosphate buffer pH 8.2 and stored at -20 °C. To perform the assay, a solution of 5 µL of 1M MgCl₂, 1 mM (250 µg/ml) DMAPP, 65 µL of Plant Extract Buffer (PEB) (50 mM Tris-HCl, pH 8.0, 20 mM MgCl₂, 5% glycerol, and 2 mM DTT) can be added to 25 µL of cell extract in a 20 ml Headspace vial with a metal screw cap and teflon coated silicon septum (Agilent Technologies) and cultured at 37°C for 15 minutes with shaking. The reaction can be quenched by adding 200 µL of 250 mM EDTA and quantified by GC/MS.

[0099] In some aspects, the isoprene synthase polypeptide is a plant isoprene synthase polypeptide or a variant thereof. In some aspects, the isoprene synthase polypeptide is an isoprene synthase from *Pueraria* or a variant thereof. In some aspects, the isoprene synthase polypeptide is an isoprene synthase from *Populus* or a variant thereof. In some aspects, the isoprene synthase polypeptide is a poplar isoprene synthase polypeptide or a variant thereof. In some aspects, the isoprene synthase polypeptide is a kudzu isoprene synthase polypeptide or a variant thereof. In some aspects, the isoprene synthase polypeptide is a polypeptide from *Pueraria* or *Populus* or a hybrid, *Populus alba* x *Populus tremula*, or a variant thereof.

[0100] In some aspects, the isoprene synthase polypeptide or nucleic acid is from the family Fabaceae, such as the Faboideae subfamily. In some aspects, the isoprene synthase polypeptide or nucleic acid is a polypeptide or nucleic acid from *Pueraria montana* (kudzu) (Sharkey *et al.*, *Plant Physiology* 137: 700-712, 2005), *Pueraria lobata*, poplar (such as *Populus alba*, *Populus nigra*, *Populus trichocarpa*, or *Populus alba* x *tremula* (CAC35696) (Miller *et al.*, *Planta* 213: 483-487, 2001), aspen (such as *Populus tremuloides*) (Silver *et al.*, *JBC* 270(22): 13010-1316, 1995), English Oak (*Quercus robur*) (Zimmer *et al.*, WO 98/02550), or a variant thereof. In

some aspects, the isoprene synthase polypeptide is an isoprene synthase from *Pueraria montana*, *Pueraria lobata*, *Populus tremuloides*, *Populus alba*, *Populus nigra*, or *Populus trichocarpa* or a variant thereof. In some aspects, the isoprene synthase polypeptide is an isoprene synthase from *Populus alba* or a variant thereof. In some aspects, the nucleic acid encoding the isoprene synthase (e.g., isoprene synthase from *Populus alba* or a variant thereof) is codon optimized.

[0101] In some aspects, the isoprene synthase nucleic acid or polypeptide is a naturally-occurring polypeptide or nucleic acid (e.g., naturally-occurring polypeptide or nucleic acid from *Populus*). In some aspects, the isoprene synthase nucleic acid or polypeptide is not a wild-type or naturally-occurring polypeptide or nucleic acid. In some aspects, the isoprene synthase nucleic acid or polypeptide is a variant of a wild-type or naturally-occurring polypeptide or nucleic acid (e.g., a variant of a wild-type or naturally-occurring polypeptide or nucleic acid from *Populus*).

[0102] In some aspects, the isoprene synthase polypeptide is a variant. In some aspects, the isoprene synthase polypeptide is a variant of a wild-type or naturally occurring isoprene synthase. In some aspects, the variant has improved activity such as improved catalytic activity compared to the wild-type or naturally occurring isoprene synthase. The increase in activity (e.g., catalytic activity) can be at least about any of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%. In some aspects, the increase in activity such as catalytic activity is at least about any of 1 fold, 2 folds, 5 folds, 10 folds, 20 folds, 30 folds, 40 folds, 50 folds, 75 folds, or 100 folds. In some aspects, the increase in activity such as catalytic activity is about 10% to about 100 folds (e.g., about 20% to about 100 folds, about 50% to about 50 folds, about 1 fold to about 25 folds, about 2 folds to about 20 folds, or about 5 folds to about 20 folds). In some aspects, the variant has improved solubility compared to the wild-type or naturally occurring isoprene synthase. The increase in solubility can be at least about any of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%. The increase in solubility can be at least about any of 1 fold, 2 folds, 5 folds, 10 folds, 20 folds, 30 folds, 40 folds, 50 folds, 75 folds, or 100 folds. In some aspects, the increase in solubility is about 10% to about 100 folds (e.g., about 20% to about 100 folds, about 50% to about 50 folds, about 1 fold to about 25 folds, about 2 folds to about 20 folds, or about 5 folds to about 20 folds). In some aspects, the isoprene synthase polypeptide is a variant of naturally occurring isoprene synthase and has improved stability (such as thermo-stability) compared to the naturally occurring isoprene synthase.

[0103] In some aspects, the variant has at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 110%, at least about 120%, at least about 130%, at least about 140%, at least about 150%, at least about 160%, at least about 170%, at least about 180%, at least about 190%, at least about 200% of the activity of a wild-type or naturally occurring isoprene synthase. The variant can share sequence similarity with a wild-type or naturally occurring isoprene synthase. In some aspects, a variant of a wild-type or naturally occurring isoprene synthase can have at least about any of 40%, 50%, 60%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% amino acid sequence identity as that of the wild-type or naturally occurring isoprene synthase. In some aspects, a variant of a wild-type or naturally occurring isoprene synthase has any of about 70% to about 99.9%, about 75% to about 99%, about 80% to about 98%, about 85% to about 97%, or about 90% to about 95% amino acid sequence identity as that of the wild-type or naturally occurring isoprene synthase.

[0104] In some aspects, the variant comprises a mutation in the wild-type or naturally occurring isoprene synthase. In some aspects, the variant has at least one amino acid substitution, at least one amino acid insertion, and/or at least one amino acid deletion. In some aspects, the variant has at least one amino acid substitution. In some aspects, the number of differing amino acid residues between the variant and wild-type or naturally occurring isoprene synthase can be one or more, *e.g.* 1, 2, 3, 4, 5, 10, 15, 20, 30, 40, 50, or more amino acid residues. Naturally occurring isoprene synthases can include any isoprene synthases from plants, for example, kudzu isoprene synthases, poplar isoprene synthases, English oak isoprene synthases, and willow isoprene synthases. In some aspects, the variant is a variant of isoprene synthase from *Populus alba*. In some aspects, the variant of isoprene synthase from *Populus alba* has at least one amino acid substitution, at least one amino acid insertion, and/or at least one amino acid deletion. In some aspects, the variant is a truncated *Populus alba* isoprene synthase. In some aspects, the nucleic acid encoding variant (*e.g.*, variant of isoprene synthase from *Populus alba*) is codon optimized (for example, codon optimized based on host cells where the heterologous isoprene synthase is expressed).

[0105] The isoprene synthase polypeptide provided herein can be any of the isoprene synthases or isoprene synthase variants described in WO 2009/132220, WO 2010/124146, WO

2012/058494, and U.S. Patent Application Publication No.: 2010/0086978, the contents of which are expressly incorporated herein by reference in their entirety with respect to the isoprene synthases and isoprene synthase variants.

[0106] Any one of the promoters described herein (*e.g.*, promoters described herein and identified in the Examples of the present disclosure including inducible promoters and constitutive promoters) can be used to drive expression of any of the isoprene synthases described herein.

[0107] Suitable isoprene synthases include, but are not limited to, those identified by Genbank Accession Nos. AY341431, AY316691, AY279379, AJ457070, and AY182241. Types of isoprene synthases which can be used in any one of the compositions or methods including methods of making microorganisms encoding isoprene synthase described herein are also described in International Patent Application Publication Nos. WO2009/076676, WO2010/003007, WO2009/132220, WO2010/031062, WO2010/031068, WO2010/031076, WO2010/013077, WO2010/031079, WO2010/148150, WO2010/124146, WO2010/078457, WO2010/148256 and WO 2012/058494, the contents of which are expressly incorporated herein by reference in their entirety with respect to the isoprene synthases and isoprene synthase variants.

Nucleic acids encoding DXP pathway polypeptides

[0108] In some aspects of the invention, the recombinant cells described in any of the compositions or methods described herein further comprise one or more heterologous nucleic acids encoding a DXS polypeptide or other DXP pathway polypeptides. In some aspects, the cells further comprise a chromosomal copy of an endogenous nucleic acid encoding a DXS polypeptide or other DXP pathway polypeptides. In some aspects, the *E. coli* cells further comprise one or more nucleic acids encoding an IDI polypeptide and a DXS polypeptide or other DXP pathway polypeptides. In some aspects, one nucleic acid encodes the isoprene synthase polypeptide, IDI polypeptide, and DXS polypeptide or other DXP pathway polypeptides. In some aspects, one plasmid encodes the isoprene synthase polypeptide, IDI polypeptide, and DXS polypeptide or other DXP pathway polypeptides. In some aspects, multiple plasmids encode the isoprene synthase polypeptide, IDI polypeptide, and DXS polypeptide or other DXP pathway polypeptides.

[0109] Exemplary DXS polypeptides include polypeptides, fragments of polypeptides, peptides, and fusions polypeptides that have at least one activity of a DXS polypeptide. Standard methods (such as those described herein) can be used to determine whether a polypeptide has DXS polypeptide activity by measuring the ability of the polypeptide to convert pyruvate and D-glyceraldehyde-3-phosphate into 1-deoxy-D-xylulose-5-phosphate *in vitro*, in a cell extract, or *in vivo*. Exemplary DXS polypeptides and nucleic acids and methods of measuring DXS activity are described in more detail in International Publication No. WO 2009/076676, U.S. Patent Application No. 12/335,071 (US Publ. No. 2009/0203102), WO 2010/003007, US Publ. No. 2010/0048964, WO 2009/132220, and US Publ. No. 2010/0003716.

[0110] Exemplary DXP pathway polypeptides include, but are not limited to any of the following polypeptides: DXS polypeptides, DXR polypeptides, MCT polypeptides, CMK polypeptides, MCS polypeptides, HDS polypeptides, HDR polypeptides, and polypeptides (*e.g.*, fusion polypeptides) having an activity of one, two, or more of the DXP pathway polypeptides. In particular, DXP pathway polypeptides include polypeptides, fragments of polypeptides, peptides, and fusions polypeptides that have at least one activity of a DXP pathway polypeptide. Exemplary DXP pathway nucleic acids include nucleic acids that encode a polypeptide, fragment of a polypeptide, peptide, or fusion polypeptide that has at least one activity of a DXP pathway polypeptide. Exemplary DXP pathway polypeptides and nucleic acids include naturally-occurring polypeptides and nucleic acids from any of the source organisms described herein as well as mutant polypeptides and nucleic acids derived from any of the source organisms described herein. Exemplary DXP pathway polypeptides and nucleic acids and methods of measuring DXP pathway polypeptide activity are described in more detail in International Publication No.: WO 2010/148150

[0111] Exemplary DXS polypeptides include polypeptides, fragments of polypeptides, peptides, and fusions polypeptides that have at least one activity of a DXS polypeptide. Standard methods (such as those described herein) can be used to determine whether a polypeptide has DXS polypeptide activity by measuring the ability of the polypeptide to convert pyruvate and D-glyceraldehyde-3-phosphate into 1-deoxy-D-xylulose-5-phosphate *in vitro*, in a cell extract, or *in vivo*. Exemplary DXS polypeptides and nucleic acids and methods of measuring DXS activity are described in more detail in International Publication No. WO 2009/076676, U.S. Patent

Application No. 12/335,071 (US Publ. No. 2009/0203102), WO 2010/003007, US Publ. No. 2010/0048964, WO 2009/132220, and US Publ. No. 2010/0003716.

[0112] In particular, DXS polypeptides convert pyruvate and D-glyceraldehyde 3-phosphate into 1-deoxy-d-xylulose 5-phosphate (DXP). Standard methods can be used to determine whether a polypeptide has DXS polypeptide activity by measuring the ability of the polypeptide to convert pyruvate and D-glyceraldehyde 3-phosphate *in vitro*, in a cell extract, or *in vivo*.

[0113] DXR polypeptides convert 1-deoxy-d-xylulose 5-phosphate (DXP) into 2-C-methyl-D-erythritol 4-phosphate (MEP). Standard methods can be used to determine whether a polypeptide has DXR polypeptides activity by measuring the ability of the polypeptide to convert DXP *in vitro*, in a cell extract, or *in vivo*.

[0114] MCT polypeptides convert 2-C-methyl-D-erythritol 4-phosphate (MEP) into 4-(cytidine 5'-diphospho)-2-methyl-D-erythritol (CDP-ME). Standard methods can be used to determine whether a polypeptide has MCT polypeptides activity by measuring the ability of the polypeptide to convert MEP *in vitro*, in a cell extract, or *in vivo*.

[0115] CMK polypeptides convert 4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol (CDP-ME) into 2-phospho-4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol (CDP-MEP). Standard methods can be used to determine whether a polypeptide has CMK polypeptides activity by measuring the ability of the polypeptide to convert CDP-ME *in vitro*, in a cell extract, or *in vivo*.

[0116] MCS polypeptides convert 2-phospho-4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol (CDP-MEP) into 2-C-methyl-D-erythritol 2, 4-cyclodiphosphate (ME-CPP or cMEPP). Standard methods can be used to determine whether a polypeptide has MCS polypeptides activity by measuring the ability of the polypeptide to convert CDP-MEP *in vitro*, in a cell extract, or *in vivo*.

[0117] HDS polypeptides convert 2-C-methyl-D-erythritol 2, 4-cyclodiphosphate into (E)-4-hydroxy-3-methylbut-2-en-1-yl diphosphate (HMBPP or HDMAPP). Standard methods can be used to determine whether a polypeptide has HDS polypeptides activity by measuring the ability of the polypeptide to convert ME-CPP *in vitro*, in a cell extract, or *in vivo*.

[0118] HDR polypeptides convert (E)-4-hydroxy-3-methylbut-2-en-1-yl diphosphate into isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP). Standard methods can be used to determine whether a polypeptide has HDR polypeptides activity by measuring the ability of the polypeptide to convert HMBPP *in vitro*, in a cell extract, or *in vivo*.

Source organisms for MVA pathway, isoprene synthase, IDI, and DXP pathway polypeptides

[0119] Isoprene synthase, IDI, DXP pathway, and/or MVA pathway nucleic acids (excluding enzymes that condense two acetoacetyl-CoA molecules to acetyl-CoA, such as acetoacetyl-CoA thiolase or AACT), MVA pathway polypeptides (excluding enzymes that condense two acetoacetyl-CoA molecules to acetyl-CoA, such as AACT) can be obtained from any organism that naturally contains isoprene synthase, IDI, DXP pathway, and/or MVA pathway nucleic acids. Isoprene is formed naturally by a variety of organisms, such as bacteria, yeast, plants, and animals. Some organisms contain the MVA pathway for producing isoprene. Isoprene synthase nucleic acids can be obtained, *e.g.*, from any organism that contains an isoprene synthase. MVA pathway nucleic acids can be obtained, *e.g.*, from any organism that contains the MVA pathway. IDI and DXP pathway nucleic acids can be obtained, *e.g.*, from any organism that contains the IDI and DXP pathway.

[0120] The nucleic acid sequence of the isoprene synthase, DXP pathway, IDI, and/or MVA pathway nucleic acids can be isolated from a bacterium, fungus, plant, algae, or cyanobacterium. Exemplary source organisms include, for example, yeasts, such as species of *Saccharomyces* (*e.g.*, *S. cerevisiae*), bacteria, such as species of *Escherichia* (*e.g.*, *E. coli*), or species of *Methanosarcina* (*e.g.*, *Methanosarcina mazei*), plants, such as kudzu or poplar (*e.g.*, *Populus alba* or *Populus alba x tremula* CAC35696) or aspen (*e.g.*, *Populus tremuloides*). Exemplary sources for isoprene synthases, IDI, and/or MVA pathway polypeptides which can be used are also described in International Patent Application Publication Nos. WO2009/076676, WO2010/003007, WO2009/132220, WO2010/031062, WO2010/031068, WO2010/031076, WO2010/013077, WO2010/031079, WO2010/148150, WO2010/078457, and WO2010/148256.

[0121] In some aspects, the source organism is a yeast, such as *Saccharomyces sp.*, *Schizosaccharomyces sp.*, *Pichia sp.*, or *Candida sp.*

[0122] In some aspects, the source organism is a bacterium, such as strains of *Bacillus* such as *B. licheniformis* or *B. subtilis*, strains of *Pantoea* such as *P. citrea*, strains of *Pseudomonas* such as *P. alcaligenes*, strains of *Streptomyces* such as *S. lividans* or *S. rubiginosus*, strains of *Escherichia* such as *E. coli*, strains of *Enterobacter*, strains of *Streptococcus*, or strains of *Archaea* such as *Methanosarcina mazei*.

[0123] As used herein, “the genus *Bacillus*” includes all species within the genus “*Bacillus*,” as known to those of skill in the art, including but not limited to *B. subtilis*, *B. licheniformis*, *B. lentus*, *B. brevis*, *B. stearothermophilus*, *B. alkalophilus*, *B. amyloliquefaciens*, *B. clausii*, *B. halodurans*, *B. megaterium*, *B. coagulans*, *B. circulans*, *B. lautus*, and *B. thuringiensis*. It is recognized that the genus *Bacillus* continues to undergo taxonomical reorganization. Thus, it is intended that the genus include species that have been reclassified, including but not limited to such organisms as *B. stearothermophilus*, which is now named “*Geobacillus stearothermophilus*.” The production of resistant endospores in the presence of oxygen is considered the defining feature of the genus *Bacillus*, although this characteristic also applies to the recently named *Alicyclobacillus*, *Amphibacillus*, *Aneurinibacillus*, *Anoxybacillus*, *Brevibacillus*, *Filobacillus*, *Gracilibacillus*, *Halobacillus*, *Paenibacillus*, *Salibacillus*, *Thermobacillus*, *Ureibacillus*, and *Virgibacillus*.

[0124] In some aspects, the source organism is a gram-positive bacterium. Non-limiting examples include strains of *Streptomyces* (e.g., *S. lividans*, *S. coelicolor*, or *S. griseus*) and *Bacillus*. In some aspects, the source organism is a gram-negative bacterium, such as *E. coli* or *Pseudomonas sp.* In some aspects, the source organism is *L. acidophilus*.

[0125] In some aspects, the source organism is a plant, such as a plant from the family Fabaceae, such as the Faboideae subfamily. In some aspects, the source organism is kudzu, poplar (such as *Populus alba x tremula* CAC35696), aspen (such as *Populus tremuloides*), or *Quercus robur*.

[0126] In some aspects, the source organism is an algae, such as a green algae, red algae, glaucophytes, chlorarachniophytes, euglenids, chromista, or dinoflagellates.

[0127] In some aspects, the source organism is a cyanobacteria, such as cyanobacteria classified into any of the following groups based on morphology: *Chroococcales*, *Pleurocapsales*, *Oscillatoriales*, *Nostocales*, or *Stigonematales*.

Exemplary host cells

[0128] One of skill in the art will recognize that expression vectors are designed to contain certain components which optimize gene expression for certain host strains. Such optimization components include, but are not limited to origin of replication, promoters, and enhancers. The vectors and components referenced herein are described for exemplary purposes and are not meant to narrow the scope of the invention.

[0129] Any microorganism or progeny thereof can be used to express any of the genes (heterologous or endogenous) described herein. Bacteria cells, including gram positive or gram negative bacteria can be used to express any of the genes described herein. In particular, the genes described herein can be expressed in any one of the group consisting of *Escherichia sp.* (e.g., *E. coli*), *L. acidophilus*, *P. citrea*, *B. subtilis*, *B. licheniformis*, *B. lentus*, *B. brevis*, *B. stearothermophilus*, *B. alkalophilus*, *B. amyloliquefaciens*, *B. clausii*, *B. halodurans*, *B. megaterium*, *B. coagulans*, *B. circulans*, *B. lautus*, *B. thuringiensis*, *Corynebacterium spp.* (e.g., *C. glutamicum*), *S. degradans* 2-40, *Alginovibrio aqualiticus*, *Alteromonas sr. strain KLIA*, *Asteromyces cruciatus*, *Beneckea pelagia*, *Enterobacter cloacae*, *Halmonas marina*, *Klebsiella pneumonia*, *Photobacterium spp.* (ATCC 433367), *Pseudoalteromonas elyakovii*, *Pseudomonas sp.* (e.g., *Pseudomonas alginovora*, *Pseudomonas aeruginosa*, *Pseudomonas maltophilia*, *Pseudomonas putida*), *Vibrio alginolyticus*, *Vibrio halioticol*, and *Vibrio harveyi*, *S. albus*, *S. lividans*, *S. coelicolor*, *S. griseus*, and *P. alcaligenes* cells. In one aspect, the bacterial cell is an *E. coli* cell. In another aspect, the bacterial cell is an *L. acidophilus* cell. There are numerous types of anaerobic cells that can be used as host cells in the compositions and methods of the present invention. In one aspect of the invention, the cells described in any of the compositions or methods described herein are obligate anaerobic cells and progeny thereof. Obligate anaerobes typically do not grow well, if at all, in conditions where oxygen is present. It is to be understood that a small amount of oxygen may be present, that is, there is some tolerance level that obligate anaerobes have for a low level of oxygen. In one aspect, obligate anaerobes engineered to produce mevalonate, isoprene, isoprenoid precursors, and isoprenoids can serve as host cells for any of the methods and/or compositions described herein and are grown under

substantially oxygen-free conditions, wherein the amount of oxygen present is not harmful to the growth, maintenance, and/or fermentation of the anaerobes.

[0130] In another aspect of the invention, the host cells described and/or used in any of the compositions or methods described herein are facultative anaerobic cells and progeny thereof. Facultative anaerobes can generate cellular ATP by aerobic respiration (e.g., utilization of the TCA cycle) if oxygen is present. However, facultative anaerobes can also grow in the absence of oxygen. This is in contrast to obligate anaerobes which die or grow poorly in the presence of greater amounts of oxygen. In one aspect, therefore, facultative anaerobes can serve as host cells for any of the compositions and/or methods provided herein and can be engineered to produce mevalonate, isoprene, isoprenoid precursors, and isoprenoids. Facultative anaerobic host cells can be grown under substantially oxygen-free conditions, wherein the amount of oxygen present is not harmful to the growth, maintenance, and/or fermentation of the anaerobes, or can be alternatively grown in the presence of greater amounts of oxygen.

[0131] The host cell can additionally be a filamentous fungal cell and progeny thereof. (See, e.g., Berka & Barnett, *Biotechnology Advances*, (1989), 7(2):127-154). In some aspects, the filamentous fungal cell can be any of *Trichoderma longibrachiatum*, *T. viride*, *T. koningii*, *T. harzianum*, *Penicillium sp.*, *Humicola insolens*, *H. lanuginosa*, *H. grisea*, *Chrysosporium sp.*, *C. lucknowense*, *Gliocladium sp.*, *Aspergillus sp.*, such as *A. oryzae*, *A. niger*, *A. sojae*, *A. japonicus*, *A. nidulans*, or *A. awamori*, *Fusarium sp.*, such as *F. roseum*, *F. gramineum*, *F. cerealis*, *F. oxysporum*, or *F. venenatum*, *Neurospora sp.*, such as *N. crassa*, *Hypocrea sp.*, *Mucor sp.*, such as *M. miehei*, *Rhizopus sp.* or *Emericella sp.* In some aspects, the fungus is *A. nidulans*, *A. awamori*, *A. oryzae*, *A. aculeatus*, *A. niger*, *A. japonicus*, *T. reesei*, *T. viride*, *F. oxysporum*, or *F. solani*. In certain embodiments, plasmids or plasmid components for use herein include those described in U.S. patent pub. No. US 2011/0045563.

[0132] The host cell can also be a yeast, such as *Saccharomyces sp.*, *Schizosaccharomyces sp.*, *Pichia sp.*, or *Candida sp.* In some aspects, the *Saccharomyces sp.* is *Saccharomyces cerevisiae* (See, e.g., Romanos et al., *Yeast*, (1992), 8(6):423-488). In certain embodiments, plasmids or plasmid components for use herein include those described in U.S. pat. No. 7,659,097 and U.S. patent pub. No. US 2011/0045563.

[0133] The host cell can additionally be a species of algae, such as a green algae, red algae, glaucophytes, chlorarachniophytes, euglenids, chromista, or dinoflagellates. (See, e.g., Saunders & Warmbrodt, “*Gene Expression in Algae and Fungi, Including Yeast*,” (1993), National Agricultural Library, Beltsville, MD). In certain embodiments, plasmids or plasmid components for use herein include those described in U.S. Patent Pub. No. US 2011/0045563. In some aspects, the host cell is a cyanobacterium, such as cyanobacterium classified into any of the following groups based on morphology: *Chlorococcales*, *Pleurocapsales*, *Oscillatoriales*, *Nostocales*, or *Stigonematales* (See, e.g., Lindberg et al., *Metab. Eng.*, (2010) 12(1):70-79). In certain embodiments, plasmids or plasmid components for use herein include those described in U.S. patent pub. No. US 2010/0297749; US 2009/0282545 and Intl. Pat. Appl. No. WO 2011/034863.

[0134] In certain embodiments, *E. coli* host cells can be used to express any of the genes described herein. In one aspect, the host cell is a recombinant cell of an *Escherichia coli* (*E. coli*) strain, or progeny thereof, capable of producing mevalonate that expresses one or more nucleic acids encoding an acetoacetyl-CoA synthase. The *E. coli* host cells can produce isoprene, isoprenoid precursors (e.g., mevalonate), and/or isoprenoids in amounts, peak titers, and cell productivities greater than that of the same cells lacking one or more heterologously expressed nucleic acids encoding an acetoacetyl-CoA synthase. In addition, the one or more heterologously expressed nucleic acids encoding an acetoacetyl-CoA synthase in *E. coli* can be chromosomal copies (e.g., integrated into the *E. coli* chromosome). In other aspects, the *E. coli* cells are in culture.

Transformation methods

[0135] Nucleic acids encoding acetoacetyl-CoA synthase, an enzyme that produces acetoacetyl-CoA synthase from malonyl-CoA and acetyl-CoA, non-thiolase MVA pathway polypeptides, DXP pathway polypeptides, isoprene synthase, IDI, polyprenyl pyrophosphate synthases and any other enzyme needed to produce isoprene, isoprenoid precursors, and/or isoprenoids can be introduced into host cells (e.g., a plant cell, a fungal cell, a yeast cell, or a bacterial cell) by any technique known to one of the skill in the art.

[0136] Standard techniques for introduction of a DNA construct or vector into a host cell, such as transformation, electroporation, nuclear microinjection, transduction, transfection (e.g.,

lipofection mediated or DEAE-Dextrin mediated transfection or transfection using a recombinant phage virus), incubation with calcium phosphate DNA precipitate, high velocity bombardment with DNA-coated microprojectiles, and protoplast fusion can be used. General transformation techniques are known in the art (*See, e.g., Current Protocols in Molecular Biology* (F. M. Ausubel *et al.* (eds.) Chapter 9, 1987; Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 3rd ed., Cold Spring Harbor, 2001; and Campbell *et al.*, *Curr. Genet.* 16:53-56, 1989). The introduced nucleic acids can be integrated into chromosomal DNA or maintained as extrachromosomal replicating sequences. Transformants can be selected by any method known in the art. Suitable methods for selecting transformants are described in International Publication No. WO 2009/076676, U.S. Patent Application No. 12/335,071 (US Publ. No. 2009/0203102), WO 2010/003007, US Publ. No. 2010/0048964, WO 2009/132220, and US Publ. No. 2010/0003716.

[0137] In one embodiment, a bacterium such as *Escherichia coli* is used as a host. In this embodiment, an expression vector can be selected and/or engineered to be able to autonomously replicate in such bacterium. Promoters, a ribosome binding sequence, transcription termination sequence(s) can also be included in the expression vector, in addition to the genes listed herein. Optionally, an expression vector may contain a gene that controls promoter activity.

[0138] Any promoter may be used as long as it can be expressed in a host such as *Escherichia coli*. Examples of such promoter that can be used include a trp promoter, an lac promoter, a PL promoter, a PR promoter, and the like from *Escherichia coli*, and a T7 promoter from a phage. Further, an artificially designed or modified promoter such as a tac promoter may be used.

[0139] A method for introduction of an expression vector is not particularly limited as long as DNA is introduced into a bacterium thereby. Examples thereof include a method using calcium ions (Cohen, S. N., et al.: *Proc. Natl. Acad. Sci., USA*, 69:2110-2114 (1972)) and an electroporation method.

[0140] When a yeast is used as a host, *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Pichia pastoris*, or the like can be used. In this case, a promoter is not particularly limited as long as it can be expressed in yeast. Examples thereof include a gal promoter, a gal10 promoter, a heat-shock protein promoter, an MF.alpha.1 promoter, a PHO5 promoter, a PGK promoter, a GAP promoter, an ADH promoter, and an AOX1 promoter.

[0141] A method for introducing a recombinant vector into yeast is not particularly limited as long as DNA is introduced into yeast thereby. Examples thereof include the electroporation method (Becker, D. M., et al. *Methods. Enzymol.*, 194: 182-187 (1990)), the spheroplast method (Hinnen, A. et al.: *Proc. Natl. Acad. Sci., USA*, 75: 1929-1933 (1978)), and the lithium acetate method (Itoh, H.: *J. Bacteriol.*, 153: 163-168 (1983)).

[0142] In particular, it is preferable to use, as a host microorganism, a microorganism with a relatively high malonyl-CoA content. Malonyl-CoA is a substance used for biosynthesis of fatty acid and is present in all microorganisms. The aforementioned acetoacetyl-CoA synthase synthesizes acetoacetyl-CoA from malonyl-CoA and acetyl-CoA. Therefore, the isoprene/isoprenoid productivity can be improved with the use of a host microorganism with a high malonyl-CoA content.

Vectors

[0143] Suitable vectors can be used for any of the compositions and methods described herein. For example, suitable vectors can be used to optimize the expression of one or more copies of a gene encoding a HMG-CoA reductase, an isoprene synthase, a polyprenyl pyrophosphate synthase, and/or one or more non-thiolase MVA pathway polypeptides. In some aspects, the vector contains a selective marker. Examples of selectable markers include, but are not limited to, antibiotic resistance nucleic acids (*e.g.*, kanamycin, ampicillin, carbenicillin, gentamicin, hygromycin, phleomycin, bleomycin, neomycin, or chloramphenicol) and/or nucleic acids that confer a metabolic advantage, such as a nutritional advantage on the host cell. In some aspects, one or more copies of HMG-CoA reductase, an isoprene synthase, a polyprenyl pyrophosphate synthase, and/or one or more non-thiolase MVA pathway polypeptides nucleic acid(s) integrate into the genome of host cells without a selective marker. Any one of the vectors characterized or used in the Examples of the present disclosure can be used.

Host cell Mutations

[0144] The invention is further directed to the use of host microorganisms having mutations that increase the intracellular pool of starting malonyl-CoA. These modified host strains provide increased substrate availability (*e.g.*, malonyl-CoA) for acetoacetyl-CoA synthase which can result in increased production of acetoacetyl-CoA and its downstream products such as isoprene

and/or isoprenoids. In certain embodiments, the host microorganism can comprise genetic manipulations which attenuate or delete the activity of the citric cycle genes *sdhCDAB* and *citE*, the amino acid transporter *brnQ*, and the pyruvate consumer *adhE*. In other embodiments, the host microorganism can comprise genetic manipulations which result in the over-expression of one or more genes, including but not limited to, acetyl-CoA carboxylase (ACC), phosphoglycerate kinase (PGK), glyceraldehyde-3-phosphatedehydrogenase (GAPD) and/or pyruvate dehydrogenase complex (PDH) thereby leading to increased intracellular malonyl-CoA levels. See, for example Fowler, *et al.*, *Applied and Environmental Microbiology*, Vol. 75, No. 18, pp. 5831-5839 (2009), Zha *et al.*, *Metabolic Engineering*, 11: 192-198 (2009), Xu *et al.*, *Metabolic Engineering*, (2011)doi:10.1016/j.ymben.2011.06.008, Okamura *et al.*, *PNAS* 107: 11265-11270 (2010), and US 2010/0285549, the contents of which are expressly incorporated herein by reference in their entirety.

[0145] The invention also contemplates additional host cell mutations that increase carbon flux through the MVA pathway. By increasing the carbon flow, more isoprene, isoprenoid precursor and/or isoprenoid can be produced. The recombinant cells comprising acetoacetyl-CoA synthase as described herein can also be engineered for increased carbon flux towards mevalonate production wherein the activity of one or more enzymes from the group consisting of: (a) citrate synthase, (b) phosphotransacetylase; (c) acetate kinase; (d) lactate dehydrogenase; (e) NADP-dependent malic enzyme, and; (f) pyruvate dehydrogenase is modulated.

Citrate Synthase Pathway

[0146] Citrate synthase catalyzes the condensation of oxaloacetate and acetyl-CoA to form citrate, a metabolite of the Tricarboxylic acid (TCA) cycle (Ner, S. *et al.* 1983. *Biochemistry* 22: 5243-5249; Bhayana, V. and Duckworth, H. 1984. *Biochemistry* 23: 2900-2905) (Figure 5). In *E. coli*, this enzyme, encoded by *gltA*, behaves like a trimer of dimeric subunits. The hexameric form allows the enzyme to be allosterically regulated by NADH. This enzyme has been widely studied (Wiegand, G., and Remington, S. 1986. *Annual Rev. Biophysics Biophys. Chem.* 15: 97-117; Duckworth *et al.* 1987. *Biochem Soc Symp.* 54:83-92; Stockell, D. *et al.* 2003. *J. Biol. Chem.* 278: 35435-43; Maurus, R. *et al.* 2003. *Biochemistry.* 42:5555-5565). To avoid allosteric inhibition by NADH, replacement by or supplementation with the *Bacillus subtilis* NADH-insensitive citrate synthase has been considered (Underwood *et al.* 2002. *Appl. Environ. Microbiol.* 68:1071-1081; Sanchez *et al.* 2005. *Met. Eng.* 7:229-239).

[0147] The reaction catalyzed by citrate synthase is directly competing with the thiolase catalyzing the first step of the mevalonate pathway, as they both have acetyl-CoA as a substrate (Hedl et al. 2002. J. Bact. 184:2116-2122). Therefore, one of skill in the art can modulate citrate synthase expression (e.g., decrease enzyme activity) to allow more carbon to flux into the mevalonate pathway, thereby increasing the eventual production of mevalonate, isoprene and isoprenoids. Decrease of citrate synthase activity can be any amount of reduction of specific activity or total activity as compared to when no manipulation has been effectuated. In some instances, the decrease of enzyme activity is decreased by at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%. In some aspects, the activity of citrate synthase is modulated by decreasing the activity of an endogenous citrate synthase gene. This can be accomplished by chromosomal replacement of an endogenous citrate synthase gene with a transgene encoding an NADH-insensitive citrate synthase or by using a transgene encoding an NADH-insensitive citrate synthase that is derived from *Bacillus subtilis*. The activity of citrate synthase can also be modulated (e.g., decreased) by replacing the endogenous citrate synthase gene promoter with a synthetic constitutively low expressing promoter. The decrease of the activity of citrate synthase can result in more carbon flux into the mevalonate dependent biosynthetic pathway in comparison to microorganisms that do not have decreased expression of citrate synthase.

Pathways involving Phosphotransacetylase and/or Acetate Kinase

[0148] Phosphotransacetylase (*pta*) (Shimizu et al. 1969. Biochim. Biophys. Acta 191: 550-558) catalyzes the reversible conversion between acetyl-CoA and acetylphosphate (acetyl-P), while acetate kinase (*ackA*) (Kakuda, H. et al. 1994. J. Biochem. 11:916-922) uses acetyl-P to form acetate. These genes can be transcribed as an operon in *E. coli*. Together, they catalyze the dissimilation of acetate, with the release of ATP. Thus, one of skill in the art can increase the amount of available acetyl Co-A by attenuating the activity of phosphotransacetylase gene (e.g., the endogenous phosphotransacetylase gene) and/or an acetate kinase gene (e.g., the endogenous acetate kinase gene). One way of achieving attenuation is by deleting phosphotransacetylase (*pta*) and/or acetate kinase (*ackA*). This can be accomplished by replacing one or both genes with a chloramphenicol cassette followed by looping out of the cassette. Acetate is produced by *E. coli* for a variety of reasons (Wolfe, A. 2005. Microb. Mol. Biol. Rev. 69:12-50). Without

being bound by theory, since ackA-pta use acetyl-CoA, deleting those genes might allow carbon not to be diverted into acetate and to increase the yield of mevalonate, isoprene or isoprenoids.

[0149] In some aspects, the recombinant microorganism produces decreased amounts of acetate in comparison to microorganisms that do not have attenuated endogenous phosphotransacetylase gene and/or endogenous acetate kinase gene expression. Decrease in the amount of acetate produced can be measured by routine assays known to one of skill in the art. The amount of acetate reduction is at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% as compared when no molecular manipulations are done.

[0150] The activity of phosphotransacetylase (pta) and/or acetate kinase (ackA) can also be decreased by other molecular manipulation of the enzymes. The decrease of enzyme activity can be any amount of reduction of specific activity or total activity as compared to when no manipulation has been effectuated. In some instances, the decrease of enzyme activity is decreased by at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%.

In some cases, attenuating the activity of the endogenous phosphotransacetylase gene and/or the endogenous acetate kinase gene results in more carbon flux into the mevalonate dependent biosynthetic pathway in comparison to microorganisms that do not have attenuated endogenous phosphotransacetylase gene and/or endogenous acetate kinase gene expression.

Pathways Involving Lactate Dehydrogenase

[0151] In *E. coli*, D-Lactate is produced from pyruvate through the enzyme lactate dehydrogenase (ldhA – Figure 5) (Bunch, P. et al. 1997. Microbiol. 143:187-195). Production of lactate is accompanied with oxidation of NADH, hence lactate is produced when oxygen is limited and cannot accommodate all the reducing equivalents. Thus, production of lactate could be a source for carbon consumption. As such, to improve carbon flow through to mevalonate production (and isoprene, isoprenoid precursor and isoprenoids production, if desired), one of skill in the art can modulate the activity of lactate dehydrogenase, such as by decreasing the activity of the enzyme.


[0152] Accordingly, in one aspect, the activity of lactate dehydrogenase can be modulated by attenuating the activity of an endogenous lactate dehydrogenase gene. Such attenuation can be achieved by deletion of the endogenous lactate dehydrogenase gene. Other ways of attenuating the activity of lactate dehydrogenase gene known to one of skill in the art may also be used. By manipulating the pathway that involves lactate dehydrogenase, the recombinant microorganism produces decreased amounts of lactate in comparison to microorganisms that do not have attenuated endogenous lactate dehydrogenase gene expression. Decrease in the amount of lactate produced can be measured by routine assays known to one of skill in the art. The amount of lactate reduction is at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% as compared when no molecular manipulations are done.

[0153] The activity of lactate dehydrogenase can also be decreased by other molecular manipulations of the enzyme. The decrease of enzyme activity can be any amount of reduction of specific activity or total activity as compared to when no manipulation has been effectuated. In some instances, the decrease of enzyme activity is decreased by at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%.

[0154] Accordingly, in some cases, attenuation of the activity of the endogenous lactate dehydrogenase gene results in more carbon flux into the mevalonate dependent biosynthetic pathway in comparison to microorganisms that do not have attenuated endogenous lactate dehydrogenase gene expression.

Pathways Involving Malic enzyme

[0155] Malic enzyme (in *E. coli* *sfcA* and *maeB*) is an anaplerotic enzyme that catalyzes the conversion of malate into pyruvate (using NAD⁺ or NADP⁺) by the equation below:



[0157] Thus, the two substrates of this enzyme are (S)-malate and NAD(P)⁺, whereas its 3 products are pyruvate, CO₂, and NADPH.

[0158] Expression of the NADP-dependent malic enzyme (maeB – Figure 5) (Iwikura, M. et al. 1979. *J. Biochem.* 85: 1355-1365) can help increase mevalonate, isoprene, isoprenoid precursors and isoprenoids yield by 1) bringing carbon from the TCA cycle back to pyruvate, direct precursor of acetyl-CoA, itself direct precursor of the mevalonate pathway and 2) producing extra NADPH which could be used in the HMG-CoA reductase reaction (Oh, MK et al. (2002) *J. Biol. Chem.* 277: 13175-13183; Bologna, F. et al. (2007) *J. Bact.* 189:5937-5946).

[0159] As such, more starting substrate (pyruvate or acetyl-CoA) for the downstream production of mevalonate, isoprene, isoprenoid precursors and isoprenoids can be achieved by modulating, such as increasing, the activity and/or expression of malic enzyme. The NADP-dependent malic enzyme gene can be an endogenous gene. One non-limiting way to accomplish this is by replacing the endogenous NADP-dependent malic enzyme gene promoter with a synthetic constitutively expressing promoter. Another non-limiting way to increase enzyme activity is by using one or more heterologous nucleic acids encoding an NADP-dependent malic enzyme polypeptide. One of skill in the art can monitor the expression of maeB RNA during fermentation or culturing using readily available molecular biology techniques.

[0160] Accordingly, in some embodiments, the recombinant microorganism produces increased amounts of pyruvate in comparison to microorganisms that do not have increased expression of an NADP-dependent malic enzyme gene. In some aspects, increasing the activity of an NADP-dependent malic enzyme gene results in more carbon flux into the mevalonate dependent biosynthetic pathway in comparison to microorganisms that do not have increased NADP-dependent malic enzyme gene expression.

[0161] Increase in the amount of pyruvate produced can be measured by routine assays known to one of skill in the art. The amount of pyruvate increase can be at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% as compared when no molecular manipulations are done.

[0162] The activity of malic enzyme can also be increased by other molecular manipulations of the enzyme. The increase of enzyme activity can be any amount of increase of specific activity or total activity as compared to when no manipulation has been effectuated. In some instances, the increase of enzyme activity is at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%,

9%, 10%, 15%, 20%, 25%, 30%, 35%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%.

Pathways Involving Pyruvate Dehydrogenase Complex

[0163] The pyruvate dehydrogenase complex, which catalyzes the decarboxylation of pyruvate into acetyl-CoA, is composed of the proteins encoded by the genes aceE, aceF and lpdA. Transcription of those genes is regulated by several regulators. Thus, one of skill in the art can increase acetyl-CoA by modulating the activity of the pyruvate dehydrogenase complex. Modulation can be to increase the activity and/or expression (e.g., constant expression) of the pyruvate dehydrogenase complex. This can be accomplished by different ways, for example, by placing a strong constitutive promoter, like PL6

(aattcatataaaaaacatacagataaccatctgcggtgataaattatctctggcggtgttgacataaataccactggcggtgatactgagcac atcagcaggacgcactgaccaccatgaaggtg - lambda promoter, GenBank NC_001416 (SEQ ID NO:2)), in front of the operon or using one or more synthetic constitutively expressing promoters.

[0164] Accordingly, in one aspect, the activity of pyruvate dehydrogenase is modulated by increasing the activity of one or more genes of the pyruvate dehydrogenase complex consisting of (a) pyruvate dehydrogenase (E1), (b) dihydrolipoyl transacetylase, and (c) dihydrolipoyl dehydrogenase. It is understood that any one, two or three of these genes can be manipulated for increasing activity of pyruvate dehydrogenase. In another aspect, the activity of the pyruvate dehydrogenase complex can be modulated by attenuating the activity of an endogenous pyruvate dehydrogenase complex repressor gene, further detailed below. The activity of an endogenous pyruvate dehydrogenase complex repressor can be attenuated by deletion of the endogenous pyruvate dehydrogenase complex repressor gene.

[0165] In some cases, one or more genes of the pyruvate dehydrogenase complex are endogenous genes. Another way to increase the activity of the pyruvate dehydrogenase complex is by introducing into the microorganism one or more heterologous nucleic acids encoding one or more polypeptides from the group consisting of (a) pyruvate dehydrogenase (E1), (b) dihydrolipoyl transacetylase, and (c) dihydrolipoyl dehydrogenase.

[0166] By using any of these methods, the recombinant microorganism can produce increased amounts of acetyl Co-A in comparison to microorganisms wherein the activity of pyruvate

dehydrogenase is not modulated. Modulating the activity of pyruvate dehydrogenase can result in more carbon flux into the mevalonate dependent biosynthetic pathway in comparison to microorganisms that do not have modulated pyruvate dehydrogenase expression.

Combinations of Mutations

[0167] It is understood that for any of the enzymes and/or enzyme pathways described herein, molecular manipulations that modulate any combination (two, three, four, five or six) of the enzymes and/or enzyme pathways described herein is expressly contemplated. For ease of the recitation of the combinations, citrate synthase (gltA) is designated as A, phosphotransacetylase (ptaB) is designated as B, acetate kinase (ackA) is designated as C, lactate dehydrogenase (ldhA) is designated as D, malic enzyme (sfcA or maeB) is designated as E, and pyruvate decarboxylase (aceE, aceF, and/or lpdA) is designated as F. As discussed above, aceE, aceF, and/or lpdA enzymes of the pyruvate decarboxylase complex can be used singly, or two of three enzymes, or three of three enzymes for increasing pyruvate decarboxylase activity.

[0168] Accordingly, for combinations of any two of the enzymes A-F, non-limiting combinations that can be used are: AB, AC, AD, AE, AF, BC, BD, BE, BF, CD, CE, CF, DE, DF and EF. For combinations of any three of the enzymes A-F, non-limiting combinations that can be used are: ABC, ABD, ABE, ABF, BCD, BCE, BCF, CDE, CDF, DEF, ACD, ACE, ACF, ADE, ADF, AEF, BDE, BDF, BEF, and CEF. For combinations of any four of the enzymes A-F, non-limiting combinations that can be used are: ABCD, ABCE, ABCF, ABDE, ABDF, ABEF, BCDE, BCDF, CDEF, ACDE, ACDF, ACEF, BCEF, BDEF, and ADEF. For combinations of any five of the enzymes A-F, non-limiting combinations that can be used are: ABCDE, ABCDF, ABDEF, BCDEF, ACDEF, and ABCEF. In another aspect, all six enzyme combinations are used: ABCDEF.

[0169] Accordingly, the recombinant microorganism as described herein can achieve increased mevalonate production that is increased compared to microorganisms that are not grown under conditions of tri-carboxylic acid (TCA) cycle activity, wherein metabolic carbon flux in the recombinant microorganism is directed towards mevalonate production by modulating the activity of one or more enzymes from the group consisting of (a) citrate synthase, (b) phosphotransacetylase and/or acetate kinase, (c) lactate dehydrogenase, (d) malic enzyme, and (e) pyruvate decarboxylase complex.

Other Regulators and Factors for Increased Production

[0170] Other molecular manipulations can be used to increase the flow of carbon towards mevalonate production. One method is to reduce, decrease or eliminate the effects of negative regulators for pathways that feed into the mevalonate pathway. For example, in some cases, the genes *aceEF-lpdA* are in an operon, with a fourth gene upstream *pdhR*. *pdhR* is a negative regulator of the transcription of its operon. In the absence of pyruvate, it binds its target promoter and represses transcription. It also regulates *ndh* and *cyoABCD* in the same way (Ogasawara, H. et al. 2007. J. Bact. 189:5534-5541). In one aspect, deletion of *pdhR* regulator can improve the supply of pyruvate, and hence the production of mevalonate, isoprene, isoprenoid precursors, and isoprenoids.

[0171] In other aspects, the introduction of 6-phosphogluconolactonase (PGL) into microorganisms (such as various *E. coli* strains) which lack PGL can be used to improve production of mevalonate, isoprene, isoprenoid precursors, and isoprenoids. PGL may be introduced using chromosomal integration or extra-chromosomal vehicles, such as plasmids. In certain embodiments, PGL may be deleted from the genome of microorganisms (such as various *E. coli* strains) which express an endogenous PGL to improve production of mevalonate and/or isoprene.

[0172] In some aspects of the invention, the recombinant cells described in any of the compositions or methods described herein can further comprise one or more nucleic acids encoding a phosphoketolase polypeptide or a polypeptide having phosphoketolase activity. In some aspects, the phosphoketolase polypeptide is an endogenous polypeptide. In some aspects, the endogenous nucleic acid encoding a phosphoketolase polypeptide is operably linked to a constitutive promoter. In some aspects, the endogenous nucleic acid encoding a phosphoketolase polypeptide is operably linked to an inducible promoter. In some aspects, the endogenous nucleic acid encoding a phosphoketolase polypeptide is operably linked to a strong promoter. In some aspects, more than one endogenous nucleic acid encoding a phosphoketolase polypeptide is used (e.g, 2, 3, 4, or more copies of an endogenous nucleic acid encoding a phosphoketolase polypeptide). In a particular aspect, the cells are engineered to overexpress the endogenous phosphoketolase polypeptide relative to wild-type cells. In some aspects, the endogenous nucleic acid encoding a phosphoketolase polypeptide is operably linked to a weak promoter.

[0173] Phosphoketolase enzymes catalyze the conversion of xylulose 5-phosphate to glyceraldehyde 3-phosphate and acetyl phosphate and/or the conversion of fructose 6-phosphate to erythrose 4-phosphate and acetyl phosphate. In certain embodiments, the phosphoketolase enzyme is capable of catalyzing the conversion of xylulose 5-phosphate to glyceraldehyde 3-phosphate and acetyl phosphate. In other embodiments, the phosphoketolase enzyme is capable of catalyzing the conversion of fructose 6-phosphate to erythrose 4-phosphate and acetyl phosphate. Thus, without being bound by theory, the expression of phosphoketolase as set forth herein can result in an increase in the amount of acetyl phosphate produced from a carbohydrate source. This acetyl phosphate can be converted into acetyl-CoA which can then be utilized by the enzymatic activities of the MVA pathway to produce mevalonate, isoprenoid precursor molecules, isoprene and/or isoprenoids. Thus the amount of these compounds produced from a carbohydrate substrate may be increased. Alternatively, production of Acetyl-P and AcCoA can be increased without the increase being reflected in higher intracellular concentration. In certain embodiments, intracellular acetyl-P or acetyl-CoA concentrations will remain unchanged or even decrease, even though the phosphoketolase reaction is taking place.

[0174] Exemplary phosphoketolase nucleic acids include nucleic acids that encode a polypeptide, fragment of a polypeptide, peptide, or fusion polypeptide that has at least one activity of a phosphoketolase polypeptide. Exemplary phosphoketolase polypeptides and nucleic acids include naturally-occurring polypeptides and nucleic acids from any of the source organisms described herein as well as mutant polypeptides and nucleic acids derived from any of the source organisms described herein. In some aspects, the phosphoketolase nucleic acid is a heterologous nucleic acid encoding a phosphoketolase polypeptide.

[0175] Standard methods can be used to determine whether a polypeptide has phosphoketolase peptide activity by measuring the ability of the peptide to convert D-fructose 6-phosphate or D-xylulose 5-phosphate into acetyl-P. Acetyl-P can then be converted into ferryl acetyl hydroxamate, which can be detected spectrophotometrically (Meile et al., J. Bact. 183:2929-2936, 2001). Any polypeptide identified as having phosphoketolase peptide activity as described herein is suitable for use in the present invention.

[0176] In other aspects, exemplary phosphoketolase nucleic acids include, for example, a phosphoketolase isolated from *Lactobacillus reuteri*, *Bifidobacterium longum*, *Ferrimonas balearica*, *Pedobactor saltans*, *Streptomyces griseus*, and/or *Nocardiopsis dassonvillei*.

Additional examples of phosphoketolase enzymes which can be used herein are described in U.S. 7,785,858, which is incorporated by reference herein.

Recombinant Cells Capable of Increased Production of Isoprene

[0177] Isoprene (2-methyl-1,3-butadiene) is an important organic compound used in a wide array of applications. For instance, isoprene is employed as an intermediate or a starting material in the synthesis of numerous chemical compositions and polymers, including in the production of synthetic rubber. Isoprene is also an important biological material that is synthesized naturally by many plants and animals.

[0178] Isoprene is produced from DMAPP by the enzymatic action of isoprene synthase. Therefore, without being bound to theory, it is thought that increasing the cellular production of mevalonate in host cells by any of the compositions and methods described above will similarly result in the production of higher amounts of isoprene. Increasing the molar yield of mevalonate production from glucose translates into higher molar yields of isoprenoid precursors and isoprenoids, including isoprene, produced from glucose when combined with appropriate enzymatic activity levels of mevalonate kinase, phosphomevalonate kinase, diphosphomevalonate decarboxylase, isopentenyl diphosphate isomerase and other appropriate enzymes for isoprene and isoprenoid production.

[0179] Production of isoprene can be made by using any of the recombinant host cells described here where acetoacetyl-CoA synthase is used to make acetoacetyl-CoA for downstream use in the MVA pathway. The use of acetoacetyl-CoA synthase can increase mevalonate production, which in turn, can be used to produce isoprene. Any of the recombinant host cells expressing one or more copies of a heterologous nucleic acid encoding upper MVA pathway polypeptides including, but not limited to, a HMG-CoA reductase and HMG-CoA synthase (e.g., an *mvaS* polypeptide from *L. grayi*, *E. faecium*, *E. gallinarum*, *E. casseliflavus* and/or *E. faecalis*) capable of increased production of mevalonate described above can also be capable of increased production of isoprene. In some aspects, these cells further comprise one or more heterologous nucleic acids encoding polypeptides of the lower MVA pathway and a heterologous nucleic acid encoding an isoprene synthase polypeptide.

[0180] Compositions of recombinant cells as described herein are contemplated within the scope of the invention as well. It is understood that recombinant cells also encompass progeny cells as well.

Exemplary Cell Culture Media

[0181] As used herein, the terms “minimal medium” or “minimal media” refer to growth medium containing the minimum nutrients possible for cell growth, generally, but not always, without the presence of one or more amino acids (*e.g.*, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more amino acids). Minimal medium typically contains: (1) a carbon source for host cell growth; (2) various salts, which can vary among host cell species and growing conditions; and (3) water. The carbon source can vary significantly, from simple sugars like glucose to more complex hydrolysates of other biomass, such as yeast extract, as discussed in more detail below. The salts generally provide essential elements such as magnesium, nitrogen, phosphorus, and sulfur to allow the cells to synthesize proteins and nucleic acids. Minimal medium can also be supplemented with selective agents, such as antibiotics, to select for the maintenance of certain plasmids and the like. For example, if a microorganism is resistant to a certain antibiotic, such as ampicillin or tetracycline, then that antibiotic can be added to the medium in order to prevent cells lacking the resistance from growing. Medium can be supplemented with other compounds as necessary to select for desired physiological or biochemical characteristics, such as particular amino acids and the like.

[0182] Any minimal medium formulation can be used to cultivate the host cells. Exemplary minimal medium formulations include, for example, M9 minimal medium and TM3 minimal medium. Each liter of M9 minimal medium contains (1) 200 ml sterile M9 salts (64 g $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 15 g KH_2PO_4 , 2.5 g NaCl , and 5.0 g NH_4Cl per liter); (2) 2 ml of 1 M MgSO_4 (sterile); (3) 20 ml of 20% (w/v) glucose (or other carbon source); and (4) 100 μl of 1 M CaCl_2 (sterile). Each liter of TM3 minimal medium contains (1) 13.6 g K_2HPO_4 ; (2) 13.6 g KH_2PO_4 ; (3) 2 g $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$; (4) 2 g Citric Acid Monohydrate; (5) 0.3 g Ferric Ammonium Citrate; (6) 3.2 g $(\text{NH}_4)_2\text{SO}_4$; (7) 0.2 g yeast extract; and (8) 1 ml of 1000X Trace Elements solution; pH is adjusted to ~6.8 and the solution is filter sterilized. Each liter of 1000X Trace Elements contains: (1) 40 g Citric Acid Monohydrate; (2) 30 g $\text{MnSO}_4 \cdot \text{H}_2\text{O}$; (3) 10 g NaCl ; (4) 1 g

FeSO₄*7H₂O; (4) 1 g CoCl₂*6H₂O; (5) 1 g ZnSO₄*7H₂O; (6) 100 mg CuSO₄*5H₂O; (7) 100 mg H₃BO₃; and (8) 100 mg NaMoO₄*2H₂O; pH is adjusted to ~3.0.

[0183] An additional exemplary minimal media includes (1) potassium phosphate K₂HPO₄, (2) Magnesium Sulfate MgSO₄ * 7H₂O, (3) citric acid monohydrate C₆H₈O₇*H₂O, (4) ferric ammonium citrate NH₄FeC₆H₅O₇, (5) yeast extract (from biospringer), (6) 1000X Modified Trace Metal Solution, (7) sulfuric acid 50% w/v, (8) foamblast 882 (Emerald Performance Materials), and (9) Macro Salts Solution 3.36ml All of the components are added together and dissolved in deionized H₂O and then heat sterilized. Following cooling to room temperature, the pH is adjusted to 7.0 with ammonium hydroxide (28%) and q.s. to volume. Vitamin Solution and spectinomycin are added after sterilization and pH adjustment.

[0184] Any carbon source can be used to cultivate the host cells. The term “carbon source” refers to one or more carbon-containing compounds capable of being metabolized by a host cell or organism. For example, the cell medium used to cultivate the host cells can include any carbon source suitable for maintaining the viability or growing the host cells. In some aspects, the carbon source is a carbohydrate (such as monosaccharide, disaccharide, oligosaccharide, or polysaccharides), or invert sugar (*e.g.*, enzymatically treated sucrose syrup).

[0185] In some aspects, the carbon source includes yeast extract or one or more components of yeast extract. In some aspects, the concentration of yeast extract is 0.1% (w/v), 0.09% (w/v), 0.08% (w/v), 0.07% (w/v), 0.06% (w/v), 0.05% (w/v), 0.04% (w/v), 0.03% (w/v), 0.02% (w/v), or 0.01% (w/v) yeast extract. In some aspects, the carbon source includes both yeast extract (or one or more components thereof) and another carbon source, such as glucose.

[0186] Exemplary monosaccharides include glucose and fructose; exemplary oligosaccharides include lactose and sucrose, and exemplary polysaccharides include starch and cellulose. Exemplary carbohydrates include C6 sugars (*e.g.*, fructose, mannose, galactose, or glucose) and C5 sugars (*e.g.*, xylose or arabinose).

Exemplary Cell Culture Conditions

[0187] Materials and methods suitable for the maintenance and growth of the recombinant cells of the invention are described *infra*, *e.g.*, in the Examples section. Other materials and methods suitable for the maintenance and growth of cell cultures are well known in the art.

Exemplary techniques can be found in International Publication No. WO 2009/076676, U.S. Patent Application No. 12/335,071 (U.S. Publ. No. 2009/0203102), WO 2010/003007, US Publ. No. 2010/0048964, WO 2009/132220, US Publ. No. 2010/0003716, *Manual of Methods for General Bacteriology* Gerhardt *et al.*, eds), American Society for Microbiology, Washington, D.C. (1994) or Brock in *Biotechnology: A Textbook of Industrial Microbiology*, Second Edition (1989) Sinauer Associates, Inc., Sunderland, MA. In some aspects, the cells are cultured in a culture medium under conditions permitting the expression of one or more HMG-CoA reductase, HMG-CoA synthase, isoprene synthase, DXP pathway (e.g., DXS), IDI, lower MVA pathway polypeptides, or PGL polypeptides encoded by a nucleic acid inserted into the host cells.

[0188] Standard cell culture conditions can be used to culture the cells (*see*, for example, WO 2004/033646 and references cited therein). In some aspects, cells are grown and maintained at an appropriate temperature, gas mixture, and pH (such as at about 20°C to about 37°C, at about 6% to about 84% CO₂, and at a pH between about 5 to about 9). In some aspects, cells are grown at 35°C in an appropriate cell medium. In some aspects, the pH ranges for fermentation are between about pH 5.0 to about pH 9.0 (such as about pH 6.0 to about pH 8.0 or about 6.5 to about 7.0). Cells can be grown under aerobic, anoxic, or anaerobic conditions based on the requirements of the host cells. In addition, more specific cell culture conditions can be used to culture the cells. For example, in some embodiments, the bacterial cells (such as *E. coli* cells) express one or more heterologous nucleic acids encoding HMG-CoA reductase under the control of a strong promoter in a low to medium copy plasmid and are cultured at 34°C.

[0189] Standard culture conditions and modes of fermentation, such as batch, fed-batch, or continuous fermentation that can be used are described in International Publication No. WO 2009/076676, U.S. Patent Application No. 12/335,071 (U.S. Publ. No. 2009/0203102), WO 2010/003007, US Publ. No. 2010/0048964, WO 2009/132220, US Publ. No. 2010/0003716. Batch and Fed-Batch fermentations are common and well known in the art and examples can be found in Brock, *Biotechnology: A Textbook of Industrial Microbiology*, Second Edition (1989) Sinauer Associates, Inc.

[0190] In some aspects, the cells are cultured under limited glucose conditions. By “limited glucose conditions” is meant that the amount of glucose that is added is less than or about 105% (such as about 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, or 10%) of the amount of

glucose that is consumed by the cells. In particular aspects, the amount of glucose that is added to the culture medium is approximately the same as the amount of glucose that is consumed by the cells during a specific period of time. In some aspects, the rate of cell growth is controlled by limiting the amount of added glucose such that the cells grow at the rate that can be supported by the amount of glucose in the cell medium. In some aspects, glucose does not accumulate during the time the cells are cultured. In various aspects, the cells are cultured under limited glucose conditions for greater than or about 1, 2, 3, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, or 70 hours. In various aspects, the cells are cultured under limited glucose conditions for greater than or about 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 95, or 100% of the total length of time the cells are cultured. While not intending to be bound by any particular theory, it is believed that limited glucose conditions can allow more favorable regulation of the cells.

[0191] In some aspects, the host cells are grown in batch culture. The host cells can also be grown in fed-batch culture or in continuous culture. Additionally, the host cells can be cultured in minimal medium, including, but not limited to, any of the minimal media described above. The minimal medium can be further supplemented with 1.0 % (w/v) glucose, or any other six carbon sugar, or less. Specifically, the minimal medium can be supplemented with 1% (w/v), 0.9% (w/v), 0.8% (w/v), 0.7% (w/v), 0.6% (w/v), 0.5% (w/v), 0.4% (w/v), 0.3% (w/v), 0.2% (w/v), or 0.1% (w/v) glucose. Additionally, the minimal medium can be supplemented 0.1% (w/v) or less yeast extract. Specifically, the minimal medium can be supplemented with 0.1% (w/v), 0.09% (w/v), 0.08% (w/v), 0.07% (w/v), 0.06% (w/v), 0.05% (w/v), 0.04% (w/v), 0.03% (w/v), 0.02% (w/v), or 0.01% (w/v) yeast extract. Alternatively, the minimal medium can be supplemented with 1% (w/v), 0.9% (w/v), 0.8% (w/v), 0.7% (w/v), 0.6% (w/v), 0.5% (w/v), 0.4% (w/v), 0.3% (w/v), 0.2% (w/v), or 0.1% (w/v) glucose and with 0.1% (w/v), 0.09% (w/v), 0.08% (w/v), 0.07% (w/v), 0.06% (w/v), 0.05% (w/v), 0.04% (w/v), 0.03% (w/v), 0.02% (w/v), or 0.01% (w/v) yeast extract.

Methods of using the recombinant cells to produce isoprene

[0192] Also provided herein are methods of producing isoprene comprising culturing any of the recombinant microorganisms described herein. In one aspect, isoprene can be produced by culturing recombinant host cells (e.g., bacterial cells) comprising one or more nucleic acids encoding a polypeptide capable of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA (e.g., acetoacetyl-CoA synthase) and one or more nucleic acids encoding: (a) an isoprene

synthase polypeptide, wherein the isoprene synthase polypeptide is encoded by a heterologous nucleic acid; and (b) one or more mevalonate (MVA) pathway polypeptides. In one aspect, one or more heterologous nucleic acids encoding a HMG-CoA reductase, a lower MVA pathway polypeptide, and an isoprene synthase polypeptide can be used. In another aspect, isoprene can be produced by culturing recombinant host cells (*e.g.*, bacterial cells) comprising one or more heterologous nucleic acids encoding a HMG-CoA reductase and HMG-CoA synthase, a lower MVA pathway polypeptide, and an isoprene synthase polypeptide. The isoprene can be produced from any of the cells described herein and according to any of the methods described herein. Any of the cells can be used for the purpose of producing isoprene from carbohydrates, including six carbon sugars such as glucose.

[0193] The cells can further comprise one or more nucleic acid molecules encoding the lower MVA pathway polypeptide(s) described above (*e.g.*, MVK, PMK, MVD, and/or IDI) and any of the isoprene synthase polypeptide(s) described above (*e.g.* *P. alba* isoprene synthase). In some aspects, the host cells can be any of the cells described herein. Any of the isoprene synthases or variants thereof described herein, any of the host cell strains (*e.g.*, bacterial strains) described herein, any of the promoters described herein, and/or any of the vectors described herein can also be used to produce isoprene using any of the energy sources (*e.g.* glucose or any other six carbon sugar) described herein. In some aspects, the method of producing isoprene further comprises a step of recovering the isoprene.

[0194] In some aspects, the amount of isoprene produced is measured at a productivity time point. In some aspects, the productivity for the cells is about any of the amounts of isoprene disclosed herein. In some aspects, the cumulative, total amount of isoprene produced is measured. In some aspects, the cumulative total productivity for the cells is about any of the amounts of isoprene disclosed herein.

[0195] In some aspects, any of the cells described herein (for examples the cells in culture) produce isoprene at greater than about any of or about any of 1, 10, 25, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1,000, 1,250, 1,500, 1,750, 2,000, 2,500, 3,000, 4,000, 5,000, or more nmole of isoprene/gram of cells for the wet weight of the cells/hour (nmole/g_{wcm}/hr). In some aspects, the amount of isoprene is between about 2 to about 5,000 nmole/g_{wcm}/hr, such as between about 2 to about 100 nmole/g_{wcm}/hr, about 100 to about 500 nmole/g_{wcm}/hr, about 150 to about 500 nmole/g_{wcm}/hr, about 500 to about 1,000 nmole/g_{wcm}/hr, about 1,000 to about 2,000

nmole/g_{wcm}/hr, or about 2,000 to about 5,000 nmole/g_{wcm}/hr. In some aspects, the amount of isoprene is between about 20 to about 5,000 nmole/g_{wcm}/hr, about 100 to about 5,000 nmole/g_{wcm}/hr, about 200 to about 2,000 nmole/g_{wcm}/hr, about 200 to about 1,000 nmole/g_{wcm}/hr, about 300 to about 1,000 nmole/g_{wcm}/hr, or about 400 to about 1,000 nmole/g_{wcm}/hr.

[0196] In some aspects, the cells in culture produce isoprene at greater than or about 1, 10, 25, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1,000, 1,250, 1,500, 1,750, 2,000, 2,500, 3,000, 4,000, 5,000, 10,000, 100,000, or more ng of isoprene/gram of cells for the wet weight of the cells/hr (ng/g_{wcm}/h). In some aspects, the amount of isoprene is between about 2 to about 5,000 ng/g_{wcm}/h, such as between about 2 to about 100 ng/g_{wcm}/h, about 100 to about 500 ng/g_{wcm}/h, about 500 to about 1,000 ng/g_{wcm}/h, about 1,000 to about 2,000 ng/g_{wcm}/h, or about 2,000 to about 5,000 ng/g_{wcm}/h. In some aspects, the amount of isoprene is between about 20 to about 5,000 ng/g_{wcm}/h, about 100 to about 5,000 ng/g_{wcm}/h, about 200 to about 2,000 ng/g_{wcm}/h, about 200 to about 1,000 ng/g_{wcm}/h, about 300 to about 1,000 ng/g_{wcm}/h, or about 400 to about 1,000 ng/g_{wcm}/h.

[0197] In some aspects, the cells in culture produce a cumulative titer (total amount) of isoprene at greater than about any of or about any of 1, 10, 25, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1,000, 1,250, 1,500, 1,750, 2,000, 2,500, 3,000, 4,000, 5,000, 10,000, 50,000, 100,000, or more mg of isoprene/L of broth (mg/L_{broth}, wherein the volume of broth includes the volume of the cells and the cell medium). In some aspects, the amount of isoprene is between about 2 to about 5,000 mg/L_{broth}, such as between about 2 to about 100 mg/L_{broth}, about 100 to about 500 mg/L_{broth}, about 500 to about 1,000 mg/L_{broth}, about 1,000 to about 2,000 mg/L_{broth}, or about 2,000 to about 5,000 mg/L_{broth}. In some aspects, the amount of isoprene is between about 20 to about 5,000 mg/L_{broth}, about 100 to about 5,000 mg/L_{broth}, about 200 to about 2,000 mg/L_{broth}, about 200 to about 1,000 mg/L_{broth}, about 300 to about 1,000 mg/L_{broth}, or about 400 to about 1,000 mg/L_{broth}.

[0198] In some aspects, the isoprene produced by the cells in culture comprises at least about 1, 2, 5, 10, 15, 20, or 25% by volume of the fermentation offgas. In some aspects, the isoprene comprises between about 1 to about 25% by volume of the offgas, such as between about 5 to about 15 %, about 15 to about 25%, about 10 to about 20%, or about 1 to about 10 %.

Recombinant cells capable of increased production of isoprenoid precursors and/or isoprenoids

[0199] Isoprenoids can be produced in many organisms from the synthesis of the isoprenoid precursor molecules which are the end products of the MVA pathway. As stated above, isoprenoids represent an important class of compounds and include, for example, food and feed supplements, flavor and odor compounds, and anticancer, antimalarial, antifungal, and antibacterial compounds.

[0200] As a class of molecules, isoprenoids are classified based on the number of isoprene units comprised in the compound. Monoterpenes comprise ten carbons or two isoprene units, sesquiterpenes comprise 15 carbons or three isoprene units, diterpenes comprise 20 carbons or four isoprene units, sesterterpenes comprise 25 carbons or five isoprene units, and so forth. Steroids (generally comprising about 27 carbons) are the products of cleaved or rearranged isoprenoids.

[0201] Isoprenoids can be produced from the isoprenoid precursor molecules IPP and DMAPP. These diverse compounds are derived from these rather simple universal precursors and are synthesized by groups of conserved polyprenyl pyrophosphate synthases (Hsieh et al., *Plant Physiol.* 2011 Mar;155(3):1079-90). The various chain lengths of these linear prenyl pyrophosphates, reflecting their distinctive physiological functions, in general are determined by the highly developed active sites of polyprenyl pyrophosphate synthases via condensation reactions of allylic substrates (dimethylallyl diphosphate (C₅-DMAPP), geranyl pyrophosphate (C₁₀-GPP), farnesyl pyrophosphate (C₁₅-FPP), geranylgeranyl pyrophosphate (C₂₀-GGPP)) with corresponding number of isopentenyl pyrophosphates (C₅-IPP) (Hsieh et al., *Plant Physiol.* 2011 Mar;155(3):1079-90).

[0202] Production of isoprenoid precursors and/or isoprenoid can be made by using any of the recombinant host cells that comprise acetoacetyl-CoA synthase. In addition, these cells can express one or more copies of a heterologous nucleic acid encoding a HMG-CoA reductase and HMG-CoA synthase for increased production of mevalonate, isoprene, isoprenoid precursors and/or isoprenoids. Any of the recombinant host cells expressing one or more copies of a heterologous nucleic acid encoding a HMG-CoA reductase and HMG-CoA synthase capable of increased production of mevalonate or isoprene described above can also be capable of

increased production of isoprenoid precursors and/or isoprenoids. In some aspects, these cells further comprise one or more heterologous nucleic acids encoding polypeptides of the lower MVA pathway, IDI, and/or the DXP pathway, as described above, and a heterologous nucleic acid encoding a polyprenyl pyrophosphate synthase polypeptide. Without being bound to theory, it is thought that increasing the cellular production of mevalonate in host cells by any of the compositions and methods described above will similarly result in the production of higher amounts of isoprenoid precursor molecules and/or isoprenoids. Increasing the molar yield of mevalonate production from glucose translates into higher molar yields of isoprenoid precursor molecules and/or isoprenoids, including isoprene, produced from glucose when combined with appropriate enzymatic activity levels of mevalonate kinase, phosphomevalonate kinase, diphosphomevalonate decarboxylase, isopentenyl diphosphate isomerase and other appropriate enzymes for isoprene and isoprenoid production.

Types of isoprenoids

[0203] The recombinant microorganisms of the present invention are capable of increased production of isoprenoids and the isoprenoid precursor molecules DMAPP and IPP. Examples of isoprenoids include, without limitation, hemiterpenoids, monoterpenoids, sesquiterpenoids, diterpenoids, sesterterpenoids, triterpenoids, tetraterpenoids, and higher polyterpenoids. In some aspects, the hemiterpenoid is prenol (*i.e.*, 3-methyl-2-buten-1-ol), isoprenol (*i.e.*, 3-methyl-3-buten-1-ol), 2-methyl-3-buten-2-ol, or isovaleric acid. In some aspects, the monoterpenoid can be, without limitation, geranyl pyrophosphate, eucalyptol, limonene, or pinene. In some aspects, the sesquiterpenoid is farnesyl pyrophosphate, artemisinin, or bisabolol. In some aspects, the diterpenoid can be, without limitation, geranylgeranyl pyrophosphate, retinol, retinal, phytol, taxol, forskolin, or aphidicolin. In some aspects, the triterpenoid can be, without limitation, squalene or lanosterol. The isoprenoid can also be selected from the group consisting of abietadiene, amorphadiene, carene, farnesene, α -farnesene, β -farnesene, farnesol, geraniol, geranylgeraniol, linalool, limonene, myrcene, nerolidol, ocimene, patchoulol, β -pinene, sabinene, γ -terpinene, terpineol and valencene.

[0204] In some aspects, the tetraterpenoid is lycopene or carotene (a carotenoid). As used herein, the term “carotenoid” refers to a group of naturally-occurring organic pigments produced in the chloroplasts and chromoplasts of plants, of some other photosynthetic organisms, such as algae, in some types of fungus, and in some bacteria. Carotenoids include the oxygen-containing

xanthophylls and the non-oxygen-containing carotenes. In some aspects, the carotenoids are selected from the group consisting of xanthophylls and carotenes. In some aspects, the xanthophyll is lutein or zeaxanthin. In some aspects, the carotenoid is α -carotene, β -carotene, γ -carotene, β -cryptoxanthin or lycopene.

Heterologous nucleic acids encoding polyprenyl pyrophosphate synthases polypeptides

[0205] In some aspects of the invention, the recombinant cells described in any of the compositions or methods herein comprising acetoacetyl-CoA synthase further comprise one or more nucleic acids encoding a non-thiolase MVA pathway polypeptide(s), as described above, as well as one or more nucleic acids encoding a polyprenyl pyrophosphate synthase polypeptides(s). The polyprenyl pyrophosphate synthase polypeptide can be an endogenous polypeptide. The endogenous nucleic acid encoding a polyprenyl pyrophosphate synthase polypeptide can be operably linked to a constitutive promoter or can similarly be operably linked to an inducible promoter. The endogenous nucleic acid encoding a polyprenyl pyrophosphate synthase polypeptide can additionally be operably linked to a strong promoter. Alternatively, the endogenous nucleic acid encoding a polyprenyl pyrophosphate synthase polypeptide can be operably linked to a weak promoter. In particular, the cells can be engineered to over-express the endogenous polyprenyl pyrophosphate synthase polypeptide relative to wild-type cells.

[0206] In some aspects, the polyprenyl pyrophosphate synthase polypeptide is a heterologous polypeptide. The cells of the present invention can comprise more than one copy of a heterologous nucleic acid encoding a polyprenyl pyrophosphate synthase polypeptide. In some aspects, the heterologous nucleic acid encoding a polyprenyl pyrophosphate synthase polypeptide is operably linked to a constitutive promoter. In some aspects, the heterologous nucleic acid encoding a polyprenyl pyrophosphate synthase polypeptide is operably linked to an inducible promoter. In some aspects, the heterologous nucleic acid encoding a polyprenyl pyrophosphate synthase polypeptide is operably linked to a strong promoter. In some aspects, the heterologous nucleic acid encoding a polyprenyl pyrophosphate synthase polypeptide is operably linked to a weak promoter.

[0207] The nucleic acids encoding a polyprenyl pyrophosphate synthase polypeptide(s) can be integrated into a genome of the host cells or can be stably expressed in the cells. The nucleic

acids encoding a polyprenyl pyrophosphate synthase polypeptide(s) can additionally be on a vector.

[0208] Exemplary polyprenyl pyrophosphate synthase nucleic acids include nucleic acids that encode a polypeptide, fragment of a polypeptide, peptide, or fusion polypeptide that has at least one activity of a polyprenyl pyrophosphate synthase. Polyprenyl pyrophosphate synthase polypeptides convert isoprenoid precursor molecules into more complex isoprenoid compounds. Exemplary polyprenyl pyrophosphate synthase polypeptides include polypeptides, fragments of polypeptides, peptides, and fusions polypeptides that have at least one activity of an isoprene synthase polypeptide. Exemplary polyprenyl pyrophosphate synthase polypeptides and nucleic acids include naturally-occurring polypeptides and nucleic acids from any of the source organisms described herein. In addition, variants of polyprenyl pyrophosphate synthase can possess improved activity such as improved enzymatic activity. In some aspects, a polyprenyl pyrophosphate synthase variant has other improved properties, such as improved stability (*e.g.*, thermo-stability), and/or improved solubility. Exemplary polyprenyl pyrophosphate synthase nucleic acids can include nucleic acids which encode polyprenyl pyrophosphate synthase polypeptides such as, without limitation, geranyl diphosphosphate (GPP) synthase, farnesyl pyrophosphate (FPP) synthase, and geranylgeranyl pyrophosphate (GGPP) synthase, or any other known polyprenyl pyrophosphate synthase polypeptide.

[0209] In some aspects of the invention, the cells described in any of the compositions or methods herein further comprise one or more nucleic acids encoding a farnesyl pyrophosphate (FPP) synthase. The FPP synthase polypeptide can be an endogenous polypeptide encoded by an endogenous gene. In some aspects, the FPP synthase polypeptide is encoded by an endogenous *ispA* gene in *E. coli*. The endogenous nucleic acid encoding an FPP synthase polypeptide can be operably linked to a constitutive promoter or can similarly be operably linked to an inducible promoter. The endogenous nucleic acid encoding an FPP synthase polypeptide can additionally be operably linked to a strong promoter. In particular, the cells can be engineered to over-express the endogenous FPP synthase polypeptide relative to wild-type cells.

[0210] In some aspects, the FPP synthase polypeptide is a heterologous polypeptide. The cells of the present invention can comprise more than one copy of a heterologous nucleic acid encoding a FPP synthase polypeptide. In some aspects, the heterologous nucleic acid encoding

a FPP synthase polypeptide is operably linked to a constitutive promoter. In some aspects, the heterologous nucleic acid encoding a FPP synthase polypeptide is operably linked to an inducible promoter. In some aspects, the heterologous nucleic acid encoding a polyprenyl pyrophosphate synthase polypeptide is operably linked to a strong promoter.

[0211] The nucleic acids encoding an FPP synthase polypeptide can be integrated into a genome of the host cells or can be stably expressed in the cells. The nucleic acids encoding an FPP synthase can additionally be on a vector.

[0212] Standard methods can be used to determine whether a polypeptide has polyprenyl pyrophosphate synthase polypeptide activity by measuring the ability of the polypeptide to convert IPP into higher order isoprenoids *in vitro*, in a cell extract, or *in vivo*. These methods are well known in the art and are described, for example, in U.S. Patent No.: 7,915,026; Hsieh et al., *Plant Physiol.* 2011 Mar;155(3):1079-90; Danner et al., *Phytochemistry*. 2011 Apr 12 [Epub ahead of print]; Jones et al., *J Biol Chem.* 2011 Mar 24 [Epub ahead of print]; Keeling et al., *BMC Plant Biol.* 2011 Mar 7;11:43; Martin et al., *BMC Plant Biol.* 2010 Oct 21;10:226; Kumeta & Ito, *Plant Physiol.* 2010 Dec;154(4):1998-2007; and Köllner & Boland, *J Org Chem.* 2010 Aug 20;75(16):5590-600.

Methods of using the recombinant cells to produce isoprenoids and/or isoprenoid precursor molecules

[0213] Also provided herein are methods of producing isoprenoid precursor molecules and/or isoprenoids comprising culturing recombinant microorganisms (e.g., recombinant bacterial cells) that comprise acetoacetyl-CoA synthase, a polyprenyl pyrophosphate synthase polypeptide, and one or more nucleic acids encoding a MVA pathway polypeptide including, but not limited to, HMG-CoA reductase, 3-hydroxy-3-methylglutaryl-CoA synthase (HMG-CoA synthase) polypeptides, 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase) polypeptides, mevalonate kinase (MVK) polypeptides, phosphomevalonate kinase (PMK) polypeptides, diphosphomevalonate decarboxylase (MVD) polypeptides, phosphomevalonate decarboxylase (PMDC) polypeptides, isopentenyl phosphate kinase (IPK) polypeptides, IPP isomerase polypeptides, IDI polypeptides, and polypeptides (e.g., fusion polypeptides) having an activity of two or more MVA pathway polypeptides.

[0214] The isoprenoid precursor molecules and/or isoprenoids can be produced from any of the cells described herein and according to any of the methods described herein. Any of the cells can be used for the purpose of producing isoprenoid precursor molecules and/or isoprenoids from carbohydrates, including six carbon sugars such as glucose.

[0215] Thus, provided herein are methods of making isoprenoid precursor molecules and/or isoprenoids comprising culturing recombinant host cells comprising acetoacetyl-CoA synthase, a polyprenyl pyrophosphate synthase polypeptide, and one or more heterologous nucleic acids encoding a HMG-CoA reductase and HMG-CoA synthase, in a suitable condition for producing isoprene and producing isoprenoid precursor molecules and/or isoprenoids. The cells can further comprise one or more nucleic acid molecules encoding the lower MVA pathway polypeptide(s) described above (e.g., MVK, PMK, MVD, and/or IDI) and any of the polyprenyl pyrophosphate synthase polypeptide(s) described above. In some aspects, the host cells can be any of the cells described herein. Any of the polyprenyl pyrophosphate synthase or variants thereof described herein, any of the host strains described herein, any of the promoters described herein, and/or any of the vectors described herein can also be used to produce isoprenoid precursor molecules and/or isoprenoids using any of the energy sources (e.g. glucose or any other six carbon sugar) described herein. In some aspects, the method of producing isoprenoid precursor molecules and/or isoprenoids further comprises a step of recovering the isoprenoid precursor molecules and/or isoprenoids.

[0216] The method of producing isoprenoid precursor molecules and/or isoprenoids can similarly comprise the steps of: (a) culturing host cells (e.g., bacterial cells including, but not limited to, *E. coli* cells) that do not endogenously have a HMG-CoA reductase and HMG-CoA synthase, wherein the host cells heterologously express one or more copies of a gene encoding a HMG-CoA reductase and HMG-CoA synthase; and (b) producing isoprenoid precursor molecules and/or isoprenoids, wherein the host cells produce greater amounts of isoprenoid precursors and/or isoprenoids when compared to isoprenoids and/or isoprenoid precursor - producing host cells that do not comprise the HMG-CoA reductase and HMG-CoA synthase. In certain embodiment, the host cell is a bacterial cell, an algal cell, a fungal cell (including filamentous fungi), or a yeast cell.

[0217] The instant methods for the production of isoprenoid precursor molecules and/or isoprenoids can produce at least 5% greater amounts of isoprenoid precursors and/or isoprenoids

when compared to isoprenoids and/or isoprenoid precursor -producing host cells that do not comprise the HMG-CoA reductase and HMG-CoA synthase and which have not been engineered for increased carbon flux to mevalonate production. Alternatively, the host cells can produce greater than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, or 15% of isoprenoid precursors and/or isoprenoids, inclusive. In some aspects, the method of producing isoprenoid precursor molecules and/or isoprenoids further comprises a step of recovering the isoprenoid precursor molecules and/or isoprenoids.

[0218] Provided herein are methods of using any of the cells described above for enhanced isoprenoid and/or isoprenoid precursor molecule production. The production of isoprenoid precursor molecules and/or isoprenoids by the cells can be enhanced by the expression of acetoacetyl-CoA synthase and one or more heterologous nucleic acids encoding HMG-CoA reductase and HMG-CoA synthase, one or more heterologous nucleic acids encoding a lower MVA pathway polypeptide, and one or more heterologous nucleic acids encoding a polyprenyl pyrophosphate synthase polypeptide. As used herein, “enhanced” isoprenoid precursor and/or isoprenoid production refers to an increased cell productivity index (CPI) for isoprenoid precursor and/or isoprenoid production, an increased titer of isoprenoid precursors and/or isoprenoids, an increased mass yield of isoprenoid precursors and/or isoprenoids, and/or an increased specific productivity of isoprenoid precursors and/or isoprenoids by the cells described by any of the compositions and methods described herein compared to cells which do not have one or more heterologous nucleic acids encoding a polyprenyl pyrophosphate synthase polypeptide, a lower MVA pathway polypeptide(s), a DXP pathway polypeptide(s), and/or the HMG-CoA reductase and HMG-CoA synthase and which have not been engineered for increased carbon flux to mevalonate production. The production of isoprenoid precursor molecules and/or isoprenoids can be enhanced by about 5% to about 1,000,000 folds. The production of isoprenoid precursor molecules and/or isoprenoids can be enhanced by about 10% to about 1,000,000 folds (*e.g.*, about 1 to about 500,000 folds, about 1 to about 50,000 folds, about 1 to about 5,000 folds, about 1 to about 1,000 folds, about 1 to about 500 folds, about 1 to about 100 folds, about 1 to about 50 folds, about 5 to about 100,000 folds, about 5 to about 10,000 folds, about 5 to about 1,000 folds, about 5 to about 500 folds, about 5 to about 100 folds, about 10 to about 50,000 folds, about 50 to about 10,000 folds, about 100 to about 5,000 folds, about 200 to about 1,000 folds, about 50 to about 500 folds, or about 50 to about 200 folds) compared to the production of isoprenoid precursor molecules and/or isoprenoids by cells

without the expression of one or more heterologous nucleic acids encoding HMG-CoA reductase and HMG-CoA synthase and which have not been engineered for increased carbon flux to mevalonate production.

[0219] The production of isoprenoid precursor molecules and/or isoprenoids can also enhanced by at least about any of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 1 fold, 2 folds, 5 folds, 10 folds, 20 folds, 50 folds, 100 folds, 200 folds, 500 folds, 1000 folds, 2000 folds, 5000 folds, 10,000 folds, 20,000 folds, 50,000 folds, 100,000 folds, 200,000 folds, 500,000 folds, or 1,000,000 folds compared to the production of isoprenoid precursor molecules and/or isoprenoids by cells without the expression of one or more heterologous nucleic acids encoding HMG-CoA reductase and HMG-CoA synthase and which have not been engineered for increased carbon flux to mevalonate production.

[0220] In addition, more specific cell culture conditions can be used to culture the cells in the methods described herein. For example, in some aspects, the method for the production of isoprenoid precursor molecules and/or isoprenoids comprises the steps of (a) culturing host cells (including bacterial cells including, but not limited to, *E. coli* cells) that do not endogenously have a HMG-CoA reductase and HMG-CoA synthase at 34°C, wherein the host cells heterologously express one or more copies of a gene encoding a HMG-CoA reductase and HMG-CoA synthase on a low to medium copy plasmid and under the control of a strong promoter; and (b) producing mevalonate. In some aspects, the method of producing mevalonate further comprises a step of recovering the isoprenoid precursor molecules and/or isoprenoids. In certain embodiment, the host cell is a bacterial cell, an algal cell, a fungal cell (including filamentous fungi), or a yeast cell.

Exemplary Purification Methods

[0221] In some aspects, any of the methods described herein further include a step of recovering the compounds produced. In some aspects, any of the methods described herein further include a step of recovering the isoprene. In some aspects, the isoprene is recovered by absorption stripping (*See, e.g.*, US Appl. No. 12/969,440). In some aspects, any of the methods described herein further include a step of recovering the heterologous polypeptide. In some aspects, any of the methods described herein further include a step of recovering the terpenoid or carotenoid.

[0222] Suitable purification methods are described in more detail in U.S. Patent Application Publication US2010/0196977 A1.

[0223] The invention can be further understood by reference to the following examples, which are provided by way of illustration and are not meant to be limiting.

EXAMPLES

Example 1: Construction of Plasmids Encoding the Upper MVA Pathway for the Production of MVA via Acetoacetyl-CoA Synthase (NphT7)

[0224] An expression plasmid was generated to encode the *nphT7* gene, *mvaS* gene, and *mvaR* gene that express Acetoacetyl-CoA synthase, HMG-CoA synthase, and HMG-CoA reductase, respectively. Briefly, forward and reverse primers were synthesized to amplify the *mvaS* gene (MCM489 and MCM490), *mvaR* gene (MCM491 and MCM492), and *nphT7* gene (MCM495 and MCM496) from synthetic genes encoding *Streptomyces* proteins (Table 1). The MCM485 forward primer and MCM486 reverse primer were used to amplify the expression vector. The DNA template for amplification of the vector is pMCM1225 (Table 2). The DNA template for amplification of *mvaS* and *mvaR* from *Streptomyces* is StrepCL190 (DNA2.0) which contains a synthetic operon encoding *mvaS* and *mvaR*, also encodes Acetyl-CoA acetyltransferase (*atoB*). The pMCM1187 template which includes a synthetic gene encoding a His-tagged NphT7 is used for amplification of the gene encoding NphT7 (Genbank BAJ10048).

Table 1. Primers used for construction of pMCM1320 and pMCM1321

Primer Name	Description	Primer Sequence
MCM485	pMCM82 USER 2 (for)	AGCTGG/IDEOXYU/ACCATA/ideoxy U/GGGAAT/IDEOXYU/C (SEQ ID NO:3)
MCM486	pMCM82 USER 1 (rev)	ATTTAA/ideoxyU/CGATACA/ideoxyU/TAATA/ideoxyU/ATACCTC(SEQ ID NO:4)
MCM489	StrepCL190_ <i>mvaS</i> USER 3 (for)	ATGAGCA/ideoxyU/TTCTA/ideoxyU/CGGTA/ideoxyU/CCATGATCTT(SEQ ID NO:5)

MCM490	StrepCL190_mvsaS USER 4 (rev)	AACGTGC/ideoxyU/TCATAGA/ideoxyU/ACGT/ideoxyU/TATGGTCGTT (SEQ ID NO:6)
MCM491	StrepCL190_mvsaR USER 1 (for)	ATAT/ideoxyU/AATGTA/ideoxyU/CGATTAAA/ideoxyU/AAGGAGGAATAAA CCATGACCGAAACTCATGCAATTGCTG (SEQ ID NO:7)
MCM492	StrepCL190_mvsaR USER 3 (rev)	ATACCGA/ideoxyU/AGAAA/ideoxyU/GCTCA/ideoxyU/TGGTATATCCTCCTAGTGCCTCTAGATTACGCACCAACT TTCGCGGTTTTGTTATCACGTTC (SEQ ID NO:8)
MCM495	StrepCL190_nphT7 USER 4 (for)	AACG/ideoxyU/ATCTA/ideoxyU/GAAGCACGT/ideoxyU/AAAGATCTCGCACTAGGAGGATATACCAATGACCGACGTGCGCTTTCGGAT (SEQ ID NO:9)
MCM496	StrepCL190_nphT7 USER 2 (rev)	AATTCCCA/ideoxyU/ATGG/ideoxyU/ACCAGC/ideoxyU/GCAGTCACCATTCATCAACGCGAAGG (SEQ ID NO:10)

Note: /ideoxyU/ indicates an internal deoxyuridine nucleotide in the primer (Bitinaite J et al., *Curr. Protoc. Mol. Biol.* 86:3.21.1-3.21.16, 2009).

Table 2. DNA Templates for construction of pMCM1320 and pMCM1321

Plasmid Name	Description	Genes of Interest
pMCM1225	pCL-Ptrc-Upper <i>E.gallinarum</i>	vector
Streptomyces CL190 Upper	Strep CL190 Upper MVA pTrcHis2A	Streptomyces mvsaS, mvsaR
pMCM1187	pET15b-NphT7 (GeneOracle GcMM134)	Streptomyces nphT7

[0225] Templates were amplified according the manufacturer's protocol for Agilent PfuTurbo Cx Hotstart DNA Polymerase (cat #600410). Reactions contain 5µL buffer, 1µL each 10µM primer, 1µL template plasmid (50-200µg/uL), 1µL 10mM dNTPs, 40µL ddH₂O, 1µL PfuCx (Table 3). Reactions were subsequently cycled as follows: one cycle at 95°C for 2 minutes, thirty heating and cooling cycles (95°C for 30 seconds, 55°C for 30 seconds, 72°C for 5 minutes and 30 seconds), and one cycle at 72°C for 10 minutes. Reactions were held overnight at 4°C.

Table 3. Polymerase Chain Reaction (PCR) Reactions

Amplicon	Primers	Template
Vector	MCM485/MCM486	pMCM1225

mvaS	MCM489/MCM490	Streptomyces CL190 Upper
mvaR	MCM491/MCM492	Streptomyces CL190 Upper
nphT7	MCM495/MCM496	pMCM1187

[0226] Following the amplification by PCR, 10 μ L of the PCR reaction are mixed with 1 μ L USER Enzyme (New England Biolabs # M5505S) and 1 μ L DpnI (Roche) and then incubated at 37°C for 2 hours. To generate an expression plasmid encoding the upper MVA pathway including the mvaR, mvaS, and NphT7 genes, ligation reactions were assembled from 2 μ L of each USER reaction plus 8 μ L of Buffer 1 and 1 μ L ligase from the Roche Rapid Ligation Kit (11635379001). Reactions proceeded at room temperature for 1 hour and were stored at -20°C overnight. To recover the ligated plasmid, 3 μ L of the ligation was used to transform chemically competent TOP10 cells (Invitrogen #C404003) according to manufacturer instructions. Following recovery in 250 μ L LB for 1hr at 37°C, transformants were selected on LB/spec50 plates at 37°C overnight. Single colonies were cultured in 5mL LB/spec50 and stored at -80°C. DNA was extracted from the isolated colonies and successful generation of constructs encoding the upper MVA pathway including mvaR, mvaS, and NphT7 was confirmed by DNA sequencing (Table 4). Plasmids pMCM1320 and pMCM1321 were isolated from these strains.

Table 4. Isolated Strains Containing Plasmids Encoding the Upper MVA Pathway

Strain	Plasmid Description	Plasmid Name
MCM1320	pCL-Ptrc-mvaR-mvaS-nphT7_StrepCL190_clone3-1	pMCM1310
MCM1321	pCL-Ptrc-mvaR-mvaS-nphT7_StrepCL190_clone3-2	pMCM1321

Example 2: Construction of Plasmid Encoding Isoprene Synthase and MVK for the Production of Isoprene

[0227] An expression plasmid for isoprene synthase and mevalonate kinase (MVK) with a bla gene encoding beta –lactamase was generated. Briefly, the bla gene from pUC19 DNA (Invitrogen) was amplified with primers MCM694 and MCM695 (Table 5). The expression plasmid pDu65 was amplified, not including the cmR marker gene, with primers MCM696 and MCM697. Amplicons were fused using the Invitrogen GENEART® Seamless Cloning and Assembly Kit (#A13288) according to the manufacturer's protocol and the product was subsequently transformed into chemically competent MD09-314 cells. Fused plasmid was

selected on LB/carb50 plates at 37°C overnight. A single colony was picked, grown in 5mL LB/carb50 at 37°C, and stored at -80°C.

Table 5. Primers for Construction of pMCM1623

Primer Name	Description	Primer Sequence
MCM694	bla - pDu65 - assemble 1	CGGTGAACGCTCTCCTGAGTAGCATGAGATTATCAAAAAGGATCTTCACC (SEQ ID NO:11)
MCM695	bla - pDu65 - assemble 2	GGGACAGCTGATAGAAACAGAAGCCAAATATGTATCCGCTCATGAGACAA (SEQ ID NO:12)
MCM696	bla - pDu65 - assemble 3	TTGTCTCATGAGCGGATACATATTTGGCTTCTGTTCCTATCAGCTGTCCC (SEQ ID NO:13)
MCM697	bla - pDu65 - assemble 4	GGTGAAGATCCTTTTTGATAATCTCATGCTACTCAGGAGAGCGTTCACCG (SEQ ID NO:14)

Example 3: Construction of Thiolase Deficient E.coli strain CMP861

[0228] An acetyl-CoA acetyltransferase (atoB) deficient strain was generated. Briefly, a DNA fragment containing the atoB gene interrupted by a kanamycin marker was amplified by PCR using strain JW2218 from the Keio collection (Baba et al. 2006. *Mol. Syst. Biol.* 2: 2006.0008) as a template, and primers atoBrecF (5'- GCAATTCCCCTTCTACGCTGGG -3'(SEQ ID NO:15)) and atoBrecR (5'- CTCGACCTTCACGTTGTTACGCC -3'(SEQ ID NO:16)). The polymerase Herculanase II Fusion (Agilent, Santa Clara, CA) was used according to the manufacturer's instructions. The PCR product obtained was used in a Recombineering Reaction (Gene Bridges, Heidelberg, Germany) as recommended by the manufacturer to integrate the PCR product at the atoB locus in strain CMP451. CMP451 is CMP258 (See U.S. Patent Application No: 12/978,324) with two modifications. Briefly, the promoter in front of the citrate synthase gene (*gltA*) in CMP258 was replaced by GI1.2 (US patent 7,371,558). Two wild-type promoters have been described for *gltA* (Wilde, R, and J. Guest. 1986. *J. Gen. Microbiol.* 132:3239-3251) and the synthetic promoter was inserted just after the -35 region of the distal promoter. A PCR product was obtained using primers UpgltACm-F (5'- TATTTAATTTTAAATCATCTAATTTGACAATCATTCAACAAAGTTGTTACAATTAACCCTCACTAAAGGGCGG-3' (SEQ ID NO:17)) and DngltA1.xgiCm-R (5'- TCAACAGCTGTATCCCCGTTGAGGGTGAGTTTTGCTTTTGTATCAGCCATATATTCCACCAGCTATTTGTTAGTGAATAAAAGTGTTGAATTATTTGCTCAGGATGTGGCATH

GTCAAGGGCTAATACGACTCACTATAGGGCTCG-3' (SEQ ID NO:18)), and FRT-gb2-Cm-FRT template DNA from Gene Bridges (Heidelberg, Germany) as a template. The PCR product was purified and used in a lambda red-mediated recombination as described by the manufacturer (Gene Bridges, Heidelberg, Germany). Several colonies were selected for further characterization. The promoter region was PCR-amplified using primers gltAPromSeqF (5'-GGCAGTATAGGCTGTTCACAAAATC-3' (SEQ ID NO:19)) and gltAPromSeqR (5'-CTTGACCCAGCGTGCCTTTCAGC-3' (SEQ ID NO:20)) and, as a template, DNA extracted by resuspending a colony in 30 μ L H₂O, heating at 95°C for 4 min, spinning down, and using 2 μ L of that material as a template in a 50 μ L reaction. After observing the sequencing results of the PCR products obtained, a colony harboring the promoter GI1.2 (US patent 7,371,558) was saved for further use and named CMP141. Strain MD09-313 was built by transducing CMP258 (See U.S. Patent Application No: 12/978,324) with a P1 lysate from strain MCM521 (See U.S. Patent Application No: 12/978,324) and selecting for colonies on Luria-Bertani plates containing 20 μ g/ml kanamycin. P1 lysates were prepared according to the method described in Ausubel, et al., *Current Protocols in Molecular Biology*, John Wiley and Sons, Inc. The kanamycin marker was removed using the protocol recommended by the manufacturer (Gene Bridges, Heidelberg, Germany) to form strain MD09-314. A P1 lysate was made from strain CMP141 and was used to transduce strain MD09-314 to form CMP440. The chloramphenicol marker was removed using the protocol recommended by the manufacturer (Gene Bridges, Heidelberg, Germany) to form strain CMP451.

[0229] To generate the CMP861 strain, CMP451 underwent a recombineering reaction with the atoB:FRT-Kan-FRT PCR product and colonies were selected on LB + 20 μ g/ml of kanamycin. A single colony was picked and this strain was named CMP856. The kanamycin marker was subsequently removed from CMP856 by FRT recombination (Datsenko and Wanner, 2000. PNAS 97:6640-5), using plasmid pCP20. Once the transformants were selected on LA+ 50 μ g/ml carbenicillin at 30°C, two colonies were re-streaked on a LB plate and incubated at 42°C. A kanamycin-sensitive colony was selected from those plates and named CMP861. The mutation was verified using primers atoBrecR and atoBcheckF (5'-GCTTATATGCGTGCTATCAGCG-3' (SEQ ID NO:21).

Example 4: Construction of Strains Encoding Pathways for the Production of MVA via Acetoacetyl-CoA Synthase (NphT7)

[0230] Strains MCM1331, MCM1681, MCM1684, MCM1685, and MCM1686 were constructed by electroporating the indicated plasmid into the indicated parent strain (Table 6). Parent cells were grown in 5mL LB supplemented with the indicated antibiotic from freezer vial scraping at 37°C with shaking at 250 rpm. When the cell density reached an OD 0.5-0.8, the culture was placed on ice until cold and a 3mL sample of the culture was washed in iced double distilled H₂O three times before resuspension in 200μL iced double distilled H₂O. A 100μL cell suspension sample was mixed with 1 to 3μL DNA in an eppendorf tube and then transferred to a 2mm electroporation cuvette for electroporation at 25uFD, 200ohms, 2.5kV, and immediately quenched with 500μL LB. Cells were recovered with shaking at 37°C for 1hr and transformants were selected overnight on LB plates with the indicated antibiotics at 37°C. A single colony was picked into 5mL LB + antibiotics, grown at 37°C and stored in 16.5% glycerol at -80°C. Strain MCM1686 contains the pCL1920 empty plasmid and therefore does not express the upper MVA pathway and directs isoprene production via the DXP pathway.

Table 6. Engineered Strains Encoding Pathways for the Production of MVA

Strain	Genotype	Parent	Plasmid	Antibiotics
MCM1331	atoB (Keio) + pCL-Ptrc-mvaR-mvaS-nphT7_StrepCL190_clone3-2	Keio <i>atoB</i>	pMCM1321	Spec50
MCM1681	HMB gi1.2-gltA atoB::FRT pACYC-pTrcAlba-mMVK CARB	CMP861	pMCM1623	Carb50
MCM1684	HMB gi1.2-gltA atoB::FRT pACYC-pTrcAlba-mMVK CARB + pCL-Ptrc-mvaR-mvaS-nphT7_StrepCL190_clone3-1	MCM1681	pMCM1320	Carb50 spec50
MCM1685	HMB gi1.2-gltA atoB::FRT pACYC-pTrcAlba-mMVK CARB + pCL-Ptrc-mvaR-mvaS-nphT7_StrepCL190_clone3-2	MCM1681	pMCM1321	Carb50 spec50
MCM1686	HMB gi1.2-gltA atoB::FRT pACYC-pTrcAlba-mMVK CARB + pCL1920	MCM1681	pCL1920 vector	Carb50 spec50

Example 5: Isoprene Production via Acetoacetyl-CoA Synthase (NphT7) using Engineered Strains

[0231] The specific productivity of isoprene from strains MCM1684, MCM1685, and MCM1686 was determined. A 10uL sample of cell culture grown in LB media containing Carb50 and Spec 50 at a density near OD 1.0 was inoculated into TM3 cell culture medium containing 1% glucose, 0.02% yeast extract, carb50, and spec50 before culture overnight at 34°C. These cultures were used to inoculate 5mL of the same TM3 media at OD 0.2 which was subsequently grown at 34°C for 2 hours and 45 minutes with shaking at 250rpm. Cultures were induced with 400uM IPTG and grown for an additional 2 hours and 15 minutes. Culture density was determined from a 1:10 dilution of the broth. A 100μL sample of the broth was incubated in a 2mL headspace vial at 34°C for 30 minutes, followed by heat kill at 70°C for 12 minutes. Levels of isoprene in the headspace were determined by flame ionization detector coupled to a gas chromatograph (Model G1562A, Agilent Technologies) (Mergen et al., *LC GC North America*, 28(7):540-543, 2010). Data analysis of the isoprene produced demonstrated that MCM1684 and MCM1685, which contain the DXP pathway as well as a pathway for the production of isoprene via NphT7, makes isoprene at 2.4 times and 2.5 times the rate of MCM1686, respectively, which contains only the DXP pathway (Table 7 and Figure1).

Table 7. Isoprene Production

Strain	Isoprene Specific Productivity (μg isoprene/L broth/OD/hr)
MCM1684	1286
MCM1685	1381
MCM1686	542

[0232] The following are sequences of various constructs made:

Strep CL190 Upper MVA pTrcHis2A

gtttgacagcttatcatcgactgcacgggtgcaccaatgcttctggcgctcaggcagccatcggaagctgtggtatggctgtgcaggctcgtaaa
tactgcataatcgtgtcgtcgaaggcgactcccgttctggataatgtttttgcgccgacatcataacggttctggcaaatattctgaaatga
gctgttgacaattaatcatcggctcgtataatgtgtggaattgtgagcggataacaatttcacacaggaaacagcggcgtgagaaaaagc
gaagcggcactgctcttaacaatttatcagacaatctgtgtggcactcgaccggaattatcgattaactttattataaaaattaaagaggtat
atattaatgtatcgattaaataaggaggaataaacatggcatctgctactaactcatctgtaattgttgctggtgcacgtactccgatgggtcg
cctgctgggttcctgaaatcttctggtgcggatctgggtggcttcgcgatcaaacgagcactggaccgcgcaggcattggcggcgac
caggtccagtacgttatcatgggtcaggtgttgaggcaggtgcgggtcagattccggctcgtcaggcagcggttaaagctggcattccga

tgaacgtaccagctctgaccatcaacaaagtgtgcctgtccggctctggacgcgacgcgctggccgatcaactgatccgcgctggtgaattt
gacattgtttagcagggcgccaggaatctatgactaacgccccgcaccttctgccgaagtctctgaaggttataagtacggcgctatcga
gatgctcgaatggcttacgacggcctgactgacctgtgggaaaacattccgatgggccagagcactgagaaacacaacacccgtct
gggtatcggctgtgaagttcaggatgagatcgcggcgctgtctcaccagcgtgctgctggccagaaaaatggcctcttcgaagctga
aatcaccggatcgaaattccgcagcgtaaaggtgaaccgggtgtattcagcaagacgaaggcattcgcgcggaaaccactgctgaatc
cctcgcaaaactcgtccggcttactaaggacgggtactatcactgcgggcaccgcgtctcagatttccgatggtgcggcagccgttgtg
tcattgtcgaaggcgaaggcgttggaactgggtctggattggatcgtgaaattggtgccacggcaacgtggcagggccggacaattctct
gcaatcccaaccatcaaacgcaatcctgcacgcactgaagaaagaaggctctgaagtagaagacctggacctgatcagatcaacgaag
cgtttgcggcggttggccaccaatctatgaaagacctgggtgtctccaccgaaaagggttaacgtgaacggtggcgcaatcggcctggggc
atccgattggcatgtccgggtgctcgtctggttctgcacctggcactggagttgaagcgtcgtggtggtggcgtaggtgcagccgccctgtgt
gggtggcggtggtcagggcgatgcactgatcgtacgtgtcccgaagcgtaagccttcttaagtagctcagatacccttataagctttacaa
ggaggaaaaaacatgagcatttctatcggtatccatgatcttctgttcgcgactaccgagttcgttctgcctcatacggctctggccgagtat
aatggtactgaaattgtaaatatcacgttggcatcggtaacagagcatgagcgtacctgcggcggtatgaggacatcgtgactatggccg
cgaccggcgacgtccgatcattgaacgcaacggtaaatccgtatccgcactgtggtgttcgctacggagtcctccattgatcaagctaaa
gcgggtggcgatatactattctctgtggtggcctggaaatccgcgtgctgtagttgaactgaaacaggcatgctacggtgcgacggca
gcattgcagttcgtattggtctggttcggcgatccggcgacgaggtgctggtgatcgaaagcagcgtttctaaatacaggttgattcg
ccgggtgaggaacccagggcgacggcggttctgtatgctggttggcgacatcctgcactgcttcgattgaagaaccgtccggcctc
ttaccggcgacgttatgatttctggcgccgaactacctgaccaccgacctgtagatggccaggagtcctcaacgcctacctgcaag
cagttgaaggtgcgtggaaggactacgcagagcaggacggctgtagccttgaagagttgcagcttctgttaccaccagccgttactaa
aatggcgtaaaagctcaccgccacctgctgaacttcaacggttacgacactgacaaagatcgattgaaggcgccctgggtcaaaactac
cgcttacaataatgtgatcggtaactcctacactgcgtcagtttatctgggcctggcgggcgcttctgtagcagggcgacgacctgaccggtc
gttctatcggcttctgtcttacggctccgtagcgtacggagttttctgggcaccgttgttctggttaccgtgaacgtctgcgtactgaa
gcgaaccagggaagctatcgacgccgtaaatctgtcgattacgcgacttatcgtgaactgcatgagtacacgctccgctctgatggtggtga
tcacgccacggcggttcagaccaccgggtccattccgtctggcaggtatcaacgaccataaacgtatctatgaagcaggttaagcctgactta
aggtagctgctttcccttatgagctctacaaggaggaaaaaacatgaccgaaactcatgcaattgctggtgtaccgatcggttgggttg
ggccgctgcgtatctctggcaacgtagcagaaaccgaaactcaggttccgctggcaacctacgaatctccgctgtggcgctctgtgggtcg
tggtgcgaaggtatccgctgacccgaaaagggtatcgttgaaccctcgttgacgaacgtatgacctgtagcgtcatcgtagaagccacc
gacggccagaccgcttatatggctgcacagaccattcatgctcgcattgatgaactgcgcgaagtggctggtgttccgttctgcgcag
ctgattaatatcaaacatgaaattaacgccaacttctgttctacccgttgaatttaccaccggtagcgcacttgccataacatggccacct
ggcgctctgacgttctgttgggtcacctcctggaaaccatccagggcatctcctacggctccatttctggaactactgactgacaagaaagc
aactgccattaacggtatctctgggtcgcggcaaaaacgttatcaccgaattgctggtgcccgcgcgatgtttagaaaaataacctgcacacca
ccgctgcgaaaaatcggtgaactgaacatccgtaaaaacctgctgggactctcctggcagggcgcatccgttctgcgaacgcgcattttgca
aatatgctgctgggtttctacctggcaactggccaggacgcagcaaacatcgttagggtagccagggcggttgaatggcggaagatcgtg
acgggtgatctgtacttgcgtgcaccttccgaatctgatcgtgggtactgttgcaacggtaaggcgctgggtttgttgaacgaatctgg
cccgtctgggtgctgcgcggatcgcgaaccggcgaaaaatgcgcgccgtctggcgttatccgctgccaccgtgctgtgtggtgaa
ctgtccctgttggccgcgcagaccaacctggtgaactgatcgtgcacatgttcagctggaacgtgatacaaaaaccgcgaaagttggtg
cgtaagatctgcagctggtaccatattgggaattcgaagcttggggccgaacaaaaactcatctcagaagaggatctgaatagcgccgctg
accatcatcatcatcattgagtttaaacggtctccagcttggctgttttggcggtatgagagaagatttccagcctgatacagattaaatcag
aacgcagaagcggtctgataaaacagaatttgcctggcgcgtagcgcggtgtcccacctgaccccatgccgaactcagaagtgaag
cgccgtagcgccgatgtagtgggtgtcctccatcgagagtagggaaactgccagcatcaataaaacgaaaggctcagtcgaaag
actggccttctgtttatctgttgttgcgggaacgctctcctgagtaggacaaatccggcgaggcggatttgaacgttgcgaagcaacg
gcccggagggtggcgggcaggacggccgataaaactgccaggcatcaataaagcagaaggccatctgacggatggccttttgcgt
ttctacaaactcttttgttttttctaaatacattcaaatatgtatccgctcatgagacaataacctgataaatgttcaataatattgaaaaagg
aagagtatgagtattcaacattccgtgtcgccttattcccttttttggcgcattttgccttctgttttctcaccagaaacgctggtgaaagt
aaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggaagatccttgagagtttgcggccgaa
gaacgttttcaatgatgagcattttaaagttctgtatgtggcgcggtattatccgtgttgacggcggaagagcaactcggtcggcg
atacactattctcagaatgacttgggtgagtactaccagtcacagaaaagcatcttaccgatggcatgacagtaagagaattatgcagtgt
gccataacctgagtgaacactgcggccaaacttcttgcacacgacggaggaccgaaggagctaaccgctttttgcacaacctgg

gggatcatgtaactgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaa
 tggcaacaacgttgcgcaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggagggcgataaagtt
 gcaggaccacttctgcgctcggcccttcggctggtgtttattgctgataaatctggagccggtgagcgtgggtctcgcgggtatcattgca
 gcactggggccagatggtaagccctcccgatcgtatgtatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatc
 gctgagataggtgcctcactgattaagcattggttaactgtcagaccaagtttactatatacttttagattgatttaaaacttcattttaatttaa
 aggatctaggtgaagatccttttgataatctcatgacaaaaatcccttaacgtgagtttcttccactgagcgtcagacccgtagaaaagat
 caaaggatcttcttgagatccttttttgcgcgtaatctgctgcttgcacaaaaaaaccaccgctaccagcgggtgtgtttgtccggatc
 aagagctaccaactcttttccgaaggtaactggttcagcagagcgcagataccaaatactgtccttctagtgtagccgtagttagccacc
 acttcaagaactctgtagcaccgcctacatacctcgtctgtaactctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgg
 gttggactcaagacgatagttaccggataaggcgcagcgggtcgggtgaacggggggttcgtgcacacagcccagcttgagcgaacg
 acctacaccgaactgagatacctacagcgtgagctatgagaaagcgcacgcttcccgaaggagaaaggcggacaggtatccggtaa
 gcggcaggggtcggaaacaggagagcgcacgagggagcgttccagggggaaacgcctggtatctttatagctctgcgggttcgccacctc
 gacttgagcgtcgtttttgtgatgctcgtcaggggggaggcctatgaaaaacgccagcaacgcggcctttttacgggttcctggcctttt
 gctggccttttgcacatgtttcttctcgttattccctgattctgttgataaccgtattaccgcctttgagtgaactgataccgctcgcgca
 gccgaacgaccgagcgcagcagtcagtgagcgaaggagcgggaagagcgcctgatcgggtattttctcttacgcatctgtgcgggtattt
 cacaccgcatatggtgactctcagtaaatctgctctgatccgcatagttaagccagtatacactccgctatcgtactgactgggtcat
 ggctgcgccccgacaccgccaacaccgctgacgcgcctgacgggcttgtctgctcccggcatccgcttacagacaagctgtgaccg
 tctccgggagctgcatgtgtcagaggtttaccgctcatcaccgaaacgcgcgagggcagcagatcaattcgcgcgcgaaggcgaagcgg
 catgcatttacgttgacaccatcgaatggtgcaaacctttcgggtatggcatgatagcgccgggaagagagtcattcagggtgtgtaat
 gtgaaaccagtaacgttatacgtatgctgcagagtatccgggtgtcttctatcagaccgtttcccgctggtgaaccaggccagccacgtttc
 gcgaaaaacgcgggaaaaagtggaaagcggcgatggcgagctgaattacattcccaaccgcgtggcacaacaactggcgggcaaacag
 tcgttgctgattggcgttgccacctccagctctggccctgcacgcgcgctgcgaattgtcgcgcgattaaatctcgcgccgatcaactggg
 tggcagcgtggtgtgtcgtatgtagaacgaagcggcgctgaagcctgtaaagcggcggtgcacaatcttctcgcgaacgcgtcagtg
 ggctgatcattaactatccgctggatgaccaggatgccattgctgtggaagctgcctgcactaatgttccggcggtatttcttgatgtcttgac
 cagacacccatcaacagttatttttctccatgaagacggtagcgcactgggcgtggagcactgtgtgcattgggtcaccagcaaatcgc
 gctgttagcggggcccaatgaattctgtctcggcgctgtcgtctggtggtggcataaatactcactcgaatcaaatcagccgatagc
 ggaacgggaaggcgcactggagtccatgtccgggttttaacaaaccatgcaaatgctgaatgagggcacgttccactgcgatgctggtt
 gccaacgatcagatggcgctggcgcaatgcgcgccattaccgagtcgggctgcgcgttggtgcggatctcggtagtggtgatacga
 cgataccgaagacagctcatgttatatcccgcgtaaccaccatcaaacaggattttcgcctgctggggcaaacagcgttgaccgcttg
 ctgcaactctctcagggccagggcgtgaagggaatcagctgttgcctgctcactggtgaaaagaaaaaccacctggcgcccaatcag
 caaacgcctctccccgcgcgttgccgattcattaatgcagctggcagcagaggttcccgactggaaagcgggcagtgagcgaacg
 caattaatgtgagttagcgcgaattgatctg (SEQ ID NO:22)

pMCM1187 - pET15b-NphT7 (GeneOracle GcMM134)

ttctcatgtttgacagcttatcatcgataagctttaatgcggtagtttatcacagttaaattgctaacgcagtcaggcaccgtgtatgaaatctaac
 aatgcgctcatcgtcatcctcggcaccgtcaccttggatgctgtaggcataggttgggtatgccgggtactccgggctcttgcgggatatc
 cggatatagttctcctttcagcaaaaaacccctcaagaccggttagaggcccaagggttatgtagttattgctcagcgttgccagca
 gccaaactcagcttcttctgggctttgttagcagccggtatccttaccattcaatcaacgcgaaggaaagctgccatgccccgccgaaac
 ctgccaacagaacgagttcgcctgggcgaaaggaccagcgcgcactgctgcatccatagtgataggtatggacgcagcgcctgtattac
 cgtatgtttcaactgtacggtgcatagtggcacgaggagatgcaattcgcgaacacttcatccagcataacgccgttcgcctggtgtggg
 acaaaagtgcgaaatgtctgcgcacatccactcctgttcatgcagaaaccccttaacagctgcgggaagggtctctgtcacgaaacgccgca
 ctctgcgaccatccattgcaaaagtattgaagaccggcatcaagcccgtctgtgtcaagaggttgcgtgaaccactgctggcacgcggat
 cagatccgtcagtcctccgaaggatgaagagcgaacccggcgacgattggcccgggtccagtggacgtcgggcctaataaccatcgcac
 cagccccgtcaccaaaaagtaccactgttttacgatccgcagggttcaggatacgcgaatacaggtccgccctattaccagagcgtatcc
 gccgcggtaaaccaacgtacccgcaactgacgaaagtgcgaaaacgcgtccgctgcacactgcgttcacatcgaatgcggcggtgcctg
 ttgaccccaaatgatgctgaacataagcagcggtaggggggctgaggacgggtccggggtcgaagtagccaccgcaataacggttaactgc
 tccggagttatgcccgcagccttcagtgccgcacgaccgcggcagtggaaggtcactagtcgcttgatcatctgcgccaccgtctct

gacgtatacccgcttgcgtgtaatccaatcatcgtccacaccagccgggtgcgccaacttcgtcattactcagatgcgttccggcacgtacg
caccgggtaccaattatccgaaagcgacgtcggatcatatggctgccgcggcaccaggccgctgctgtgatgatgatgatggctgct
gccccatggtatatctccttctaaaggttaaaaaattatttctagaggggaattgttatccgctcacaattccccctatagttagtgcgtattaatttc
gcgggatcgagatctcgtacgtcgcggacgcacgtggtggccggcatcaccggcgccacagggtgcggttgcgtggcgccctatatcgcc
gacatcaccgatggggaagatcgggctcggcacttcgggctcatgagcgcttgtttcggcggtgggtatgggtggcaggccccgtggccgg
gggactgttggcgccatctccttgcacacattccttgcggcgccgggtgctcaacggcctcaacctactactgggctgcttctaatgc
aggagtcgcataaggagagcgctcgagatcccgacaccatcgatggcgcaaaaccttgcgggtatggcatgatagcgcccgggaag
agagtcaattcagggtggtgaatgtgaaaccagtaacgttatagatgtcgcagagatgccgggtgtctcttatcagaccgttcccgcgtgg
tgaaccaggccagccacgtttctgcgaaaacgcgggaaaaagtggaagcggcgatggcgaggctgaattacattcccaaccgcgtggc
acaacaactggcgggcaaacagtcgttgcgtgattggcggttgcacacctccagctctggccctgcacgcgccgtcgcaaatgtcgcggcgatt
aaatctcgcgccgatcaactgggtgccagcgtggtggtgctgatgtagaacgaagcggcgctgaagcctgtaaagcgcggtgcacaa
tcttctcgcgaacgcgtcagtggtgctgacattaactatccgctggtgacacaggatgccattgctgtggaagctgcctgcactaatgttcc
ggcggtatttcttgcgtctgaccagacacctcaaacagtatttttctcccatgaagacggtagcgactggcggtggagcatctggtc
gcattgggtcaccagcaaatcgcgtgttagcggggccattagtctcgcgcgtctgcgttgcgttgggtggcataaatatctcact
cgcaatcaaatcagccgatagcggaaacgggaaggcgactggagtgccatgtccgggtttcaacaaccatgcaaatgctgaatgagggc
atcgttccactgcgatgctggttccaacgatcagatggcgctggcgcaatgcgcgccattaccgagtcggggtcgcggttgggtcg
gatctcggtagtggtgatacgacgataccgaagacagctcatgtatatcccgccgttaaccacctcaaacaggatttgcctgctggg
gcaaacacgcgtggaccgcttgcgtgcaactctcagggccaggcggtgaaggcgcaatcagctgttggccgtctcactggtgaaaagaaa
aaccacctggcgcccaatacgaacacgcctctccccgcggttggcggttcattaatgcagctggcacgacaggttcccactgga
aagcgggcagtgagcgcaacgaattaatgtaagttagctcactcattaggcaccgggatctcgaccgatgcccttgagagccttcaacc
agtcagctccttccgggtggcgcgggggcatgactatcgtcggcgcacttatgactgtcttcttatcatgcaactcgtaggacaggtgccggc
agcgctctgggtcatttccggcgagggaccgcttgcgtggagcgcgacgatgacggcctgtcgttgcgttaccggaatcttgcacgcc
tcgctcaagccttgcactggtcccgcacaaacgttccggcgagaagcagggccattatccggcgcatggcgccgacgcgctgggct
acgtcttgcgtggcgttcgcgacgcgaggctggatggccttccccattatgattcttctcgttccggcgcatcgggatgccgcgttgcag
gccatgctgtccaggcaggtagatgacgaccatcagggacagcttcaaggatcgctcgcggctcttaccagcctaactcgtactggac
cgctgatcgtcagggcatttatccgcctcggcgagcacatggaacgggttggcatggaattgtaggcggcgccctataccttgcctc
cccgcgttgcgtcgggtgcatggagccggggccacctgcacctgaatggaagcggcgccacctcgttaacggattcaccactccaag
aattggagccaatcaattcttgcggagaactgtgaatgcgcaaaccaaccttggcagaacataccatcgcgctccgcatctccagcagc
cgcacgcggcgcatctcgggcagcgttgggtcctggccacgggtgcgcgatgacgtgctcctgtcgttggagacccggctaggctggcg
gggttgccttactggttagcagaatgaatcaccgatcgcgagcgaacgtgaagcactgctgctgcaaaacgtctgcgacctgagcaac
aacatgaatggtcttcggttccgtgttctgtaaagtctgaaacgcgggaagtcagcgccctgcaccattatgttccggatctgcacgcagg
atgctgctggctacctgtggaacacctacatctgtattaacgaagcgttgcattgacctgagtgattttctctgttcccgcgcacccat
accgccagtgtttacctcacaacgttccagtaaccggcgatgttcatcatcagtaaccgtatcgtgagcactctctctgttcatcgggtat
cattacccccatgaacagaatcccccttacacggaggcatcagtgaccaaacaggaaaaaacgcccttaacatggcccgtttatcaga
agccagacattaacgcttctggagaactcaacgagctggacgcggatgaacaggcagacatctgtaatcgttccagaccacgctgat
gagctttaccgagctgcctcgcgcgttctgggtgatgacgggtgaaaacctctgacacatgcagctccggagacgggtcacagcttgcgtga
agcggatgccgggagcagacaagcccgtcaggcgcgctcagcggtgttggcggtgtcggggcgagccatgaccagtcacgta
gcgatagcggagtgtatactggcttaactatgcggcatcagagcagattgtactgagagtcaccatatatggcggtgtgaaataccgcaca
gatgcgtaaggagaaaataccgcatcaggcgctcttccgcttctcgtcactgactcgtgcgtcggctgttcggctgcggcgagcgggt
atcagctcactcaaaaggcggttaatacgggttatccacagaatcaggggataacgcaggaaagaacatgtgagcaaaaggccagcaaaag
gccaggaaccgtaaaaaggccgcgttgcgtggcgttttccataggctccgccccctgacgagcatcacaataacgacgctcaagtcag
aggtggcgaaaccgacaggactataaagatacaggcggttccccctggaagctccctcgtgcgtctcctgttccgacctgccgtta
ccggatacctgtccgcttctcccttccgggaagcgtggcgcttctcatagctcacgctgtaggtatctcagttcgggtgtaggtcgttcgctcc
aagctgggctgtgtgcacgaacccccgttcagcccagccgctgcgcttatccggtaactatcgttctgagtcacccccggtaagacacg
acttatccgactggcagcagccactgtaacaggattagcagagcgaggtatgtaggcgggtgctacagagtcttgaagtgggtgcctaa
ctacggctacactagaaggacagtatttggatctgcgctctgctgaagccagttaccttcgaaaaagagttggtagctcttgatccggcaa
acaaaccaccgctggtagcgggtgttttttggcaagcagcagattacgcgcagaaaaaaaggatcgaagaagatccttgcattttct
acggggtctgacgctcagtggaacgaaaactcacgttaagggttttggcatgagattatcaaaaggatcttcacctagatccttttaatt

aaaaatgaagttttaaataatcctaagatatatgagtaaacttggtctgacagttaccaatgcttaacagtgaggcacctatctcagcgatct
gtctatttcgttcatccatagttgctgactccccgtcgtgtagataactacgatacgggagggttaccatctggccccagtgctgcaatgat
accgcgagaccacgctcaccggctccagatttatcagcaataaaccagccagccggaagggccgagcgcagaagtggtcctgcaactt
taccgcctccatccagctctattaattgttgccgggaagctagagtaagtagttcgccagttatagtttgcgcaacgttggtgccattgctgca
ggcatcgtggtgtcacgctcgtcgtttggtatggcttcattcagctccggttcccaacgatcaaggcgagttacatgatccccatgttgca
aaaaagcggtagctccttcggtcctccgatcgttgtagaagtaagttggccgagtggttatcactcatggttatggcagcactgcataattct
cttactgtcatgccatccgtaagatgcttttctgtgactggtgagtactcaaccaagtcattctgagaatagtgtatggggcgaccgagttgctc
ttgcccggcgtaaacacgggataataccgcgccacatagcagaactttaaaagtgtcatcattggaaaacgttctcggggcgaaaactct
caaggatcttaccgctgttgagatccagttcgtatgtaaccactcgtgcaccaactgatcttcagcatcttttactttaccagcggtttctgggt
gagcaaaaaacaggaaggcaaaatgccgcaaaaaagggaataaggcgacacggaaatgttgataactcatactcttcttttcaatattat
tgaagcatttatcaggggtattgtctcatgagcggatacatattgaatgtatttagaaaaataaacaataaggggttcgcgcacatttccccg
aaaagtgccactgacgtctaagaaaccattattatcatgacattaacctataaaaataggcgtatcacgagggcccttcgtctcaagaa
(SEQ ID NO:23)

pMCM1320 and pMCM1321 - pCL-Ptrc-mvaR-mvaS-nphT7_StrepCL190

ctgcagctggtaccatatgggaattcgaagcttgggcccgaacaaaaactcatctcagaagaggatctgaatagcgccgtcgaccatcatc
atcatcatcattgagtttaaacggtctccagcttggtgttttggcggatgagagaagattttcagcctgatacagattaaatcagaacgcaga
agcggcttgataaaacagaatttgcctggcggcagtagcgcgggtggtcccactgaccccatgccgaactcagaagtgaacgccgtag
cgccgatggtagtgtgggtctccccatgcgagagtaggggaactgccaggcatcaataaaacgaaaggctcagtcgaaagactggggcc
tttcgtttatctgttgttgcgtgaacgctctcctgagtaggacaaatccgccgggagcggattgaacgttgcgaaagcaacggcccga
gggtggcggcagggacggccgataaactgccaggcatcaaatgaagcagaaggccatctgacggatggccttttgcgtttctacaa
actcttttgttttttctaaatcattcaaatatgtatccgctcatgagacaataacctgataaatgcttcaataatctggcgtaatagcgaag
aggcccgcaccgatcgcccttcccaacagttgcgcagcctgaatggcggaatggcgccgtgatgcgggtattttctccttacgcactgtgcgg
atttcacaccgcataatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagccccgacaccggccaacaccgctgacga
gcttagtaaaagccctcgttagatttaagcggatgttgcgattacttcgcaactattgcgataacaagaaaagccagcctttcatgatata
ctcccaattgtgtagggttattatgcacgttaaaaaataaaaagcagacttgacctgatagtttggctgtgagcaattatgtgcttagtgca
tctaacgcttgagttaaagccgcgccgcgaagcggcgtcggctgaacgaattgttagacattattgccgactaccttggtgatctgccttc
acgtagtggacaaatttccaactgatctgcgcgcgagggccaagcgtcttcttctgtccaagataagcctgtctagcttcaagatgacgg
gctgatactggccggcagggcgtccattgccagtcggcagcgacatccttcggcgcgattttgccgggttactgcgctgtaccaaatgcg
ggacaacgtaagcactacatttgcctcagccagcccagtcgggcggcgagtccatagcgtaaggtttcattagcgccctcaaatagat
cctgttcaggaaccggatcaaaagagttctccgccgctggacctaccaaggcaacgctatgttctctgttttgcagcaagatagccagat
caatgtcgategtggctggctcgaagatactgcaagaatgtcattgcgctgccatttccaaattgcagttcgcgcttagcttgataacgcc
acggaatgatgtcgtcgtgcacaacaatggtgacttctacagcgcggagaatctcgtctctccaggggaagccgaagtttccaaaaggctc
gttgatcaaaagctcggcgtgtttcatcaagccttacggtaaccagcaaatcaatcactgtgtggttcagggccgcatccact
gcggagccgtacaaatgtacggccagcaacgtcgggttcgagatggcgctcgtatgacgcaactacctctgatagttgagtcgatactcgg
cgatcaccgcttccctcatgatgtttaactttgttttagggcgactgccctgctcgtgaacatcgttgctgctccataacatcaaacatcgaccc
acggcgtaacgcgcttgctgcttgatggcgaggcatagactgtacccccaaaaaacagtcataacaagccatgaaaaccgccactgcg
ccgttaccaccgctgcgttcgggtcaaggttctggaccagttgcgtgagcgcatacgtacttgattacagcttacgaaccgaacaggcttat
gtccactgggttcgtgccttcatccgtttccacgggtgctgcgtcacccggcaaccttgggcagcagcgaagtcgaggaatttctgtcctggct
ggcgaacgagcgaagggttcggctccacgcatcgcaggcattggcggccttgctgttcttctacggcaaggtgctgtgcacggatctg
ccctggcttcaggagatcgggaagacctcggcgctcggcgcttgccgggtggtgctgacccggatgaagtgttcgcatcctcgggtttc
tggaaggcgagcatcgtttgttcgccagcttctgtatggaacgggcatcggtatcagtgagggtttgcaactgcgggtcaaggatctgga
tttcgatcacggcacgatcatcgtgcgggagggcaagggtccaaaggatcgggccttgatgttaccggagagcttggcaccagcctgcg
cgagcaggggaattaattcccacgggtttgctggccgcaaacgggctgttctggtgttgctagtgtttgatcagaatcgagatccggctca
gccggtttgcggctgaaagcgtatttctccagaattgccatgatttttccccacgggagggcgtcactggctcccgtgttcggcagcttt
gattcgataagcagcatcgctgtttcaggtgtctatgtgtgactgttgagctgtaacaagttgtctcaggtgttcaatttcatgttctagtgtt
gttttactgggttcacctgttctattagggtgttacatgctgttcatctgttacattgtcgtatctgttcattggtgaacagctttgaatgcacaaaaact

cgtaaaagctctgatgtatctatctttttacaccgtttcatctgtgcatatggacagttttccctttgatatgtaacgggtaacagttgttctactttt
gtttgttagcttgatgcttactgtagatacaagagccataagaacctcagatcctccgatttagccagtatgttctctagtgtggttcgttgt
ttttgcgtgagccatgagaacgaaccattgagatcatacttacttttgcattgacacaaaattttgcctcaaaactggtgagctgaatttttgca
gttaaagcatcgtgtagtgttttcttagtccgttatgtaggtaggaactctgatgtaattgggtgttgggtattttgtcaccattcattttatctggttgtt
ctcaagttcgggttacgagatccattgtctatctagtccaacttggaaaatcaacgatcagtcgggcggcctcgttatcaaccaccaatttcat
attgctgtaagtgttaaatctttacttattggtttcaaaaccattggtaagccttttaactcatgtagttattttcaagcattaacatgaacttaa
attcatcaaggctaactctatatttgccttgtgagttttcttttgtgttagttcttttaataaccactcataaatcctcatagagtattgtttcaaaag
acttaacatgttccagattatattttgaatttttaactggaaaagataaggcaatattcttccactaaaaactaatttctaattttgccttgagaa
cttggcatagtttgcactggaaaatcctaaagcctttaaccaaaggattcctgatttccacagttctcgtcagcgtctctggttgccttagct
aatacaccataagcattttccctactgatgttcatcatctgagcgtatttgggtataagtgaacgataccgtccgttcttcttctgtagggtttcaat
cgtgggggtttagtagtgccacacagcataaaattagcttgggttcatgctccgttaagtcatagcgactaatcgttagttcatttgccttgaaaa
caactaattcagacatacatctcaattggtctaggtgattttaactactataccaattgagatgggctagtcattgataaactactagctcttttcttt
gagttgtgggtatctgtaaattctgctagacccttgcgtgaaaacttgtaaattctgctagaccctctgtaaattccgctagacccttgtgtgttttt
ttgtttatattcaagtgggtataattatagaataaaagaaagataaaaaaagataaaaaagaatagatcccagcctgtgtataactactacttta
gtcagttccgcagtattacaaaaggatgtcgcacacgtgtttgtcctctacaaaacagaccttaaaacctaaaggcttaagtagcacct
cgcaagctcgggcaaatcgtgaatttcttttgcctccgaccatcaggcacctgagtcgtcttttctgtgacattcagttcgtcgtcgcgtc
acggctctggcagtgaaatgggggttaattggcactacaggcgcttttatggattcatgcaaggaaactaccataatacaagaaaagcccg
tcacgggcttctcaggggcgttttatggcgggtctgctatgtgtgctatctgacttttgcgtgttcagcagttcctgcctctgtatttccagtctg
accacttccgattatcccgtagcaggtcattcagactggctaattgcaccagtaaggcagcgggtatcatcaacaggcttaccgtcttactgt
cgggaattcgcgttggccgattcattaatgcagattctgaaatgagctgttgacaattaatcatccggctctgataatgtgtggaattgtgagcg
gataacaatttcacacaggaaacagcggcgtgagaaaaagcgaagcggcactgctcttaacaatttatcagacaatctgtgtgggactc
gaccgggaattatcgattaactttattataaaaattaaagaggtatatattaatgtatcgattaaataaggaggaataaaccatgaccgaaactca
tgcaattgctggtgtaccgatgcgttgggttggcccgtcgtatctctggcaacgtagcagaaaccgaaactcaggttccgctggcaacct
acgaatctccgctgtggccgtctgtgggtcgtggtgcgaaggatcccgtctgaccgaaaagggtatcgttgaacccctcgttgacgaacgt
atgaccgtagcgtcagtagaaggcaccgacgcccagaccgcttatatgctgcacagaccattcatgctcgcattgatgaactgcgcg
aagtgttctgtgtgttcccggttcgcgcagctgattaatcaaacatgaaattaacgcaacttgcgttcatccgcttgaatttaccaccg
gtgacgcatctggccataacatggccacctggcgtctgacgttctgttgggtcaccctctggaaccatcccaggcattcctacgggtcc
atttctggcaactactgactgacaagaaagcaactgccattaacgggtatcctgggtcgcggcaaaaacgttatcaccgaattgctggtgcc
gcgcgatgtttagaaaataacctgcacaccaccgctgcgaaaatcgttgaaactgaacatccgtaaaaacctgctgggactctcctggca
ggcggcatccgttctgcgaacgcgcattttgcaaatatgctgctgggtttctacctggcaactggccaggacgcagcaaacatcgttgagg
gtagccaggggcgttgaatggcgggaagatcgtgacgggtatctgtacttgcgtgcacccttccgaattctgatcgtgggtactgttggcaac
ggtaagggcctgggtttgtgaaacgaatctggcccgtctgggtctgcgcggatcgcgaaccgggcgaaaatgcgcgccgtctggc
cgttatcgcgcgtgcccagctgctgtgtgtgaactgtccctgttggccgcgcagaccaacctggtgaactgatgcgtgcacatgttcagc
tggaacgtgataaaaaaccgcgaaagtgtgtgcgtaatttagacgcactaggaggatataccaatgagcatttctatcgggtatccatgatct
ttcgttcgcgactaccgagttcgttctgcctcatagcgtctggccgagtataatgttactgaaattggtaaataacggttggcatcgggtcaac
agagcatgagcgtacctgcggcggatgaggacatcgtgactatggccgcgaccgccgcacgtccgatcattgaacgcaacggtaaatcc
cgtatccgactgtggtgttcgctacggagtcctccattgatcaagctaaagcgggtggcgtatagtcatttctgctgggcctggaatcc
gcgtgccgtgtagtgaactgaaacaggeatgctacgggtgcgacggcagcattgcagttcgtattgttctgggtccgcgcatccggcgc
agcaggtgctgtgatcgaagcgcggtttctaaatacaggttgattcggcgggtgaggcaaccaggcgcagcggccgttgcattgc
tggttggcgcagatcctgactgcttcgattgaagaaccgtccggccttccaccgcggacgttatggatttctggcggccgaactactg
accaccgccctggtagatggccaggagtccatcaacgcctacctgcaagcagttgaagggtgcgtggaaggactacgcagagcaggacg
gtcgtagcctgaagagtttgcagctttcgtttaccaccagccgttactaaaatggcgtacaaagctcaccgccacctgctgaactcaacg
gttacgactgacaaagatgcgattgaaggcgccttgggtcaactaccgcttacaataatgtgatcggtaactcctacactgcgtcagtt
atctgggccttggcggcgttctggatcaggcggacgacctgaccggctgttctatcgggttctctgttctacggctccggtagcgtagcggg
gttttctcgggcaccgttgttgcgttaccgtgaacgtctgcgtactgaagcgaaccagggaagctatcgcacgccgtaaatctgtcgttacc
gcgacttatcgtgaactgcagtagacacgtcccgtctgatgtgtgtgatcacgccacgggttcagaccaccggtccattccgtctggc
aggtatcaacgaccataaacgtatctatgaagcacgttaagatctcgcactaggaggatataccaatgaccgacgtcgcgttccgataatt
ggtagcgggtgcgtacgtgccggaacgcacgtgagtaatgacgaagttggcgcaccggctggtgtgacgatgattggattacacgcaag

acgggtatacgtcagagacgggtggcgccagatgatcaagcgactagtaccttgccactgccgcgggtcgtgcggcactgaaggctg
 cgggcataactccggagcagttaaccgttattgcggtggctacttcgaccccgaccgtcctcagccccctaccgtgcttatgttcagcat
 catttgggtgcaacaggcaccgccgcatcgtatgtgaacgcagtggtgcagcgggacgggtttcgcactttcgtcagttgcgggtacgttggt
 ttaccgcggcggtacgctctggttaataaggggcgacgtgtattcgcgtatcctgaaccctgcggatcgtaaaacagtgggtacttttgggtga
 cggggctggtgcgatggtattaggcccacgtccactggaaccgggccaatcgtgcggcggtcgtcttcatacttcggaggactgac
 ggatctgatccgcgtgccagcaggtggttcacggcaacctcttgacacagacgggcttgatgccggtcttcaatactttgcaatggatggtc
 gcgaagtgcggcggttcgtgacagagcacctccgcagctgattaagggggtttctgcatgaagcaggagtggtggtgcggcagacatttcga
 ctttgtccacaccaggcggaacggcggttatgctggtgaagtgttcggcggaattgcacatccctcgtgccactatgcaccgtacagttgaaac
 atacggtaatacaggcgctgcgtccatactatcactatggatgcagcagtgccgctgggtccttcgccaggcgaaactcgttctgttg
 caggtttcggcgggggcatggcagcttccttcgcgttgattgaatgggtga (SEQ ID NO:24)

Example 6: Isoprenoid Production via Acetoacetyl-CoA Synthase (NphT7) using Engineered Strains

(i) Materials

TM3 media recipe (per liter fermentation media):

[0233] K_2HPO_4 13.6 g, KH_2PO_4 13.6 g, $MgSO_4 \cdot 7H_2O$ 2 g, citric acid monohydrate 2 g, ferric ammonium citrate 0.3 g, $(NH_4)_2SO_4$ 3.2 g, yeast extract 0.2 g, 1000X Trace Metals Solution 1 ml. All of the components are added together and dissolved in diH_2O . The pH is adjusted to 6.8 with ammonium hydroxide (30%) and brought to volume. Media is then filter-sterilized with a 0.22 micron filter. Glucose 10.0 g and antibiotics are added after sterilization and pH adjustment.

1000X Trace Metal Solution (per liter fermentation media):

[0234] Citric Acid $\cdot H_2O$ 40g, $MnSO_4 \cdot H_2O$ 30g, NaCl 10g, $FeSO_4 \cdot 7H_2O$ 1g, $CoCl_2 \cdot 6H_2O$ 1g, $ZnSO_4 \cdot 7H_2O$ 1g, $CuSO_4 \cdot 5H_2O$ 100mg, H_3BO_3 100mg, $NaMoO_4 \cdot 2H_2O$ 100mg. Each component is dissolved one at a time in diH_2O . The pH is adjusted to 3.0 with HCl/NaOH, and then the solution is brought to volume and filter-sterilized with a 0.22 micron filter.

(ii) Experimental procedure

[0235] Cells are grown overnight in Luria-Bertani broth + antibiotics. The day after, they are diluted to an OD₆₀₀ of 0.05 in 20 mL TM3 medium containing 50 ug/ml of spectinomycin and 50 ug/mL carbenicillin (in a 250-mL baffled Erlenmeyer flask), and incubated at 34°C and 200 rpm. Prior to inoculation, an overlay of 20% (v/v) dodecane (Sigma-Aldrich) is added to the

culture flask to trap the volatile sesquiterpene product as described previously (Newman et. al., *Biotechnol. Bioeng.* 95:684–691, 2006).

[0236] After 2h of growth, OD₆₀₀ is measured and 0.05-0.40 mM isopropyl β -D-1-thiogalactopyranoside (IPTG) is added. Samples are taken regularly during the course of the fermentation. At each time point, OD₆₀₀ is measured. Also, isoprenoid concentration in the organic layer is assayed by diluting the dodecane overlay into ethyl acetate. Dodecane/ethyl acetate extracts are analyzed by GC–MS methods as previously described (Martin et. al., *Nat. Biotechnol.* 2003, 21:96–802). Isoprenoid samples of known concentration are injected to produce standard curves for isoprenoid. The amount of isoprenoid per sample is calculated using the isoprenoid standard curves.

Example 7: Production of Isoprene by *Saccharomyces cerevisiae* engineered to have Acetoacetyl-CoA Synthase (NphT7) Activity

[0237] Yeast strains are generated by transformation of the abovementioned plasmids into a parent strain using the protocol described in the s.c. EasyComp Transformation kit (Invitrogen). Yeast strains harboring the plasmid are selected for and maintained on SC Minimal Medium with 2% glucose supplemented with the indicated selective marker. Isolated colonies harboring the plasmid are chosen for further experimentation.

[0238] The specific productivity of isoprene from the engineered yeast strains is determined. To induce expression of the genes encoded by the plasmid, cultures are grown overnight in liquid SC Minimal Medium supplemented with the selective marker. The cultures are then diluted to an OD₆₀₀ of approximately 0.2 and grown for 2-3 hours. A 100 μ L sample of the broth is incubated in a 2mL headspace vial at 34°C for 30 minutes, followed by heat kill at 70°C for 12 minutes. Levels of isoprene in the headspace are determined, for example, by flame ionization detector coupled to a gas chromatograph (Model G1562A, Agilent Technologies) (Mergen et al., *LC GC North America*, 28(7):540-543, 2010).

Example 8: Improving isoprene production with Acetoacetyl-CoA Synthase (nphT7) utilizing the upper MVA pathway enzymes derived from *Streptococcus suis* in *E. coli*.

Generation of plasmid pMCM1221

[0239] Plasmid encoding an MVA upper pathway was constructed by GeneOracle (Mountain View, CA) using the following design. A synthetic DNA encoding Acetyl-CoA-acetyltransferase-RBS-3-hydroxy-3-methylglutaryl-CoA-synthase-RBS-hydroxymethylglutaryl-CoA-reductase was created and then cloned into pMCM82 (see U.S. Patent Appl. Pub. No. US 2011/0159557) between the NcoI and PstI sites, replacing the existing operon. The vector provided an RBS for *mvaE*. See figure 5 for plasmid map.

Table 8. Description of pMCM1221

Plasmid Name	Source Organism	Acetyl-CoA acetyltransferase	3-hydroxy-3-methylglutaryl-CoA synthase	hydroxymethylglutaryl-CoA reductase	Origin and Selection
pCL-Ptrc-Upper_GcMM_159 (Streptococcus suis)	Streptococcus suis	gil146321498 reflYP_001201209.1 _Acetyl-CoA acetyltransferase_[Streptococcus_suis_98HAH33]	gil146321499 reflYP_001201210.1 _3-hydroxy-3-methylglutaryl-CoA synthase_[Streptococcus_suis_98HAH33]	gil146321500 reflYP_001201211.1 _hydroxymethylglutaryl-CoA reductase_[Streptococcus_suis_98HAH33]	pSC101, Spectinomycin (50ug/mL)

DNA sequence of plasmid construct pMCM1221- pCL-Ptrc-Upper_GcMM_159 (Streptococcus suis).

cccgcttactgtcgggaattcgcgttggccgattcataatgcagattctgaaatgagctgttgacaattaatcatccggctcgataatgtgtg
gaattgtgagcggataacaatttcacacaggaaacagcgcgcgtgagaaaaagcgaagcggcactgctctttacaatttatcagacaatct
gtgtgggcactcgaccggaattatcgaatatttattattaaaaattaaagagggtatatattaatgtatcgattaaataaggagggaataaacat
gagcacgtttagtgtgttttacaagaaaagtcgccaggagcgcacgcgatatcttacgtcagaaccggtccttggcagaagattctctggatat
tctgtacaaggacgaaaacctgcctgaagctatcgcggggcaaaatggccgaaaaccacttggggacgttcagcctgcccttctcgggtactg
cctgagctgctggtagatgggcagacatactctgttctatggttaactgaggagcctagcgtgtgtagcagccgcctcgttcggggcaaaaa
ttatcgcgaaatccggtggtttacaacaaccatccacaaccgtataatgatcggccaaggtagcggttatatgatataagtaccattctcgcgc
cacgcaagcaattctggtacacaaggagagtatacttgaaaacgtaaccaagctcatcccagtatagtcaaacgcggcgagggggctag
agagcttacagttgagctaaaggatgaatttctgacgtctaccttcaggtagatgtgcaagaagcaatgggtgcaaacatactgaacaacat
gcttgaagccgtgaaaagatgatctggaagaactttccaaaggccaggcgcttatgggaatcctcagcaactacgccaccgagtcattaatc
acagcacagtgtcatatcgcaatatcaagcctggcgacttctctgccattgtcaggagaccgccagaaaattgcactcgcgagcaaatt
agcgcgaagttgaccatatactgtgccgcgacacacaataaagggtatttttaattgggattgacgctgtcgtcattgcagctgggaacgactggc
gtgctgttgaggcaggtgctcatgcgtatgccagccgcgatggacaataataaaggcctgagtagctggtcgatcgatggggaacacttagt
tggctccattacattgccgttgccatatagcttcagttggcggaagtataggcctgaatccgaaggttgcgctcgcatttgacttactgcaacag
ccaaaagcacgccaaattagccagcattattgcctcagtggtgtcttgcacaaatttcgctgctctccggggcgctggttaactagtgtgtattcag

gccggtcacatgaagttacatgctaaatcgtggctttactggccggggcggaagaacatgaggtcgaccaactggctcagctgctccgc
aaggaataacattccaatcttgaaacggctcagaacttactggcaaaaatcggtgaacattgggaatgggaaagacatccttgatctagac
gcactaggaggatataccaatgcgtaaacaaagttacctttcttttgtcataaggggtacattatgaacattggtattgacaagatcggtttcg
cagcccccgattatgtgttagactttagcggatttagcccaggcgcgtaattgttgatcctaacaatttaagatcgggttacttcagagcgagat
ggccgtcgccccgggtgacgcaggatatacatcgttaggcgccaaagctgccgaggcaattctgaccgaagaggacaaacaaacgatcg
atatggttatcgtgggcaccgaaagtccgctgatcaaaagcaagccggcggtgacaatacacggactgttaggcacccagcctttcgc
tcggctgattgaaatgaaggaggcttgttatggcgcgactgccggattaagtgttgctaaagtctcatatcggccagtttctgaaagcaaaagt
ttagtcatagcctcgatattgctaaatatgggttagcttccggaggtgaacctactcagggtgcgggagccgtggcaatgcttgtagcggc
gaaccctcgattctggtgtgaaacacgataatgtctgcaaacgcgcgatatatacgaattttggcgtccgaattatgacaagtaccacgt
gtcgacggcaagttctccaccgaacagtatacagactgcttaactactacattcgattactatcaacagaagacggggaaaacccctgaacg
actttgccgaatgtgcttgcacatcccccttcttaaacaaaggtctgaaaggcttacaggcgattgcccaagatgaagaaacccctcagccgg
ttaacggagcgcttcagggaagccattgtctacaacaaagtggtggggaatatctataccggcagcattttcttgagctcctgtctccttg
aaaattcacgggctctgaaacaggagatcagattctgttctacagttacggctctggtgctgtatgcgaaattttcttggaactggtcga
agggtaccgcaatcacctgcaagagaatcgctggaacagttgaaccagcgtaccaaaactgtccgtaaggaaatcgaacaggtgttttt
gaggaaataacccctggatgaaactgggtcctccttgatctccagaagatcagtcctccgttcgcttattaaagtgcataaccacaaacg
tatctatcgtaaatgaagatctcgactaggaggatataccaatgaagaaagtcgcgacgtctctgcttaccggagcgcaatcggtccttt
ggcggatcattgaaggacatcgagattgccgatttaggcgcacaggtattggagacggccctcgctcgaagaacataccggcggtatag
cgtggacgaagtattcttcggtaacgtactgtccgccgggtcaagggtcagaacatagcaagacagatagccatacgtgccgggattccacaa
acagcatcagcgtagccgtaataaagtggtgtggttcgggtttaaatacagtgcttctgcgggcacagtcgattatgtggcgacaacga
tgtcgtcgttgacagtggaattgaaatcatgtccaggcaccgtattttgcaaaaactagtcgctttgggagtaagttcgggcacatcacctt
gaagattccatgctgacggatggtctcactgatgcgtttaatgactaccacatgggcatcactgcggaatgtagcggagcattatcaggt
aagccgtgccgagcaggacgcttcacttactatctcaggaaaaagctgccaaggcgatagcagaaggacgtttgtgacgaaatcggt
cctatccgtctcaaaaacggcaagggcgaaacgatattcgcaactgatgagatccttagactgaccccaattgaaaagttagctaccctccg
cccatcttttaagaaggatggaaccgtcacagcagcaaacgcctccggcattatgacgggtgcgcgggtgctgatacttatgtcagacgag
aaagcgctccgagttaaacatccagccgctgacatacatagaagcctatgcaacctcgggtctcgcgtcccgcccttatgggactgggtccga
ttaccgcctctcaaaaagcccttcagaaattgaacaaaacgggtgaagacatcgactgtttgaattaaatgaagcgctcgtcgacagagta
ttcccggtgtgaaacagctcgggatcgatccggcgaaagtcaacgttaacgggtgggcaatagctttaggtcaccccatcgccgcttcagg
tagccgcattctgtcacgcttatccacgaactcatcaaacagaagaagaactcggcttatgctcactgtgtattggcgcggtcaggggat
tagtctgatatgataacgctcaacttctgactgcagctggtaccatattgggaattcgaagcttggggccgaacaaaaactcatctcaga
agaggatctgaatagcgccgtcgaccatcatcatcatcattgagtttaaacggtctccagcttgctgttttgccggatgagagaagattt
tcagcctgatacagattaaatcagaacgcagaagcgggtctgataaaacagaatttgctggcgcgagtagcgcggtgtccacctgacc
ccatgccgaactcagaagtgaacgccgtagcgccgatgtagtggtgggtctcccatcgagagtaggggaactgccaggcatcaaat
aaaacgaaaggctcagtcgaaagactgggcctttcgtttatctgtgtttgtcgggtgaacgctctcctgagtaggacaaatccggcgagc
ggattgaacggttcgaagcaacggccggagggtggcgggcaggacggccgataaaactgccaggcatcaaatgaagcagaagggc
catcctgacggatggccttttgcgtttctacaactcttttgtttattttctaaatacattcaaatatgtatccgctcatgagacaataacccctgat
aatgttcaataatctggcgtaatagcgaagaggccgcaccgatcgcccttcccaacagttgcgacgctgaatggcggaatggcgccct
gatgcggatttttctccttacgcatctgtgcggtatttcacaccgcataatggtgcactctcagtaacaatctgctctgatccgcatagttaagcca
gccccgacacccgccaacacccgctgacgagcttagtaaacccctcgtagattttaatgcggatgttgcgattacttcgccaaactattgcg
ataacaagaaaaagccagcctttcatgatatactcccaatttgtgtagggcttattatgcacgcttaaaaataataaaagcagacttgacctga
tagtttggtgtgagcaattatgtgcttagtgcataacgcttgagttgaagccgcgccgcgaagcgcgctcggttgaaacgaattgttagac
attatttggcactaccttgggtgatctgcctttcacgtagtggaacaaattcttccaactgatctgcgcgcgagggcaagcgatcttcttctgtc
caagataagcctgtctagcttcaagtatgacgggctgatactggggcgagcggcgtccattggccagtcggcagcgacatccttcggcg
cgattttggcggttactgcgtgtacaaaatgcgggacaacgtaagcactacatttcgctcatcgccagccagtcggcgggcgagttccat
agcgtaagggtttcatttagcgccctcaaatagatcctgttcagggaaccggatcaaaagatttcccgccgctggacctaccaaggcaacgct
atgttctcttctgtttgtcagcaagatagccagatcaatgtcgtatcggtggctcgaagatacctgcaagaatgtcattgcgctgccattctc
caaattgcagttcgcgcttagctggataacgccacggaatgatgtcgtcgtgcacaacaaatggtgacttctacagcgcggaatctcgtc
tctccaggggaagccgaagtttccaaaaggtcgttgatcaaaagctcgccgctgttttcatcaagccttacggteaccgtaaccagcaaatc
aatatcactgtgtggttcaggccgccatccactgcggagccgtacaaatgtacggccagcaacgtcgggttcgagatggcgctcgtatgac

gccaactacctctgatagttgagtcgatacttcggcgatcaccgctccctcatgatgtttaactttgttttagggcgactgcctgctgcgtaac
atcgttgctgctccataacatcaaacatcgaccacggcgtaacgcgcttgctgcttgatgccgaggcatagactgtaccccaaaaaa
cagtcataacaagccatgaaaaccgccaactgcgccgttaccaccgctgcgttcggtaaggttctggaccagttgctgagcgcatacgt
acttgcaatcagcttacgaaccgaacaggcttatgtccactgggttcgtgccttcacgtttccacgggtgtgctgcacccggcaaccttg
gcagcagcgaagtcgaggcatttctgtcctggctggcgaacgagcgaaggttccggtctccacgcacgtcaggcattggcggccttgct
gttctctacggcaaggtgctgtgcacggatctgccctggcttcaggagatcggaagacctcggccgtcgcggcgcttgccggtggtgctg
accccggtatgaagtggctgcacctcgggtttctggaaggcgagcatcgtttgtcggccagcttctgtatggaacgggcatgcggatcgt
gaggggttgcaactgcgggtcaaggatctggatttcgacacggcagcatcgtcgggaggggcaagggtccaaggatcgggcctt
gatgttaccgagagcttgccaccagcctgcgcgagcagggaattaattccacgggtttgctgccgcaaacgggctgttctggtgtt
gctagttgttatcagaatcgagatccggcttcagccggttgcgggctgaaagcgctatttctccagaattgccatgatttttcccacgg
gagggcgtcactggctcccgtgttgcggcagcttgattcgataagcagcatcgctgttcaggctgtctatgtgtgactgttgagctgtaac
aagttgtctcaggtgtcaatttcattgttctagtgttctgttttactggttcacctgttctattaggtgttacatgctgttcactgttacattgtc
ctgttcattggtgaacagcttgaatgcacaaaaactcgtaaaagctctgatgtatctatctttttacaccgttttctctgtgcatatggacagtt
ttcccttgatgtgaacgggtgaacagttgttctactttgtttgttagtcttgatgcttactgatagatacaagagccataagaacctcagatcctt
ccgtatttagccagtatgttctctagtgtggttcgtgtttttgcgtgagccatgagaacgaaccattgagatcatacttactttgcatgtcactca
aaaatttgcctcaaaactggtgagctgaattttgcagttaaagcatcgtgtagtgttttcttagtccgttatgtaggtaggaaatcgtatgaatg
gttgttggtattttgtcaccattcattttatctggtgttctcaaggttcgggtacgagatccattgtctatctagtgtcaacttgaaaatcaacgtatc
agtcggcgccgctcgttataaccaccaatttcattgtctgtaagtgttaaatcttactattggtttcaaaacccattggttaagccttttaa
actcatggtagtattttcaagcattaacatgaacttaattcatcaaggctaattctctatatttgccttgtagttttctttgtgttagttcttttaata
accactcataaatctcatagagtatttgtttcaaaagacttaacatgttcagattatattttatgaattttttaaactggaaaagataaggcaata
tctcttcaaaaaactaattctaattttgcgttgagaacttggcatagttgtccactggaaaatctcaaacgctttaaccaaaggattcctgatt
tccacagttctcgtcatcagctctctggtgtttagtaataacaccataagcatttccctactgatgttcacatctgagcgtattggtataagt
gaacgataccgtccgttcttctgttaggggtttcaatcgtggggttgagtagtccacacagcataaaattagcttggttcattgctccgttaa
gtcatagcgactaatcgctagtctatttgccttgaaaacaactaattcagacatacatcattggtctaggtgatttaactataccaattga
gatgggctagtcaatgataattactagtccttttctttaggttggtggtatctgtaaattctgtagaccttctggtgaaaacttgtaaattctgcta
gacctctgtaaattccgtagaccttctgtgtttttttgtttatattcaagtggttataatttatagaataaagaaagataaaaaagataaaaa
gaatagatcccagccctgtgtataactcactacttttagtcagttccgcagattacaaaaggatgtcgaaacgctgttctcctctacaaaac
agaccttaaaacctaaaggcttaagtagcacccctcgcaagctcgggcaaatcgctgaatattcctttgtctccgacctcagggcacctgag
tcgctgtcttttctgtacattcagttcgtgcgtcacggctctggcagtgaaatgggggtaaatggcactacaggcgccctttatggattcatg
caaggaaactaccataatacaagaaaagccggtcacgggtctcaggcggtttatggcggtctgctatgtgtgctatctgacttttgc
tgttcagcagttcctgccctctgattttcagctctgaccacttcggattatcccgtagcaggtcattcagactgggctaatagcaccaagtaaggca
gcggtatcatcaacaggctta (SEQ ID NO:25)

Example 9: Preparation of an Acetoacetyl-CoA Synthase (NphT7) containing plasmid

[0240] A three component upper MVA pathway derived from *Streptococcus suis* and harbored by plasmid construct pMCM1221 (pCL-Ptrc-Upper_GcMM_159) was used. Acetoacetyl-CoA Synthase derived from *Streptomyces* sp. strain CL190 and encoded by *nphT7* within plasmid construct MCM1187 has been described previously (see Table 2). The *nphT7* gene was PCR amplified using PfuUltra II Fusion HS DNA Polymerase (Agilent Technologies, Santa Clara, CA) from the MCM1187 template using primers 5' BglII rbs *nphT7* primer and 3' PstI *nphT7* primer according to the manufacturer's suggested protocol. Using standard molecular biology techniques: the *nphT7*-containing PCR product was verified via agarose gel electrophoresis (E-

gel 0.8% (GP), Invitrogen); the PCR reaction was then cleaned using QIAquick PCR purification Kit (Qiagen, Germantown, MD); both the clean PCR product and an aliquot of purified pMCM1221 were cut using Bgl II and Pst I (Roche, Indianapolis, IN); the completed restriction digests were cleaned using QIAquick Gel Extraction Kit (Qiagen, Germantown, MD); and the resulting clean Bgl II – Pst I fragments were ligated using T4 DNA ligase from New England Biolabs. The ligation was later transformed into electroporation competent Top10 cells (Invitrogen, Carlsbad, CA) using a Bio-Rad a 0.1cm electrode gap cuvette and the Bio-Rad Gene Pulser system (Bio-Rad Laboratories, Hercules, CA). Transformed cells were selected on LB media containing 50ug/ml spectinomycin (Teknova, Hollister, CA). Plasmid was prepared from cultures generated by spectinomycin resistant colonies using a QIAprep Spin Miniprep Kit (Qiagen, Germantown, MD) along with the suggested protocol. The subsequent positive Top10 clone harboring the npHT7-containing plasmid construct, now designated strain REM B5_25, was identified via DNA sequence analysis (Sequetech, Mountain View, CA) utilizing primers npHT7 top seq primer, npHT7 bot seq primer, pSE3803 (Sequetech in-house primer), 5' BglIII rbs npHT7 primer, and 3' PstI npHT7 primer. The npHT7-containing plasmid construct has been named “npHT7 with S suis HMGRS/pCL” and is illustrated in Figure 6.

Primer sequences used to create and verify plasmid construct npHT7 with S suis HMGRS/pCL.

5' BglIII rbs npHT7 primer: 5' - GGGCagatctcgactaggaggatataccaatgaccgacgtgcgctttcgg (SEQ ID NO:26)

3' PstI npHT7 primer: 5' - TATCCTGCAG tcaccattcaatcaacgcgaaggaagc (SEQ ID NO:27)

npHT7 top seq primer: 5' - CGGCACTGAAGGCTGCGG (SEQ ID NO:28)

npHT7 bottom seq primer: 5' - CCGCAGCCTTCAGTGCCG (SEQ ID NO:29)

(Sequetech in house primer) pSE3803: 5' - GGCATGGGGTCAGGTGGG (SEQ ID NO:30)

DNA sequence of plasmid construct npHT7 with S suis HMGRS/pCL.

5' -

cccgcttactgtcgggaattcgcgttgccgattcattaatgcagattctgaaatgagctgttgacaattaatcatccggctcgataatgtg
tgggaattgtgagcggataacaatttcacacaggaaacgcgcgctgagaaaaagcgaagcggcactgctctttacaatttatcagacaat
ctgtgtgggcactcgaccggaattatcgattaactttattataaaaattaaagggtatatattaatgtatcgattaataaggaggaataaacc

atgagcacgttagtggttttacaagaaaagtcgccaggagcgcacgcgatatcttacgtcagaaccggctcctggcagaagattctctggat
attctgtacaaggacgaaaacctgcctgaagctatcgcgggcaaaatggccgaaaaccacttggggacgttcagcctgcccttctcggtag
tgcctgagctgctggtagatgggcagacatactctgttctatggtaactgaggagcctagcgtggttagcagccgcctcgttcggggcaaa
aattatcgcgaaatccgggtggtttacaacaaccatccacaaccgtataatgatcggccaggtagcgttatatgatataagtaccattctcgc
gccacgcaagcaattctggatcacaaggagagtatacttgaaaacgctaaccaagctcatcccagtagtcaaacgcggcggagggggt
agagagcttacagttgagtctaaggatgaatttctgatcgtctacctcaggtagatgtgcaagaagcaatgggtgcaaacatactgaacaac
atgcttgaagccgtgaaagatgatctggaagaactttccaaaggccaggcgttatgggaatcctcagcaactacgccaccgagtcattaat
cacagcacagtgtcatatcgaatatcaagcctggcgacttctctgccattgctcaggagaccgccagaaaattgcactcgcgagcaaa
ttagcgcaagttgaccatatactgctccgcgacacacaataaaggatatttttaattgggattgacgctgtcgtcattgcagctgggaacgactgg
cgtgctgttgaggcaggtgctcatgcgtatgccagccgcgatggacaataaaggcctgagtacctggctcgtcgtatggggaacacttag
ttggtccattacattgccgttgctatagcttcagttggcggaagtataggcctgaatccgaaggttgccgtgcatttgacttactgaaca
gccaaaagcacgccaaattagccagcattattgcctcagtggtgtcttgccaaaatttcgtgctctccgggcgtggttaactagtgttattca
ggccgggtcacatgaagttacatgctaatacgttggttactggccggggcggaagaacatgaggtcgaccaactggctcagctgtcctcg
caaggaaaaacattccaatcttgaaacggctcagaacttactggcaaaaatgcgtgaacattgggaatgggaaagacatccttgatctagac
gcactaggaggatataccaatgcgtaaacaaagttaacctttctttgtgcataagggttacattatgaacattgttattgacaagatcggtttcg
cagcccccgattatgtgttagacttagcggatttagcccaggcgcgtaattgtgatcctaacaataaagatcggtttacttcagagcgagat
ggcgtcgccccgggtgacgcaggatatactatcgttaggcgcaaaagctgccgaggcaattctgaccgaagaggacaaacaaacgatcg
atatggttatcgtgggcaccgaaagtccgtcgatcaaagcaaagccgcggcggtgacaatacacggactgttaggcattccagcctttcgc
tcggctgattgaaatgaaggaggctgttatggcgcgactgccggattaagtttggttaagtctcatatcgcccagtttctgaaagcaaagtt
ttagtcatagcctcgatattgctaataatggggttagcttccggagggtgaacctactcagggtgcgggagccgtggcaatgcttgtgacggc
gaaccctcggattctggtgttgaacaacgataatgtctgcaaacgcgcgatataacgatttttggcgtccgaattatgacaagtaccacgt
gtcgacggcaagttctccaccgaacagtatacagactgcttaactactacattcgattactatcaacagaagacggggaaaaccctgaacg
actttgccgcaatgtgcttgacatcccccttcttaacaaggtctgaaaggcttacaggcgattgcccagatgaagaaaccctcagccgg
ttaacggagcgcttcagggaagccattgtctacaacaaagtgggtgggaatatctataccggcagcattttcttgagctcctgtctcctgg
aaaattcacgggctctggaacaggagatcagattctgttctacagttacggctctggtgctgtatgcgaaattttcttggaactggcga
agggtaccgcaatcacctgcaagagaatgcctggaacagttgaaccagcgtaccaaactgtccgtcaaggaatacgaacaggtgttttt
gaggaaataaccctggatgaaactgggtcctccttgatctcccagaagatcagtcctccgttcgcttattaaagtcgataaccacaaacg
tatctatcgtaaatgaagatctcgcactaggaggatataccaatgaccgacgtgcgctttcggataattgggtaccggtgcgtacgtgccgga
acgcacgtgagtaatgacgaagttggcgaccggctggtgtggacgatgattggattacacgaagacgggtatacgtcagagacggtg
ggcggcagatgatcaagcgactagtaccttgccactgccgcgggtcgtgcggcactgaaggctgcgggcataactccggagcagttaa
ccgttattgcgggtggtacttcgaccccgaccgtcctcagccccctaccgtgcttatgttcagcatcatttgggtgcaacaggcaccgcc
gcattcgatgtgaacgcagtggtgcagcgggacgggttttcgcactttcgtcagttgcgggtacgttggtttaccgcggcggtacgctctggtgta

ataggggcgacgtgtatcgcgtatcctgaaccctgcggatcgtaaacagtggtacttttggtagcgggctggtgcgatggtattagg
cccgacgtccactggaaccgggccaatcgtgcggcgggtcgtcttcataccttcggaggactgacggatctgatccgctgccagcag
gtggttcacggcaacctcttgacacagacgggcttgatgccgggtcttcaatactttgcaatggatggcgcgaagtgcggcggttcgtgaca
gagcacctccgcagctgattaaggggttctgcatgaagcaggagtggatgcggcagacatttcgactttgtcccacaccaggcgaacg
gcgttatgctggatgaagtgttcggcgaattgcatctccctcgtgccactatgcaccgtacagttgaaacatacggtaatacaggcgtgcgt
ccatacctatcactatggatgcagcagtgccgctgggtccttcgccaggcgaactcgttctgttgccaggttcggcgggggcatggc
agcttccttcgcgttgattgaatggtgactgcagctggtaccatatgggaattcgaagcttggggccgaacaaaaactcatctcagaagagg
atctgaatagcggcgtcgaccatcatcatcatcattagttaaacggctcagcttggctgtttggcggatgagagaagattttcagcc
tgatacagattaaatcagaacgcagaagcgggtctgataaacagaatttcctggcggcagtagcgggtggtcccactgaccccatgc
cgaactcagaagtgaacgccgtagcggcgtatgtagtggtgggtcctccatgcgagagtaggggaactgccaggcatcaataaacg
aaaggctcagtcgaaagactgggccttctgtttatctgttgttcgggtgaacgctctcctgagtaggacaaatccggcgggagcggatttg
aacgttgcgaagcaacggccggagggtggcgggcaggacggccgataaactgccaggcatcaataaagcagaaggccatcctg
acggatggccttttgcgtttctacaaactctttgtttatctttaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgct
tcaataatctggcgtaatagcgaagaggcccgaccgatcgccctcccaacagttgcgcagcctgaatggcgaatggcgcctgatgcgg
tattttctcttacgcactctgtgcggattttcacaccgcataatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagccccga
caccgccaacacccgctgacgagcttagtaaagccctcgttagattttaatgggatgttgcgattacttcgccaactattgcgataacaag
aaaaagccagcctttcatgatatatctcccaatttgtagggcttattatgcacgcttaaaaaataaaaaagcagacttgacctgatagtttggc
tgtgagcaattatgtgcttagtgcatctaacgcttgagttaagccgcggcgcgaagcggcgtcggcttgaacgaattgtagacattatttgc
gactaccttggtgatctcgcctttcacgtagtggaacaaattctccaactgatctgcgcgcgaggccaagcgaatcttcttctgtccaagataa
gcctgtctagcttcaagtatgacgggctgatactggggcggcaggcgtccattgccagtcggcagcgacatccttcggcgcgattttgc
cggttactgcgctgtacaaatgcgggacaacgtaagcactacatttcgctcatcgccagcccagtcggggcggcgagttccatagcgtaa
ggtttcatttagcgctcaaatagatcctgttcagggaaccggatcaaagagttcctccggcgtggacctaccaaggaacgctatgttctctt
gcttttgcagcaagatagccagatcaatgtcgtatcgtggtcggctcgaagatacctgcaagaatgtcattgcgctgccattctccaaattgca
gttcgcgcttagctggataacgccacgggaatgatgtcgtcgtgcacaacaatggtgacttctacagcgcggagaatctcgtctctccaggg
gaagccgaagtttccaaaaggctgttgatcaaaagctcggcgggtgttcatcaagccttacggtcaccgtaaccagcaaatcaatacactg
tgtggcttcaggccgcatccactgcggagccgtacaaatgtacggccagcaacgtcggttcagatggcgtcgtatgacgccaactacc
tctgatagttgagtcgatacttcggcgatcaccgcttcctcatgatgtttaactttgttttagggcgactgccctgctgcgtaacatcgttgctg
ctccataacatcaaacatcgaccacggcgtaacgcgcttgcgttgatgccgaggcatagactgtacccccaaaaaacagtcataac
aagccatgaaaaccgccactgcggcgttaccaccgctgcgttcgggtcaaggttctggaccagttgcgtgagcgcatacgtacttgcatc
agcttacgaaccgaacaggcttatgtccactgggttcgtgccttcacgtttccacgggtgtcgtcaccggcaaccttgggcagcagcga
agtcgaggcatttctgtcctggctggcgaacgagcgaaggttccggtcctccacgcacgtcaggcattggcggccttgcgttctctacgg
caaggtgctgtgcacggatctgccttgggtcaggagatcggaagacctcgccgtcgcggcgcttggcggtggtgctgaccccgatg

aagtgggttcgcatcctcgggtttctggaaggcgagcatcggtttggtcggcagcttctgtatggaacgggcatgcggatcagtgagggtttgc
 aactgcgggtcaaggatctggatttcgatcacggcacgatcatcgtcgggagggaagggtccaaggatcgggccttgatgttaccg
 agagcttggcaccagcctgcgcgagcaggggaattaattcccacgggtttgctgcccgaacgggctgttctggtgtgctagtgttga
 tcagaatcgcatcgggttcagccgggttgcggctgaaagcgctatttctccagaattgccatgattttcccacgggaggcgctact
 ggctcccgtgtgtcggcagcttggattcgataagcagcatcgctgttcaggctgtctatgtgtgactgttgagctgtaacaagttgtctcag
 gtgttcaatttcattgttctagtgttctgtttactgggttcacctgttctattaggtgttcatgctgttcactgttaccattgtcgtatctgttcaggtga
 acagctttgaatgcacaaaaactcgtaaaagctctgatgtatctatctttttacaccgtttcatctgtgcatatggacagttttccctttgatatg
 taacgggtgaacagttgttctacttttgtttagtcttgatgcttcactgatagatacaagagccataagaacctcagatcctccgtatttagcc
 agtatgttctctagtgtggttcgtgttttgcgtgagccatgagaacgaaccattgagatcatacttactttgcatgtcactcaaaaattttgcctc
 aaaactgggtgagctgaattttgcagttaaagcatcgtgtagtgttttcttagtccgttatgtaggtaggaaatctgatgtaatggtgttggtatttt
 gtcaccattcattttatctggtgttctcaagttcggttacgagatccattgtctatctagtccaacttggaataaacgtatcagtcggcgggc
 ctgcttatcaaccaccaatttcattgtgtgaagtgttaaatcttactattgtttcaaaaccattggtaagccttttaactcatggtagt
 attttcaagcattaacatgaacttaattcatcaaggctaattctctatatttgccttgtagttttctttgtgttagttctttaataaccactcataaat
 cctcatagagtatttgtttcaaaagacttaacatgttccagattatattttatgaatttttaactggaaaagataaggcaatatctctcactaaaa
 actaattctaattttcgttgagaacttgcatagttgtccactggaaaatctcaaagccttaaccaaaggattcctgattccacagttctcgt
 catcagctctctggttgccttagctaatacaccataagcattttccctactgatgttcacatctgagcgtattggtataagtgaacgataccgctc
 cgttcttcccttgtaggggtttcaatcgtggggtgagtagtgcacacagcataaaattagcttggttcatgctccgttaagtcatacgacta
 atcgctagtctcatttgccttgaaaacaactaattcagacatacatctcaattgggtctaggtgattttaactactataccaattgagatgggctagtc
 aatgataattactagtcctttccttgagttgtgggtatctgtaaattctgctagaccttgcctggaaaactgtaaattctgctagacctctgtaa
 attccgctagaccttgcgtgtttttttgtttatattcaagtggttataatttatagaataaagaaagataaaaaaagataaaaaaagataagatccc
 agccctgtgtataactactacttttagtcagttccgcagttattacaaaaggatgtcgcaaacgctgtttgctcctctacaaaacagaccttaaaa
 ccctaaaggcttaagtagcacctcgcagctcgggcaaatcgtgaatttctttgtctccgaccatcaggcacctgagtcgctgtctttt
 cgtgacattcagttcgtgcgtcacggctctggcagtgaaatgggggtaaatggcactacaggcgccctttatggattcatgcaaggaaact
 acccataatacaagaaaagccgacgggcttctcagggcgtttatggcgggtctgctatgtgtgctatctgacttttgcgttcagcagc
 tctgcctctgattttccagctgaccacttcggattatcccgtgacaggtcattcagactggctaagtcacccagtaaggcagcggtatcat
 caacaggctta – 3' (SEQ ID NO:31)

Example 10: Creation of upper MVA pathway strains REM C8 25, REM C9 25, and REM D1 25 and control strains REM D2 25, REM D3 25, and REM D4 25.

[0241] A host strain CMP865 harboring the *atoB* deletion locus (loss of endogenous Thiolase activity) as well as a set of previously described mutations shown to support high level MVA production was used to generate the test and controls strains described here. To generate

CMP865, a P1 lysate of CMP646 (containing BL21 pgl+ PL.2 mKKDyI GI 1.2 gltA ML ackA-pta ldhA attB::Cm) was made and was used in a transduction reaction on strain CMP856, thereby removing the lower mevalonate pathway (e.g. mevalonate kinase, phosphomevalonate kinase, diphosphomevalonate decarboxylase, and isopentenyl diphosphate isomerase) from the chromosome of that strain. The transduction reaction was plated on LB + chloramphenicol 5 ug/ml and one colony was picked and named CMP859. The kanamycin (in atoB locus) and chloramphenicol markers (in attB locus) were looped out concurrently by electroporation of pCP20 (Datsenko and Wanner. 2000. PNAS 97:6640-5) in CMP859, selecting for carbenicillin 50 mg/L-resistant colonies at 30 C, then streaking two transformants at 42 C. A kanamycin-sensitive, chloramphenicol-sensitive colony was selected and named CMP865 (BL21 PL.2mKKDyI GI 1.2 gltA ML atoB attB).

[0242] Control strains REM D2_25, REM D3_25, D4_25 were generated by introducing pMCM1221 into strain CMP865 and selecting on LB media containing 50ug/ml spectinomycin (Teknova, Hollister, CA) using a standard electroporation protocol and the Bio-Rad Gene Pulser cuvettes and electroporation system detailed above. From the resulting spectinomycin resistant colonies, 3 were chosen for further analysis and are now referred to as strains REM D2_25, REM D3_25, and REM D4_25. The upper MVA only test strains REM C8_25, REM C9_25, and REM D1_25 were generated in an identical fashion to that just described for the control strains, with the exception that plasmid construct nphT7 with S suis HMGRS/pCL was introduced into the CMP865 host.

Example 11: MVA production from upper MVA only strains REM C8_25, REM C9_25, and REM D1_25 and control strains REM D2_25, REM D3_25, and REM D4_25.

[0243] The MVA titers produced from the MVA only test strains REM C8_25, REM C9_25, and REM D1_25 and control strains REM D2_25, REM D3_25, D4_25 over the course of a 22 hour production period following IPTG-mediated induction of the upper MVA pathway genes. Briefly, control and test strains were grown in 4 ml 1% glucose 0.025% yeast extract TM3 media at 34 °C and induced with 200uM IPTG at time zero. MVA was measured from cell-free supernatant. Control strains expressing the MVA pathway components from pMCM1221 generated notable MVA titers compared to the test strains. MVA was detected at low levels from 2 of the 3 test strains. It is notable that MVA was detected in these atoB (thoilase) deletion strains thereby establishing that nphT7 was functional within the E. coli BL21 host.

Example 12: Creation of full MVA pathway, isoprene producing strains REM F7_25, REM F8_25, and REM F9_25 and the IspS only control strain REM F3_25.

[0244] The E. coli BL21 strain CMP861 (see Example 3) was used as a host strain. The host strain CMP861 is the same background used to generate the previously described MCM1684 and MCM1685 strains which utilize the upper MVA pathway enzymes encoded by *nphT5*, *nphT6*, and *nphT7* genes derived from *Streptomyces* sp. strain CL190 to produce isoprene at an enhanced level over that offered by the endogenous DXP pathway of E. coli. Plasmid construct pDW240 (pTrc P. alba IspS MEA -mMVK (Carb50)), carried an IPTG-inducible *ispS* (Isoprene Synthase) variant and a carbenicillin resistance gene. encodes an IPTG-inducible allele of *ispS* (Isoprene Synthase) and a carbenicillin resistance gene. Briefly, the full MVA pathway, isoprene producing test strains REM F7_25, REM F8_25, and REM F9_25 were generated by introducing plasmid construct *nphT7* with S suis HMGRS/pCL together with plasmid construct pDW240 into strain CMP861 and selecting on LB media containing 50ug/ml spectinomycin and 50ug/ml carbenicillin (Teknova, Hollister, CA) using a standard electroporation protocol and the Bio-Rad Gene Pulser cuvettes and electroporation system detailed above. From the resulting spectinomycin and carbenicillin resistant colonies, 3 were chosen for further analysis and are now referred to as strains strains REM F7_25, REM F8_25, and REM F9_25. Similarly, the IspS alone control strain was generated by introducing the pDW240 plasmid construct alone into strain CMP861 via electroporation and selecting on LB media containing only 50ug/ml carbenicillin (Teknova, Hollister, CA). One carbenicillin resistant colony was chosen to serve as a control strain in subsequent experiments and was named REM F3_25. The isoprene produced by the IspS alone control strain REM F3_25 reflects the endogenous level of the IspS substrate (DMAPP) the DXP pathway of E. coli supports under the growth conditions assessed.

Example 13: Isoprene production from full MVA pathway only test strains REM F7_25, REM F8_25, and REM F9_25, previously described MCM1684 and MCM1685 NphT7-utilizing strains, and the IspS alone control strain.

[0245] Shown in Figure 7 is the specific productivity of isoprene (ug/L OD Hr) calculated from the optical density (OD) and level of isoprene measured for each culture of the full MVA pathway only test strains REM F7_25, REM F8_25, and REM F9_25 (represented as strains NphT7 a-c in fig. 8 respectively), the previously described MCM1684 and MCM1685 NphT7-utilizing strains, and the IspS alone control strain after a 3.5 hour growth period following IPTG-

mediated induction of relevant gene expression. Briefly, control and test strains were grown in 20 ml 1% glucose 0.05% yeast extract TM3 media at 34 °C and induced with 200uM IPTG at time zero. Isoprene and OD measurements were performed essentially as described before, as was calculation of the specific productivities of isoprene reported in Figure 7. Cell pellets from 18ml of each of the aforementioned cultures were generated 5.5 hours after IPTG-induction and subsequently analyzed for upper MVA pathway and IspS activities (see below). As previously observed, the MCM1684 and MCM1685 NphT7-utilizing strains expressing all 3 upper MVA pathway components derived from *Streptomyces* sp. strain CL190 could support a modestly higher specific productivity of isoprene than an IspS alone control strain. Interestingly, the newly created test strains REM F7_25, REM F8_25, and REM F9_25 described here generated roughly 3-fold higher levels of isoprene than the previously characterized MCM1684 and MCM1685 strains. This data again supports the idea that NphT7 is functional within the *E. coli* BL21 host. This data also suggests that the plasmid construct nphT7 with *S. suis* HMGRS/pCL encoding NphT7 Acetoacetyl-CoA Synthase together with the *Streptococcus suis* HMG-CoA Synthase and HMG-CoA Reductase produces a more active upper MVA pathway than the previously described 3 component pathway derived solely from *Streptomyces* sp. strain CL190 genes which strains MCM1684 and MCM1685 express.

Example 14: Catalytic Activity Assays for Acetoacetyl-CoA Synthase (NphT7) strains.

Materials:

[0246] Acetyl-CoA, malonyl-CoA, NADPH, TRIS base, AEBSF, DNAase, lysozyme, sodium chloride, and magnesium chloride were purchased from Sigma. DMAPP was chemically synthesized.

Cell Growth and Lysate Preparation.

[0247] Cells were grown at 34°C in TM3 media containing 1% glucose, 0.05% yeast extract and 200 µM IPTG for 5.5 hrs. Cells were then centrifuged at 5000 RPM for 15 minutes at 4°C in an Eppendorf 5804R centrifuge. Cell pellets were resuspended in a solution containing 100 mM Tris, 100 mM NaCl, 0.5 mM AEBSF, 1 mg/ml lysozyme, 0.1 mg/ml DNAase, pH 7.6. The cell suspension was lysed using a french pressure cell at 14,000 psi. The lysate was then

centrifuged at 15,000 RPM for 10 minutes at 4°C in an Eppendorf 5804R centrifuge. The supernatant was collected for enzyme activity assays.

(A) Coupled Acetoacetyl-CoA Synthase (NphT7), HMG-CoA synthase, HMG-CoA Reductase Catalytic Activity Assay.

[0248] Cell lysate acetyl-CoA and malonyl-CoA activity assays were conducted with 1 mM acetyl-CoA, 1 mM malonyl-CoA, or both, and 0.4 mM NADPH, 100 mM Tris, 100 mM NaCl, pH 7.6 and 20 µl of clarified cell lysate. Reactions were initiated by the addition of acetyl-CoA, malonyl-CoA or both. NADPH oxidation was monitored in a 96-well plate at 340 nm using a SpectraMax Plus190 (Molecular Devices, Sunnyvale, CA). All reactions were conducted at 25°C in a final volume of 100 µl. The oxidation rate of NADPH in the absence of acetyl-CoA or malonyl-CoA was subtracted from reaction rates in the presence of acetyl-CoA, malonyl-CoA or both.

(B) Isoprene Synthase Catalytic Activity Assay

[0249] Twenty five µL of E.coli lysate were incubated with 5 mM DMAPP, 50 mM MgCl₂, and 100 mM Tris/NaCl, pH 7.6 at 34°C in a total volume of 100 µL in a 2 mL gas-tight vial for 15 minutes. Reactions were terminated by the addition of 100 µL of 250 mM EDTA. The glass vials were analyzed by GC-MS to determine the concentration of isoprene generated in the reactions.

Results:

[0250] In these studies, the oxidation of NADPH was monitored in the presence of cell lysate and acetyl-CoA, malonyl-CoA or both acetyl-CoA and malonyl-CoA. The results indicate that the rate of oxidation of NADPH in acetoacetyl-CoA Synthase (nphT7) containing strains is the greatest in the presence of acetyl-CoA and malonyl-CoA (see Figure 8). The rate of NADPH oxidation in control strains lacking acetoacetyl-CoA Synthase (nphT7) was decreased compared to strains containing acetoacetyl-CoA Synthase (nphT7) and the rate of oxidation of control strains was not dependent on the presence of acetyl-CoA or malonyl-CoA (Figure 8). These results are consistent with composite acetoacetyl-CoA Synthase (nphT7), HMG-CoA synthase, and HMG-CoA reductase activities being dependent on the presence of malonyl-CoA and acetyl-CoA. HMG-CoA synthase catalytic activity is dependent on the presence of acetyl-CoA,

therefore, one can conclude that the acetoacetyl-CoA Synthase (nphT7) activity requires the presence of malonyl-CoA. These results clearly support acetoacetyl-CoA Synthase (nphT7) utilization of both malonyl-CoA as a substrate in the production of acetoacetyl-CoA. Isoprene synthase activity was assayed to ensure that differences in isoprene specific productivity (see Figure 7) were not due to differences in isoprene synthase activity (Figure 9).

Example 15: Construction of amorphadiene- or farnesene-producing strains

[0251] A lower mevalonate pathway is introduced by transduction into MCM1684 using a lysate from MCM521. The kanamycin marker is looped out according to the manufacturer (Gene Bridges, Heidelberg, Germany). The lower pathway from MCM521 can be modified by changing the promoter upstream of the operon by modifying the rbs in front of each gene via the use of alternative genes. Farnesyl diphosphate synthase (ispA) is overexpressed, either by altering the promoter and/or rbs on the chromosome, or by expressing it from a plasmid. Plasmid pMCM1321 is co-electroporated with a variation of plasmid pDW34 (See U.S. Patent Application Publication No: 2010/0196977; Figure 2). The plasmids which are variants of pDW34 contain the farnesene synthase codon optimized for E. coli or amorphadiene synthase codon optimized for E. coli, instead of isoprene synthase. Colonies are selected on LB+ spectinomycin 50 ug/mL + carbenicillin 50 ug/mL.

Example 16: Production of amorphadiene or farnesene in strains containing the plasmids with acetoactetyl-CoA synthase

[0252] (i) Materials

[0253] TM3 media recipe (per liter fermentation media): K₂HPO₄ 13.6 g, KH₂PO₄ 13.6 g, MgSO₄*7H₂O 2 g, citric acid monohydrate 2 g, ferric ammonium citrate 0.3 g, (NH₄)₂SO₄ 3.2 g, yeast extract 0.2 g, 1000X Trace Metals Solution 1 ml. All of the components are added together and dissolved in diH₂O. The pH is adjusted to 6.8 with ammonium hydroxide (30%) and brought to volume. Media is then filter-sterilized with a 0.22 micron filter. Glucose 10.0 g and antibiotics are added after sterilization and pH adjustment.

[0254] 1000X Trace Metal Solution (per liter fermentation media): Citric Acid*H₂O 40g, MnSO₄*H₂O 30g, NaCl 10g, FeSO₄*7H₂O 1g, CoCl₂*6H₂O 1g, ZnSO₄*7H₂O 1g, CuSO₄*5H₂O 100mg, H₃BO₃ 100mg, NaMoO₄*2H₂O 100mg. Each component is dissolved

one at a time in diH₂O. The pH is adjusted to 3.0 with HCl/NaOH, and then the solution is brought to volume and filter-sterilized with a 0.22 micron filter.

(ii) Experimental procedure

[0255] Cells are grown overnight in Luria-Bertani broth + antibiotics. The day after, they are diluted to an OD₆₀₀ of 0.05 in 20 mL TM3 medium containing 50 ug/ml of spectinomycin and 50 ug/mL carbenicillin (in a 250-mL baffled Erlenmeyer flask), and incubated at 34°C and 200 rpm. Prior to inoculation, an overlay of 20% (v/v) dodecane (Sigma-Aldrich) is added to each culture flask to trap the volatile sesquiterpene product as described previously (Newman et. al., 2006).

[0256] After 2h of growth, OD₆₀₀ is measured and 0.05-0.40 mM isopropyl β -D-1-thiogalactopyranoside (IPTG) is added. Samples are taken regularly during the course of the fermentation. At each timepoint, OD₆₀₀ is measured. Also, amorphadiene or farnesene concentration in the organic layer is assayed by diluting the dodecane overlay into ethyl acetate. Dodecane/ethyl acetate extracts are analyzed by GC-MS methods as previously described (Martin et. al., Nat. Biotechnol. 2003, 21:96-802) by monitoring the molecular ion (204 m/z) and the 189 m/z fragment ion for amorphadiene or the molecular ion (204 m/z) for farnesene. Amorphadiene or farnesene samples of known concentration are injected to produce standard curves for amorphadiene or farnesene, respectively. The amount of amorphadiene or farnesene in samples is calculated using the amorphadiene or farnesene standard curves, respectively.

(iii) Results

[0257] When the strains containing pMCM1321 are compared to the same background without the acetoacetyl-CoA synthase gene, increased specific productivity, yield, CPI and/or titer of amorphadiene or farnesene are observed.

(iv) References

[0258] Newman, J.D., Marshal, J.L., Chang, M.C.Y., Nowroozi, F., Paradise, E.M., Pitera, D.J., Newman, K.L., Keasling, J.D., 2006. High-level production of amorpha-4,11-diene in a two-phase partitioning bioreactor of metabolically engineered *E. coli*. Biotechnol. Bioeng. 95:684-691.

[0259] Martin, V.J., Pitera, D.J., Withers, S.T., Newman, J.D., Keasling, J.D., 2003. Engineering a mevalonate pathway in *E. coli* for production of terpenoids. *Nat. Biotechnol.* 21:796–802.

CLAIMS

What is claimed is:

1. A recombinant microorganism capable of producing isoprene comprising one or more nucleic acids encoding a polypeptide capable of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA and one or more nucleic acids encoding:
 - a. an isoprene synthase polypeptide, wherein the isoprene synthase polypeptide is encoded by a heterologous nucleic acid; and
 - b. one or more mevalonate (MVA) pathway polypeptides,wherein culturing of said recombinant microorganism in a suitable media provides for the production of said polypeptides and synthesis of isoprene.
2. The recombinant microorganism according to claim 1, wherein the one or more nucleic acids encoding a polypeptide capable of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA is an acetoacetyl-CoA synthase gene.
3. The recombinant microorganism according to claim 2, wherein the acetoacetyl-CoA synthase gene is a gene from an actinomycete.
4. The recombinant microorganism according to claim 3, wherein the acetoacetyl-CoA synthase gene is from the genus *Streptomyces*.
5. The recombinant microorganism according to claim 4, wherein the acetoacetyl-CoA synthase gene encodes a protein having the amino acid sequence of SEQ ID NO: 1 or a protein having an amino acid sequence with an 80% or more identity to the amino acid sequence of SEQ ID NO: 1 and having a function of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA.
6. The recombinant microorganism of any one of claim 1-5, wherein the isoprene synthase polypeptide is a plant isoprene synthase polypeptide or a variant thereof.
7. The recombinant microorganism of claim 6, wherein the isoprene synthase polypeptide is a polypeptide from *Pueraria* or *Populus* or a hybrid, *Populus alba* x *Populus tremula* or a variant thereof.
8. The recombinant microorganism of claim 7, wherein the isoprene synthase polypeptide is selected from the group consisting of *Pueraria montana* or *Pueraria lobata*, *Populus tremuloides*, *Populus alba*, *Populus nigra*, and *Populus trichocarpa* or a variant thereof.

9. The recombinant microorganism of any one of claims 1-8, wherein said one or more nucleic acids encoding one or more MVA pathway polypeptides of (b) is a heterologous nucleic acid.
10. The recombinant microorganism of any one of claims 1-8, wherein said one or more nucleic acids encoding more MVA pathway polypeptides of (b) is a copy of an endogenous nucleic acid.
11. The recombinant microorganism of any one of claims 1-10, wherein the one or more MVA pathway polypeptides is selected from (a) an enzyme that condenses acetoacetyl-CoA with acetyl-CoA to form HMG-Co-A; (b) an enzyme that converts HMG-CoA to mevalonate; (c) an enzyme that phosphorylates mevalonate to mevalonate 5-phosphate; (d) an enzyme that converts mevalonate 5-phosphate to mevalonate 5-pyrophosphate; and (e) an enzyme that converts mevalonate 5-pyrophosphate to isopentenyl pyrophosphate.
12. The recombinant microorganism of any one of claim 1-11, wherein the enzyme that phosphorylates mevalonate to mevalonate 5-phosphate is selected from the group consisting of *M. mazei* mevalonate kinase, *M. burtonii* mevalonate kinase polypeptide, *Lactobacillus* mevalonate kinase polypeptide, *Lactobacillus sakei* mevalonate kinase polypeptide, yeast mevalonate kinase polypeptide, *Saccharomyces cerevisiae* mevalonate kinase polypeptide, *Streptococcus* mevalonate kinase polypeptide, *Streptococcus pneumoniae* mevalonate kinase polypeptide, and *Streptomyces* mevalonate kinase polypeptide, or *Streptomyces CL190* mevalonate kinase polypeptide.
13. The recombinant microorganism of claim 12, wherein the enzyme that phosphorylates mevalonate to mevalonate 5-phosphate is *M. mazei* mevalonate kinase.
14. The recombinant microorganism of any one of claims 1-13, further comprising one or more nucleic acids encoding an isopentenyl-diphosphate delta-isomerase (IDI) polypeptide
15. The recombinant microorganism of any one of claims 1-14, further comprising one or more nucleic acids encoding one or more 1-deoxy-D-xylulose-5-phosphate (DXP) pathway polypeptides.
16. The recombinant microorganism of claim 15, wherein said one or more nucleic acids encoding one or more DXP pathway polypeptides of is a heterologous nucleic acid encoding.
17. The recombinant microorganism of claim 15, wherein said one or more nucleic acids encoding one or more DXP pathway polypeptides is a copy of an endogenous nucleic acid.

18. The recombinant microorganism of claim 15, wherein the one or more DXP pathway polypeptides is selected from (a) 1-deoxy-D-xylulose-5-phosphate synthase (DXS), (b) 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR), (c) 4-diphosphocytidyl-2C-methyl-D-erythritol synthase (MCT), (d) 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (CMK), (e) 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase (MCS), (f) 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate synthase (HDS), and (g) 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate reductase (HDR).
19. The recombinant microorganism of claim 18, wherein the DXP pathway polypeptide is DXS.
20. The recombinant microorganism of any one of claims 1-19, wherein the one or more heterologous nucleic acids is placed under an inducible promoter or a constitutive promoter.
21. The recombinant microorganism of any one of claims 1-20, wherein the one or more heterologous nucleic acids is cloned into one or more multicopy plasmids.
22. The recombinant microorganism of any one of claims 1-20, wherein the one or more heterologous nucleic acids is integrated into a chromosome of the cells
23. The recombinant microorganism of any one of claims 1-22, wherein the microorganism is a bacterial, algal, fungal or yeast cell.
24. The recombinant microorganism of claim 23, wherein the microorganism is a bacterial cell.
25. The bacterial cell of claim 24, wherein the bacterial cell is a gram-positive bacterial cell or gram-negative bacterial cell.
26. The bacterial cell of claim 25, wherein the bacterial cell is selected from the group consisting of *E. coli*, *L. acidophilus*, *Corynebacterium sp.*, *P. citrea*, *B. subtilis*, *B. licheniformis*, *B. lentus*, *B. brevis*, *B. stearothermophilus*, *B. alkalophilus*, *B. amyloliquefaciens*, *B. clausii*, *B. halodurans*, *B. megaterium*, *B. coagulans*, *B. circulans*, *B. lautus*, *B. thuringiensis*, *S. albus*, *S. lividans*, *S. coelicolor*, *S. griseus*, *Pseudomonas sp.*, and *P. alcaligenes cells*.
27. The bacterial cell of claim 26, wherein the bacterial cell is an *E. coli* cell.
28. The bacterial cell of claim 26, wherein the bacterial cell is a *L. acidophilus* cell.
29. The bacterial cell of claim 26, wherein the bacterial cell is a *Corynebacterium sp.* cell.

30. The recombinant microorganism of claim 23, wherein the microorganism is an algal cell.
31. The alga cell of claim 30, wherein the algal cell is selected from the group consisting of green algae, red algae, glaucophytes, chlorarachniophytes, euglenids, chromista, or dinoflagellates.
32. The recombinant microorganism of claim 23, wherein the microorganism is a fungal cell.
33. The fungal cell of claim 32, wherein the fungal cell is a filamentous fungi.
34. The recombinant microorganism of claim 23, wherein the microorganism is a yeast cell.
35. The yeast cell of claim 34, wherein the yeast cell is selected from the group consisting of *Saccharomyces sp.*, *Schizosaccharomyces sp.*, *Pichia sp.*, or *Candida sp.*
36. The yeast cell of claim 35, wherein the yeast cell is a *Saccharomyces cerevisiae* cell.
37. A recombinant microorganism capable of producing an isoprenoid comprising one or more nucleic acids encoding a polypeptide capable of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA and one or more nucleic acids encoding:
- a. one or more nucleic acids encoding a polyprenyl pyrophosphate synthase; and
 - b. one or more nucleic acids encoding one or more mevalonate (MVA) pathway polypeptides,
- wherein culturing of said recombinant microorganism in a suitable media provides for production of said polypeptides and synthesis of a recoverable amount of isoprenoid.
38. The recombinant microorganism of claim 37, wherein said one or more nucleic acids encoding one or more MVA pathway polypeptides of (b) is a heterologous nucleic acid.
39. The recombinant microorganism of any one of claims 37-38, wherein the one or more MVA pathway polypeptides is selected from the group consisting of (a) an enzyme that condenses acetoacetyl-CoA with acetyl-CoA to form HMG-Co-A; (b) an enzyme that converts HMG-CoA to mevalonate; (c) an enzyme that phosphorylates mevalonate to mevalonate 5-phosphate; (d) an enzyme that converts mevalonate 5-phosphate to mevalonate 5-pyrophosphate; and (e) an enzyme that converts mevalonate 5-pyrophosphate to isopentenyl pyrophosphate.

40. The recombinant microorganism of any one of claim 37-39, wherein the enzyme that phosphorylates mevalonate to mevalonate 5-phosphate is selected from the group consisting of *M. mazei* mevalonate kinase, *M. burtonii* mevalonate kinase polypeptide, *Lactobacillus* mevalonate kinase polypeptide, *Lactobacillus sakei* mevalonate kinase polypeptide, yeast mevalonate kinase polypeptide, *Saccharomyces cerevisiae* mevalonate kinase polypeptide, *Streptococcus* mevalonate kinase polypeptide, *Streptococcus pneumoniae* mevalonate kinase polypeptide, and *Streptomyces* mevalonate kinase polypeptide, *Streptomyces CLI90* mevalonate kinase polypeptide.
41. The recombinant microorganism of claim 40, wherein the enzyme that phosphorylates mevalonate to mevalonate 5-phosphate is *M. mazei* mevalonate kinase.
42. The recombinant microorganism of any one of claims 37-41, further comprising one or more nucleic acids encoding an isopentenyl-diphosphate delta-isomerase (IDI) polypeptide
43. The recombinant microorganism of any one of claims 37-42, wherein the one or more heterologous nucleic acids is placed under an inducible promoter or a constitutive promoter.
44. The recombinant microorganism of any one of claims 37-43, wherein the one or more heterologous nucleic acids is cloned into one or more multicopy plasmids.
45. The recombinant microorganism of any one of claims 37-43, wherein the one or more heterologous nucleic acids is integrated into a chromosome of the cells
46. The recombinant microorganism of any one of claims 37-45, wherein the microorganism is a bacterial, algal, fungal or yeast cell.
47. The recombinant microorganism of claim 46, wherein the microorganism is a bacterial cell.
48. The bacterial cell of claim 47, wherein the bacterial cell is a gram-positive bacterial cell or gram-negative bacterial cell.

49. The bacterial cell of claim 47, wherein the bacterial cell is selected from the group consisting of *E. coli*, *L. acidophilus*, *Corynebacterium sp.*, *P. citrea*, *B. subtilis*, *B. licheniformis*, *B. lentus*, *B. brevis*, *B. stearothermophilus*, *B. alkalophilus*, *B. amyloliquefaciens*, *B. clausii*, *B. halodurans*, *B. megaterium*, *B. coagulans*, *B. circulans*, *B. lautus*, *B. thuringiensis*, *S. albus*, *S. lividans*, *S. coelicolor*, *S. griseus*, *Pseudomonas sp.*, and *P. alcaligenes cells*.
50. The bacterial cell of claim 49, wherein the bacterial cell is an *E. coli* cell.
51. The bacterial cell of claim 49, wherein the bacterial cell is a *L. acidophilus* cell.
52. The bacterial cell of claim 49, wherein the bacterial cell is a *Corynebacterium sp.* cell.
53. The recombinant microorganism of claim 46, wherein the microorganism is an algal cell.
54. The alga cell of claim 53, wherein the algal cell is selected from the group consisting of green algae, red algae, glaucophytes, chlorarachniophytes, euglenids, chromista, or dinoflagellates.
55. The recombinant microorganism of claim 46, wherein the microorganism is a fungal cell.
56. The fungal cell of claim 55, wherein the fungal cell is a filamentous fungi.
57. The recombinant microorganism of claim 46, wherein the microorganism is a yeast cell.
58. The yeast cell of claim 57, wherein the yeast cell is selected from the group consisting of *Saccharomyces sp.*, *Schizosaccharomyces sp.*, *Pichia sp.*, or *Candida sp.*
59. The yeast cell of claim 58, wherein the yeast cell is a *Saccharomyces cerevisiae* cell.
60. The recombinant microorganism of any one of claims 37-59, wherein the isoprenoid is selected from group consisting of monoterpenes, diterpenes, triterpenes, tetraterpenes, sesquiterpene, and polyterpene.
61. The recombinant microorganism of claim 60, wherein the isoprenoid is a sesquiterpene.

62. The recombinant microorganism of any one of claims 37-61, wherein the isoprenoid is selected from the group consisting of abietadiene, amorphadiene, carene, farnesene, α -farnesene, β -farnesene, farnesol, geraniol, geranylgeraniol, linalool, limonene, myrcene, nerolidol, ocimene, patchoulol, β -pinene, sabinene, γ -terpinene, terpine and valencene.
63. A method of producing isoprene, the method comprising:
- culturing a recombinant microorganism comprising one or more nucleic acids encoding (i) a polypeptide capable of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA and one or more nucleic acids encoding: (ii) an isoprene synthase polypeptide, wherein the isoprene synthase polypeptide is encoded by a heterologous nucleic acid; and (iii) one or more mevalonate (MVA) pathway polypeptides, and
 - producing isoprene.
64. The method of claim 63, further comprising recovering the isoprene produced by the recombinant microorganism.
65. The method of claim 63, wherein the one or more nucleic acids encoding a polypeptide capable of synthesizing acetoacetyl Co-A from malonyl Co-A and acetyl-CoA is an acetoacetyl-CoA synthase gene.
66. The method of claim 63, wherein the isoprene synthase polypeptide is a plant isoprene synthase polypeptide.
67. The method of claim 63, wherein the one or more MVA pathway polypeptides is selected from the group consisting of (a) an enzyme that condenses acetoacetyl-CoA with acetyl-CoA to form HMG-Co-A; (b) an enzyme that converts HMG-CoA to mevalonate; (c) an enzyme that phosphorylates mevalonate to mevalonate 5-phosphate; (d) an enzyme that converts mevalonate 5-phosphate to mevalonate 5-pyrophosphate; and (e) an enzyme that converts mevalonate 5-pyrophosphate to isopentenyl pyrophosphate.
68. The method of claim 63, further comprising one or more nucleic acids encoding an isopentenyl-diphosphate delta-isomerase (IDI) polypeptide.
69. The method of claim 63, wherein said recombinant microorganism further comprises one or more nucleic acids encoding one or more 1-deoxy-D-xylulose-5-phosphate (DXP) pathway polypeptides.
70. The method of claim 63, wherein the microorganism is a bacterial, algal, fungal or yeast cell.

71. The method of claim 70, wherein the microorganism is a bacterial cell.
72. The method of claim 71, wherein the bacterial cell is a gram-positive bacterial cell or gram-negative bacterial cell.
73. The method of claim 72, wherein the bacterial cell is an *E. coli* cell.
74. The method of claim 72, wherein the bacterial cell is a *L. acidophilus* cell.
75. The bacterial cell of claim 72, wherein the bacterial cell is a *Corynebacterium sp.* cell.
76. The method of claim 70, wherein the microorganism is a yeast cell.
77. The method of claim 76, wherein the yeast cell is a *Saccharomyces cerevisiae* cell.
78. A method of producing an isoprenoid, the method comprising:
- a. culturing a recombinant microorganism comprising one or more nucleic acids encoding (i) a polypeptide capable of synthesizing acetoacetyl-CoA from malonyl-CoA and acetyl-CoA and one or more nucleic acids encoding: (ii) a polyprenyl pyrophosphate synthase polypeptide, wherein the polyprenyl pyrophosphate synthase polypeptide is encoded by a heterologous nucleic acid; and (iii) one or more mevalonate (MVA) pathway polypeptides, and
 - b. producing said isoprenoid.